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Background: Oxaliplatin-induced peripheral neuropathy (OIPN) occurs in 85-95% of 
patients receiving FOLFOX or FOLFIRINOX, oxaliplatin-based chemotherapy for invasive 
gastrointestinal (GI) cancers. Persistent OIPN can impair long-term quality of life (QOL). No 
OIPN cures are known. Aerobic physical activity (PA) may reduce OIPN by enhancing 
circulation and re-distributing neurotoxic oxaliplatin away from vulnerable neurons. However, 
no trials have evaluated solely aerobic exercise for OIPN. This dissertation reports the results of 
a 1) literature review on exercise for chemotherapy-induced peripheral neuropathy, and 2) pilot 
randomized controlled trial (RCT) of brisk walking for OIPN in FOLFOX/FOLFIRINOX-
receiving GI cancer survivors. The “MI-Walk Intervention”—an eight-week motivational 
enhancement therapy (MET)- home-based aerobic walking intervention—was tested in this 
study. 
Purpose: The RCT aims were to explore the 1) effect of the MI-Walk Intervention on 
eight-week OIPN severity and QOL compared to PA education alone, and 2) intervention 
feasibility among patients receiving FOLFOX/FOLFIRINOX. The primary hypothesis was that 
the intervention participants would report less severe OIPN and higher QOL at eight weeks than 
participants who received PA education alone. 
Methods: Recruitment of 60 GI cancer patients from two cancer clinics occurred at the 
second FOLFOX/FOLFIRINOX visit. All participants received PA education and regular phone 





the MI-Walk Intervention, which included theory-based motivational supports (e.g., a Fitbit 
Charge 2, three MET sessions, and goals worksheets). Ongoing peer support was encouraged via 
peer email, phone, and walking groups. Self-report surveys of OIPN (primary outcome) and 
QOL were administered pre-and post-intervention. Feasibility, including intervention 
acceptability survey scores, were also explored. Intergroup differences at eight weeks were 
explored using multiple imputation for intention-to-treat linear regression analyses. Linear mixed 
model regression was used to evaluate intergroup differences in PA. Randomization was 
stratified by clinic and diabetes diagnosis.  
Results: The enrollment and completion rates were 62% (N = 57) and 87%, respectively. 
The intervention compared to the control condition had no effect on sensory OIPN (mean 
difference [𝑋∆] = -0.01; p > .99), motor OIPN (𝑋∆ = 2.39; p = .17) and QOL (𝑋∆ = -1.43; p 
> .99). Eight-week sensory (𝑋 = 11.48 ± 0.38) and motor OIPN severities (𝑋 = 7.48 ± 0.36) both 
increased from baseline (p ≤ .01) but were mild. The intervention group’s Fitbit-measured 
weekly minutes of aerobic PA increased from baseline to eight weeks (𝑋∆ = 17.39; p = .03). 
However, self-reported PA increases over time were slightly higher on average in the control than 
the intervention group (𝑋∆ = -24.02; p = .30). Satisfaction with the intervention was high (𝑋 = 
4.32 ± 0.9), but overall acceptability scores were low (𝑋 = 47.91 ± 11.45); the Fitbit and MET 
were rated most helpful in encouraging walking; the email and walking groups were unhelpful. 
No adverse events were noted. 
Conclusions: This study failed to detect significant beneficial effects of aerobic walking 
on OPIN, however small sample size and notable PA increases in the control group suggest that 
further research is necessary in order to replicate or refute our null findings among GI cancer 





aerobic exercise may not completely prevent OIPN), they were mild at eight weeks. Some 
intervention components were “unhelpful.” Studies are needed to identify the most helpful 
intervention components to tailor interventions for individuals receiving 








Over 1.7 million individuals will be diagnosed with cancer in 2019 in the United States 
(American Cancer Society 2019a). Colorectal cancer is the second most commonly diagnosed 
cancer worldwide (World Health Organization and International Agency for Research on Cancer 
2012) and third most common in the United States (American Cancer Society 2019a). Over half 
of the new cases of gastrointestinal (GI) cancer are distant or metastasized (stage II-IV) (National 
Cancer Institute 2016), necessitating more aggressive therapy including neurotoxic 
chemotherapy (American Cancer Society 2019b). Various neurotoxic chemotherapy drugs, 
including taxanes (paclitaxel and docetaxel), platinums (cisplatin, oxaliplatin, and carboplatin), 
vinca alkaloids (vincristine and vinblastine), proteasome inhibitors (bortezomib), and 
thalidomide, have known antitumor benefits. However, these drugs may cause life-altering 
chemotherapy-induced peripheral neuropathy (CIPN). This dissertation focuses specifically on 
CIPN that is caused by oxaliplatin, a mainstay chemotherapy treatment for many GI cancers. 
Statement of the Problem 
About 85%-95% of patients who receive FOLFOX or FOLFIRINOX—standard 
chemotherapy regimens for stage II-III GI cancers—develop a type of CIPN called oxaliplatin-
induced peripheral neuropathy (OIPN). The FOLFOX and FOLFIRINOX regimens contain 





dose of 680-1,020 mg/m2 (André, Boni, and Navarro 2009; Choi et al. 2019; Drott et al. 
2016; Meyers et al. 2017).  
The hallmark symptoms of OIPN common among all types of CIPN include numbness, 
tingling, and neuropathic (e.g., burning, freezing, and shock-like) pain. These symptoms are 
generally preceded by unique acute OIPN symptoms, including muscle cramps, and cold 
sensitivity in the face, throat, hands, and feet (Carozzi, Canta, and Chiorazzi 2015; Jaggi and 
Singh 2012; S. B. Park et al. 2013). The severity of OIPN increases with increasing cumulative 
oxaliplatin dosages (Pachman et al. 2015, 2016); and acute OIPN predicts long-term OIPN 
severity and associated-deficits (Argyriou et al. 2013; Beijers et al. 2015; Loprinzi et al. 2014; 
Pachman et al. 2015, 2016; Ventzel et al. 2015; Ventzel, Madsen, et al. 2016).  
Eventually, FOLFOX and FOLFIRINOX may cause irreversible neuronal damage and 
permanent OIPN sensory and motor deficits (Ahmed Hussein Zedan et al. 2014). Up to 11 years 
after chemotherapy completion, 20-75% of patients still report OIPN symptoms, and impaired 
balance, physical function (Mols et al. 2013; S. B. Park et al. 2013; Ventzel et al. 2015), and 
quality of life (QOL) (Kidwell et al. 2012; Mols et al. 2013; Soveri et al. 2019; Speck et al. 2012; 
Tofthagen 2010b, 2010a; Tofthagen et al. 2013; Tofthagen, McAllister, and McMillan 2011). 
Individuals with OIPN commonly report difficulty with daily tasks, such as buttoning shirts or 
climbing stairs (Bakitas 2007; Monfort et al. 2016; Speck et al. 2012; Tofthagen 2010b, 2010a). 
These deficits may lead to a sense of a loss of purpose and ability to engage in usual work and 
leisure activities, leading to social isolation and frustration (Boehmke and Dickerson 2005; 
Exposito Vizcaino et al. 2018; Tofthagen, McAllister, and McMillan 2011; Zanville et al. 2016). 
There are no known effective curative treatments or preventive agents for OIPN 





regimens (Beijers et al. 2015; Ventzel et al. 2015). Current practices to address OIPN include 
altering the chemotherapy regimen and using drugs often used to treat other neuropathic pain 
conditions (e.g., tricyclic antidepressants, gabapentin, amitriptyline, baclofen, and ketamine) 
(Argyriou et al. 2013; Guido Cavaletti 2014; Majithia et al. 2016). However, over 80 trials have 
tested these drugs and other therapies and found that only duloxetine (Smith et al., 2013) is 
effective for treating existing OIPN (Hershman et al. 2014; Lee et al. 2019; Majithia et al. 2016).  
Exercise may be an effective intervention for OIPN (Henke et al. 2014; McCrary et al. 
2019; Streckmann, Kneis, et al. 2014; Wonders 2014; Zimmer et al. 2018). Specifically, aerobic 
exercise practiced at least 10 minutes per day, two to five days per week, at moderate-intensity 
(Borg Rating of Exertion of 12 to 14), for at least six to eight weeks may be a consistently 
effective intervention for OIPN (Henke et al. 2014; Kleckner et al. 2018; Streckmann, Kneis, et 
al. 2014; Wonders 2014; Zimmer et al. 2018). Mechanistically, aerobic exercise may target 
OIPN’s main proposed pathophysiologic mechanism: oxidative stress-induced neuronal 
apoptosis (Carozzi, Marmiroli, and Cavaletti 2010; Imai et al. 2017). Aerobic exercise may 
reduce oxaliplatin-induced oxidative stress by increasing circulation and sweeping oxaliplatin 
away from vulnerable neurons such as the dorsal root ganglia where it is known to accumulate 
(Ashor et al. 2015; Azizbeigi et al. 2015; Di Cesare Mannelli et al. 2012; Chang et al. 2015; 
Gomez-Cabrera et al. 2015; Karimi and Roshan 2013; Jong-Hwan Park et al. 2013; Schaun et al. 
2011; Tofthagen, Visovsky, and Hopgood 2013; Zhou et al. 2016). 
However, no trials have been designed specifically to evaluate the effects of aerobic 
exercise on OIPN (Brayall et al. 2018; Duregon et al. 2018; Jung, Rein, and Fuchs 2018). All the 
trials tested multimodal exercise interventions, and only one trial focused on OIPN independent 





key confounding factors such as type, dosage, and prior receipt of neurotoxic chemotherapy, and 
CIPN-influencing comorbidities.  
Purpose 
The purpose of this prospective, randomized, controlled, pilot experiment was to 
evaluate the effect of an aerobic walking intervention for OIPN in GI cancer patients 
receiving FOLFOX or FOLFIRINOX. The primary objective was to evaluate the effect of the 
“MI-Walk Intervention”—an eight-week motivational enhancement therapy- and home-based 
aerobic walking intervention—on OIPN severity at eight weeks, compared to physical 
activity (PA) education alone. Intervention feasibility (including fidelity and acceptability) 
and secondary outcomes were also evaluated, including the effects on eight-week QOL and 
physical and emotional function.  
Theoretical Framework 
The Theory of Unpleasant Symptoms (TOUS) provided the overall framework for the 
study (Lenz et al. 1997). The Social Cognitive Theory (SCT) (Bandura, 1986, 2004; Rogers et 
al., 2004, 2005; Stacey, James, Chapman, Courneya, & Lubans, 2015) and Self-
Determination Theory (SDT) (Deci & Ryan, 1985; Ryan, 1991, 1995) were merged and 
provided the framework for the aerobic exercise (“MI-Walk”) intervention.  
The Theory of Unpleasant Symptoms 
Figure I.1—the study theoretical model—depicts the relationships among the key 
study variables—aerobic exercise (independent), OIPN severity (primary dependent), total 
oxaliplatin dose (covariate), mood (covariate), and QOL/function (secondary dependent). 
These variables were deduced from the TOUS constructs: influencing factors, symptoms, and 






Theoretical Model of Exercise to Reduce Oxaliplatin-Induced Peripheral Neuropathy 
 
Note. The theoretical model was deduced from the Theory of Unpleasant Symptoms (Lenz et al. 1997).   
Abbreviations. OIPN, oxaliplatin-induced peripheral neuropathy; QOL, quality of life. 
 
Symptoms. The main symptom of focus in the theoretical model and dissertation is 
OIPN; however, other cancer treatment-related symptoms may cluster and interact with 
OIPN: fatigue, pain, sleep disturbance, anxiety, and depression (Berger 2010; Binkley et al. 
2012; El-Shami et al. 2015; Fernandez et al. 2015; Kamath 2012; Knoerl, Chornoby, and 
Smith 2018, 2019; Mols et al. 2013; Pachman et al. 2012; Skerman, Yates, and Battistutta 
2012). Evidence suggests these symptoms may share pathophysiologic pathways such as 
inflammation (Beijers et al. 2015; Berger 2010; Binkley et al. 2012; El-Shami et al. 2015; 





Battistutta 2012). These symptoms were evaluated indirectly using a cancer-related QOL 
survey and may be explored in future secondary cluster analyses.  
Performance. Performance in patients with OIPN refers to the physical and 
subsequently emotional function and QOL outcomes of the symptom experience (Lenz, Pugh, 
Milligan, Gift, & Suppe, 1997). Specifically, OIPN may impair QOL by affecting various 
functional domains, including physical (Bakitas, 2007; Monfort et al., 2016; Speck et al., 
2012; Tofthagen, 2010a, 2010b) and emotional function (Boehmke & Dickerson, 2005; 
Exposito Vizcaino, Casanova-Molla, Escoda, Galan, & Miro, 2016; Tofthagen, McMillan, & 
Kip, 2011; Zanville et al., 2016). Performance feeds back to the influencing factors. For 
example, OIPN-induced QOL and functional impairments lead to oxaliplatin dose reductions 
in about 70% of patients (Andre et al. 2004; Huang et al. 2015; Ventzel, Madsen, et al. 2016). 
Various functional domains of and global QOL are key performance outcomes of this study. 
Influencing factors. Situational, physiological, and psychological influencing factors 
interact and influence OIPN. Situational factors encompass culture and lifestyle behaviors 
(social environmental factors), and climate and geographical location (physical environmental 
factors) that influence symptom perception and expression. Lifestyle behaviors including 
aerobic exercise are conceptualized as social situational factors in the TOUS and in the 
study’s theoretical model. Aerobic exercise may moderate OIPN through its physiological and 
psychological effects (e.g., improving blood circulation and mood). Environmental factors 
such as cold weather may exacerbate OIPN (Tofthagen, McAllister, and McMillan 2011). 
Thus, aerobic exercise was a key situational OIPN influencing factor evaluated in this study; 
the winter and summer seasonal temperature variation during the study emphasized the 





Physiological influencing factors of OIPN include type, dosage, and prior receipt of 
neurotoxic chemotherapy, age, body mass index, concomitant neuropathic pain drugs and 
supplements, smoking status, and pre-existing peripheral neuropathy (measured in the study); 
comorbidities such as diabetes, HIV, peripheral vascular disease, vitamin B deficiency, and 
alcohol dependence (exclusion criteria in the study); and genes (Beijers et al. 2015; E. I. Chen 
et al. 2015; M.-Y. Chen et al. 2011; Hershman et al. 2016; Kleckner et al. 2018; S. B. Park et 
al. 2013; Petrovchich et al. 2019; Seretny et al. 2014; Terrazzino et al. 2015; Ahmed H Zedan 
and Vilholm 2014). Further, OIPN may be influenced indirectly by factors associated with 
aerobic exercise. Obesity may be associated with lower levels of moderate to vigorous 
physical activity (MVPA) (van Putten et al. 2016) and lower adherence to vigorous aerobic 
exercise interventions (Courneya, Segal, et al. 2014). Additionally, impaired mobility, 
comorbidity, and cancer treatment-related symptoms such as fatigue, insomnia, and 
depression have commonly been cited as barriers to MVPA (Courneya et al., 2005; Fernandez 
et al., 2015; Hawkes et al., 2013; Henriksson, Arving, Johansson, Igelstrom, & Nordin, 2016; 
Kamath, 2012; Mikkelsen, Nielsen, Vinther, Lund, & Jarden, 2019). Mixed evidence suggests 
that older age may predict lower levels of PA (van Putten et al. 2016) or higher adherence 
(Courneya, Segal, et al. 2014) and response to exercise interventions for OIPN (Kleckner et 
al. 2016). Due to the pilot nature of our study, genetic factors were not evaluated but 
oxaliplatin dose was surveyed as a covariate in the study. 
Finally, psychological factors—more specifically, mood, and SCT/SDT constructs—
may directly and indirectly influence OIPN. The direct potential neurobiological link among 
anxiety, depression, and OIPN, is described above in the symptoms section. Additionally, 





& Petruzzello, 2011; Hawkes et al., 2013; Henriksson, Arving, Johansson, Igelstrom, & 
Nordin, 2016; Kwan & Bryan, 2010; Mas, Quantin, & Ninot, 2015; Morielli et al., 2016; 
Shang, Wenzel, Krumm, Griffith, & Stewart, 2012; Williams et al., 2008). For example, 
anxiety and depressive mood disorders are common after cancer diagnosis and predict less 
immediate PA behavior (Liao et al. 2016; Liao, Shonkoff, and Dunton 2015; Mata et al. 2012; 
Shang et al. 2012). Mood was measured in the study using the emotional functioning subscale 
of the European Organisation for Research and Treatment of Cancer QLQ 30-Item 
Questionnaire. This subscale has been shown to predict response to chronic CIPN treatment 
(Smith et al., 2015). Despite the inconsistent terminology, the emotional functioning subscale 
items refer to mood (a chronic, event-independent, affective state), not emotion (an acute, 
high-intensity, real-time emotional experiences induced by a specific event) and affect (a non-
cognitively processed neurophysiological feeling) (Ekkekakis, 2013). Self-efficacy—a SCT 
construct—to manage OIPN (e.g., beliefs in pain control) may negatively moderate OIPN 
severity (Knoerl et al. 2018). The remaining psychological factors derived from the SCT and 
SDT that informed the MI-Walk Intervention are described below. 
The Social Cognitive and Self-Determination Theories 
Several key constructs of the SCT and SDT (e.g., self-efficacy, autonomous 
motivation, and perceived social support) form the basis of the MI-Walk Intervention. The 
propositions and their application to the study are described below.  
The Social Cognitive Theory (Bandura, 1986, 2004). Knowledge; self-efficacy 
(perceived ability to perform a task and overcome barriers to performing the task); goals; 
physical, psychological, and material outcome expectations; and perceived physical, social, 





Self-efficacy is a key construct proposed to influence behavior directly and indirectly through 
the other constructs. Personal task-specific skills and prior accomplishments (mastery) may 
be the greatest contributing factor toward self-efficacy. Additionally, self-efficacy may be 
drawn from inspiration from observing influential role models’ task-specific successes 
(vicarious experience), affirmation and encouragement from a trusted source (verbal 
persuasion), and less interpretation of physiological and affective barriers as indicators of 
incapability (physiological and affective states) (Bandura 1977; B. J. Zimmerman 2000). 
The Self-Determination Theory (Deci and Ryan 1985; Ryan 1995; Ryan and Deci 
2000). The SDT suggests that three basic psychological needs drive motivation: competency 
(akin to self-efficacy), autonomy (perceived internal volitional control over one’s behavior 
and outcomes), and relatedness (social belongingness). These needs are akin to the four 
sources of self-efficacy: mastery (task-specific competence), vicarious influences 
(relatedness), verbal persuasion (competence and relatedness), and physiological and 
affective states (competence and autonomy). Motivation may be either intrinsic (derived from 
inherent pleasure in a behavior or the challenge and novelty of the behavior) or extrinsic 
(controlled motivation resulting from external or self-evaluative pressures or integrated 
regulation-derived: identification and integration of aerobic exercise’s importance with 
personal beliefs and value). Further, autonomous motivation—intrinsic and integrated-
regulated extrinsic motivation—is proposed to be a key mediator of behavior change. 
Integration of the behavioral theories for exercise in cancer survivors. Self-efficacy as 
outlined in the SCT, and autonomous motivation, a key variable in the SDT, may act 
synergistically and/or through distinct mechanisms to influence one’s effort, persistence, 





exercise performance (E. I. Chen et al. 2015; Hartman et al. 2013; Hershman et al. 2016; Van 
Hoecke et al. 2013; Janssen et al. 2014; Knittle et al. 2015; Ryan and Deci 2000; Seretny et al. 
2014; Slovinec D’Angelo et al. 2014; Teixeira et al. 2015). Self-efficacy and mastery-bolstering 
self-regulation techniques may be particularly important in establishing short term exercise 
behaviors among chronic illness populations (Anderson-Bill, Winett, and Wojcik 2011; Ashford, 
Edmunds, and French 2010; Ayotte, Margrett, and Hicks-Patrick 2010; Bandura 2004; Hawkes et 
al. 2013; Knittle et al. 2015; Phillips and McAuley 2013; Slovinec D’Angelo et al. 2014; 
Swenson, Nissen, and Henly 2010; S. M. White, Wojcicki, and McAuley 2012). Further, cancer 
survivors who have previously reported fears of exercise injury, lack of confidence in physical 
abilities, and perceived limitations from ageing may particularly benefit from self-efficacy 
support (Henriksson et al. 2016; Mas, Quantin, and Ninot 2015).  
Autonomous motivation may moderate the influences of cancer survivor-reported 
barriers—loss of meaning, lack of motivation, coddling from friends and family, and fatigue—on 
ultimate exercise engagement (Courneya et al. 2005; Henriksson et al. 2016; Mas, Quantin, and 
Ninot 2015; Morielli, Usmani, Boule, Severin, et al. 2016). Some evidence suggests autonomous 
motivation predicts exercise behavior more strongly than self-efficacy (Littlecott et al. 2014) and 
may be the critical mediator between self-efficacy and long term exercise (Rothman et al. 2004; 
Sweet et al. 2009; H. E. Tulloch, Reid, and Fortier 2007).  
Finally, social networks—linked to vicarious experience (SCT), and relatedness (SDT)—
may be another key exercise-promoting factor (Anderson-Bill, Winett, and Wojcik 2011; Van 
Hoecke et al. 2013; Janssen et al. 2014; Rogers et al. 2005). Low- to no-cost group 





the evidence that suggests cold weather and exercise facility accessibility influence lower 
adherence to aerobic exercise interventions (Chou et al. 2017; Courneya, Segal, et al. 2014). 
Application of the behavioral theories to the MI-Walk Intervention. The MI-Walk 
Intervention employed motivational interviewing to bolster autonomous motivation, 
relatedness, and self-efficacy/competence through verbal persuasion (i.e., affirmation) 
(Hawkes et al. 2013; Spencer and Wheeler 2016; Swenson, Nissen, and Henly 2010). 
Additional autonomous motivation-facilitating techniques were also used: if-then 
implementation statements and SMART (specific, measurable, action-oriented, realistic, and 
time-based) goals (Apodaca and Longabaugh 2009; Miller and Rose 2009; Resnicow and 
McMaster 2012; Webber, Tate, and Quintiliani 2008; Ziegelmann et al. 2007).  Further, 
Fitbits, exercise logs, and progress summaries were used to promote sense of 
mastery/competence (Cadmus et al. 2009; Hawkes et al. 2013; Mock et al. 2005; Swenson, 
Nissen, and Henly 2010). The progress summaries targeted vicarious experience by providing 
individuals’ PA levels in comparison to their peers and facilitate self-efficacy (Ashford, 
Edmunds, and French 2010). Additionally, survivor exercise testimonies targeted vicarious 
experience/competence and an email group and weekly walking events targeted relatedness 
(Mas, Quantin, and Ninot 2015; Mock et al. 2005; Rogers et al. 2005). Finally, cancer 
treatment and exercise education were provided to support the last source of self-efficacy: 
adaptive perceived physiological and affective states (Hawkes et al. 2013; Mock et al. 2005; 
Spencer and Wheeler 2016; Swenson, Nissen, and Henly 2010).  
Self-efficacy, autonomous motivation, and perceived social support were not formally 
evaluated in this study due to its pilot nature and focus on testing the efficacy of aerobic 





sessions to rate their perceived level of importance and confidence in performing aerobic 
exercise during cancer treatment. Although not described in the dissertation, this data may be 
explored post-hoc. 
Specific Aims and Hypotheses 
The specific aims and hypotheses were to: 
Aim 1: Evaluate the effect of the MI-Walk Intervention on OIPN severity at eight weeks 
compared to PA education alone.  
Hypothesis: Participants who received the MI-Walk Intervention would exhibit less 
severe OIPN at eight weeks than participants who received PA education alone.  
Aim 2: Evaluate the effect of the MI-Walk Intervention on QOL and function at eight 
weeks compared to PA education alone. 
Hypothesis: Participants who received the MI-Walk Intervention would report higher 
QOL and physical and emotional function at eight weeks than participants who received PA 
education alone. 
Aim 3: Evaluate the feasibility of the MI-Walk Intervention. 
Research Questions: Among patients receiving FOLFOX, 1) how acceptable was the 
intervention? 2) what percent of patients enrolled in, completed, and adhered to the 
intervention? 3) what participant characteristics were associated with intervention uptake, 
completion, and acceptability and attained levels of MVPA? 4) What, if any, adverse events 






This chapter introduced the scope of the problem associated with CIPN, and aerobic 
exercise to potentially, non-pharmacologically prevent and/or ameliorate OIPN, a type of CIPN. 
It also described the formation of the theoretical framework for the study, based on the TOUS 
(Lenz et al. 1997), SCT (Bandura, 1986, 2004; Rogers et al., 2004, 2005; Stacey et al., 2015), 
SDT (Deci & Ryan, 1985; Ryan, 1991, 1995), and empirical evidence. Further, the specific aims 
and hypotheses of the proposed study were presented. The following chapter (Chapter II) will 
comprehensively outline the literature regarding the evidence supporting exercise as a treatment 
for various types of CIPN, including OIPN. Chapters III and IV will present the results of the 
dual-site pilot randomized-controlled study of the MI-Walk Intervention compared to PA 
education alone among GI cancer survivors who were actively receiving FOLFOX or 
FOLFIRINOX.  
Specifically, in Chapter III, results that address Aims one and two of this dissertation 
research are presented: effects of the MI-Walk Intervention on OIPN and QOL at eight weeks, 
compared to PA education alone. In Chapter IV, findings addressing Aim three are presented: the 
feasibility of the MI-Walk Intervention, including study enrollment and attrition rates, and 
intervention acceptability, uptake, and fidelity; and participant PA trends. The participant 
characteristics associated with completion and acceptability of the intervention as well as MVPA 
levels were also explored. Chapter V will close the dissertation with a summary of the results, 
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Review of the Literature 
 
Chemotherapy-induced peripheral neuropathy (CIPN) is among the most prevalent and 
debilitating side effects of cancer treatment. Approximately 60% of cancer survivors develop 
CIPN from neurotoxic chemotherapies, such as taxanes (paclitaxel, docetaxel), platinums 
(oxaliplatin, cisplatin, carboplatin), vinca alkaloids (vincristine, vinblastine, vinorelbine), 
bortezomib, and anti-angiogenesis agents (thalidomide, lenalidomide) (Banach, Juranek, and 
Zygulska 2017; Ventzel, Jensen, et al. 2016). These chemotherapies can damage the peripheral 
sensory, motor, and autonomic nerves and lead to CIPN manifestations: most commonly 
numbness, tingling, burning or shooting pain, extremity weakness, and loss of proprioception 
and deep tendon reflexes. Long-term pain and sensorimotor deficits associated with CIPN 
increase risk for falls and impair physical function and quality of life (QOL) (Bakitas 2007; 
Tofthagen et al. 2013). Thus, CIPN is a primary dose-limiting factor for patients who are 
receiving neurotoxic chemotherapy for the treatment of their cancer (Beijers et al. 2015). 
Currently, there are no evidence-based preventive or curative treatments for CIPN 
(Hershman et al. 2014; Majithia et al. 2016); however, some studies suggest exercise may be 
beneficial for other types of peripheral neuropathy (Quigley et al., 2014b, 2014a) and in treating 
other cancer-treatment-associated symptoms: pain, fatigue, mood, emotional distress, sleep 
disturbance, balance, and decreased QOL (Mustian et al. 2009; van Waart et al. 2015). Large 





CIPN (Greenlee et al. 2017; Mols et al. 2015). Exercise may attenuate CIPN through its 
influence on blood circulation/oxidative stress (Marcelino et al. 2013; Marques-Aleixo et al. 
2012), inflammation (Y.-W. Chen et al. 2014; S. B. Jones et al. 2013; Yoon et al. 2015), pain-
inhibiting neurotransmitters (Bobinski et al. 2015), endogenous opioids (Stagg et al. 2011), 
growth factors (Molteni et al. 2004), neuroplasticity (Taube, Gruber, et al. 2007), and coping and 
symptom interaction mechanisms (Cooper, Kluding, and Wright 2016; Courneya 2014; Peddle, 
Au, and Courneya 2008). Although exercise is recommended for cancer survivors (Buffart et al. 
2014), little is known about specific exercise prescriptions’ effectiveness in reducing CIPN and 
feasibility among individuals who have received neurotoxic chemotherapy. 
Purpose 
The purpose of this integrative review was to synthesize research literature published 
since 2006, reporting the effects of exercise interventions on CIPN and other relevant outcomes 
among previously or currently neurotoxic chemotherapy-receiving people of all age groups. In 
this population, the specific aims were to (a) investigate the effects of exercise and physical 
therapy on CIPN severity and related outcomes, (b) identify the exercise type, delivery mode, 
and dosage associated with superior participant adherence rates, and effects on CIPN, and (c) 
explore feasibility, including the rates and influencing factors of exercise intervention trial 
enrollment and completion, and adverse events. This review will add to the existing systematic 
reviews (Brayall et al. 2018; Duregon et al. 2018; Jung, Rein, and Fuchs 2018) by providing 
critical appraisal and numerical synthesis of the most recent literature to identify patterns among 
the sample characteristics; exercise types, dosages, and delivery settings; and CIPN and other 






PubMed, CINAHL, Scopus, PsycINFO, and SportDiscus were searched for all trials and 
meta-analyses that evaluated the effects of exercise on CIPN. Two re-iterations of the full search 
were conducted: first between May and November 2016 to evaluate the literature published from 
2006 to 2017, then in April 2019 to evaluate the literature published from 2017 to 2019. The 
authors preliminarily reviewed all literature published since database inception before 
conducting the full search and had identified that only the studies published since 2006 had 
evaluated peripheral neuropathy outcomes of exercise. Article references, ScienceDirect 
recommendations, PEDro, and select journals and grey-literature databases were hand-searched, 
including American College of Sports Medicine’s, Health & Fitness Journal, Advances in 
Physiotherapy, Human Kinetics and Neurology journals, clinicaltrials.gov, opengrey.eu, 
ProQuest Dissertations and Theses, and eric.edu.gov. The following keywords were used to find 
relevant studies: exercise, physical activity, physical therapy, physiotherapy, peripheral 
neuropathy, polyneuropathy, and neurotoxicity.  
Inclusion and Exclusion Criteria 
Articles were considered if they met all of the following inclusion criteria 1) randomized 
controlled trial (RCT), meta-analysis, or quasi-experimental (QE) design, 2) published within 
2006 to 2019, 3) human subjects of any age, 4) most (≥ 50%) participants had received or were 
receiving neurotoxic chemotherapy, 5) at least 10 participants, 6) tested exercise interventions, 
including physical therapy and exercise counseling, 7) measured CIPN outcomes, and 8) 
published in English.  Articles were excluded if they 1) were an abstract or protocol only, 2) 





splinting), and 3) tested concurrent non-exercise physiological interventions (e.g. drugs, 
supplements, transcutaneous electrical nerve stimulation).  
Data Abstraction and Measurement Strategy 
The following information was abstracted from the studies: 1) study design; 2) sample 
size; 3) sample characteristics (neuropathy and cancer type and grade/stage, age, gender, body 
mass index (BMI), and fitness/activity level);  4) intervention characteristics—type, prescribed 
dose and intensity, duration, and delivery settings; 5) control condition; 6) CIPN and related 
outcomes; 7) long-term post-intervention outcomes; 8) intervention adherence; 9) enrollment and 
completion rates; 10) reasons for participation refusal or discontinuation; and 8) adverse effects. 
Analysis/Quality Appraisal Methods 
All ns refer to the number of studies being quantified/described. Descriptive analyses 
were used to describe the sample and intervention characteristics. Multi-arm trials that lacked a 
true control condition (e.g., evaluated side-by-side physical interventions, or compared the 
intervention only to healthy controls) were analyzed as pre-posttest QE studies. Those classified 
as mixed sample studies included participants with mixed cancer types; and/or who were 
receiving various chemotherapy regimens. In cases where, the articles only provided ranges (and 
no means), the average of that range was used in this review’s descriptive analysis (e.g., 40 
minutes per day was used in the analysis for prescriptions of 30-50 min per day).  
Regarding the exercise type, studies of functional and sensorimotor training were 
grouped in with balance training due to the similarity in their methods and intentions. One 
intervention focused on elastic band training and increasing step counts was categorized as an 





The efficacy of the interventions on/among various outcomes and populations were 
evaluated based on the percentage of studies that showed clinically (≥ 30% difference) (Farrar et 
al. 2001) and statistically (p ≤ .05) significant effects for each outcome. Effect sizes were 
considered in the synthesized outcome discussion if provided by the studies. This review only 
presents results on outcomes that were evaluated in at least three studies. Two studies—from 
which only pre-posttest results were gleanable in active neurotoxic chemotherapy-receiving 
individuals with no baseline CIPN—were excluded from the dichotomous quantification of 
outcomes (1, significant improvement; 0, no improvement), because they had no room for 
improvement. Description and further explanation for the exclusion of these studies are provided 
in the Outcome measures and results section. 
Critical appraisal. The articles were critically appraised by the primary author using the 
CONSORT checklist.(Schulz et al. 2011) The author categorized studies as having a low or 
moderate risk of bias if the study met key CONSORT criteria and did not present with other 
critical confounding factors. No studies met 100% of the criteria; thus, the in-depth critical 
appraisal and results from all eligible studies are described below. 
Results 
Figure II.1 is a flowchart of the literature search. The search yielded 758 results from the 
databases and 4 from hand-searching. Studies were mostly excluded because they did not 
evaluate a CIPN outcome or did not test an active exercise intervention. Ultimately, 13 studies (7 
RCTs (Dhawan et al. 2019; Henke et al. 2014; Kleckner et al. 2018; Streckmann et al. 2018; 
Streckmann, Kneis, et al. 2014; Vollmers et al. 2018; Zimmer et al. 2018) and 6 QE studies 





2014; Fernandes and Kumar 2016; McCrary et al. 2019; Mizrahi et al. 2015; Wonders 2014)) 
remained and are summarized in Table II.1.  
 
Figure II.1 









































    





























(n = 4) 
Total search yield 
(n = 758) 
Records screened after 
duplicates removed 
(n = 630) 
Records excluded 
(n = 610) 
Full-text articles assessed 
for eligibility 
(n = 22) 
Full-text articles excluded, 
with reasons 
(n = 15) 
- No CIPN outcome (n = 2) 
- Non-exercise trial (n = 9) 
- Study protocol only (n = 2) 
- Abstract only (n = 2) 
Articles included  
(n = 14; 13 studies) 
CINAHL 
(n = 268) 
PubMed 
(n = 85) 
Scopus 
(n = 327) 
PsycINFO 
(n = 78) 
May-Nov. 2016 review 





Table II.1  














No baseline CIPN 
(N = 301) 
Intervention: 3 days/week; 16-32 weeks (duration of 
chemo); vigorous intensity; clinic 
1. STAN – Standard Aerobic; 75-90 min/week 
(25-30 min/day); 55-75% VO2peak 
2. HIGH – High-Dose Aerobic; 150-180 
min/week (50-60 min/day); 55-75% VO2peak 
3. COMB – Aerobic + Strength; 150-180 
min/week (25-30 min/day aerobic at 55-75% 
VO2peak; 8 strength tasks, 2 sets of 10-12 reps 
each, 60-75% 1RPM)  
 
Measurement Timepoints: Baseline (chemo start); 
1/3 & 2/3 mid-chemo; post-intervention (3-4 weeks 
post-chemo); and 6, 12, & 24 months post-chemo 
Pre-Post Test Results: CIPN (FACT-Taxanev all groups), 
Pain (SF-36^ HIGH; - STAN), Physical Function & QOL 
(SF-36v all groups), Fitness (lower body^ COMB, upper 
body^ STAN & COMB, VO2peakv all groups), Other Sx 
(FACTv all groups) 
Key Inter-Group Results: HIGH beneficial for pain 
and better at blunting the worsening in VO2peak 
compared to COMB. COMB-induced strength 





Chemo type NR 
Established CIPN 
(N = 25) 
 
Intervention: 3 weeks in clinic  
   Balance - 60 min/week (7 tasks; 2-3 sets of 10 reps 
       12 min/day; 5 days/week);  
 
Measurement Timepoints: Baseline & 3 weeks 




Balance 4-arm RCT 
Mixed chemo types 
Established CIPN 
(N = 40) 
Intervention: 6 weeks in clinic 
   Balance - 23 min/week (4 tasks; 3 sets of 20 s  
      11-12 min/day; 2 days/week) 
Comparison: Whole Body Vibration 
Control 1: No intervention; patients with CIPN 
Control 2: No intervention; healthy age/gender-matched 
 
Measurement Timepoints: Baseline & 6 weeks 
Results: CIPN (tendon reflexes^, vibration 
sensitivity^, light touch perceptionn.d., 
proprioceptionn.d., LE strengthn.d., FACT/GOG-
NTXn.d., NCSn.d.) 





Mild-no baseline CIPN 
(N = 29) 
Intervention: Over 3 chemo cycles (9-12 weeks) in 
clinic 
   Aerobic - 40 min/week (8 min/day, 5 days/week); 
       moderate intensity (55-70% HRreserve) 
   Strength – 4 tasks; 3 sets of 10 reps; 50% repsmax 
Control: Conventional Physiotherapy 
 
Measurement Timepoints: Baseline & post-
intervention (after 3 cycles of chemo) 
Results: CIPN & Pain (QLQ-C30/LC-13 PN item^), 
Physical Function (Barthel Index^) & QOL (QLQ-
C30/LC-13n.d.), Fitness (6MWT^, stair walking^, 












No baseline CIPN 
(N = 355) 
Intervention: 6 weeks at home 
   Aerobic – Increase mean daily step count 5-20% 
      each week 
   Strength – 10-14 tasks; max 4 sets of 15 reps;  
      RPE 3-5 (3 progressive resistance elastic bands 
      provided) 
Control: No exercise 
 
Measurement Timepoints: Baseline (pre-chemo) & 6 
weeks 







Taxane or vinorelbinea 
Baseline CIPN present 
(N = 38) 
Intervention: 12 weeks in clinic; 2 days/week 
   Aerobic – 50 min/week (20-30 min/day); moderate 
      intensity (40-60% VO2max) 
   Strength 2-3 sets of 10-12 reps 
Measurement Timepoints: Baseline & 12 weeks 
Results: CIPN (Leeds Assessment of Neuropathic 
Symptoms and Signs^), Physical Function 
(flexibilityn.d.), QOL (McGill QOL^), Fitness 










Baseline CIPN present 
(N = 46) 
Intervention: 10 weeks at home; 7 days/week 
   Strength – 8 tasks (20 min lying and sitting 
      tasks); light intensity (body weight only) 
   Balance – 4 tasks (10 min) 
Control: Usual Care 
 
Measurement Timepoints: Baseline & 10 weeks 
Results: CIPN (CIPNAT^, NCSNR), Pain (Leeds 










Unclear baseline CIPN 
presence 
(N = 36) 
Intervention: Duration and through 6 weeks post 
completion of chemo in clinic; 2 days/week 
   Strength – 6 tasks (2 sets of 20 reps); moderate 
      intensity (RPE 13-15) 
   Balance – no dose specified 
Control: Pamphlet about physical activity & cancer 
 
Measurement Timepoints: Baseline (pre-chemo) & 
post-intervention (6 weeks post-chemo completion) 
Results: CIPN (EORTC QLQ CIPN20n.d.), QOL 
(QLQ-C30n.d., EORTC-BR23n.d.), Balance 
(Posturometry sway area^, Fullerton Advanced 
Balance Scale PRO^), Fitness (Hand dynamometer^, 









Mixed chemo types 
Established CIPN 
(N = 29) 
Intervention: 8 weeks in home & clinic; 3 days/week 
   Aerobic - 60 min/week (20 min/day); moderate 
      intensity (RPE 13-15) 
   Strength – 4 tasks (2 sets/task  20 min/day) 
   Balance – 4 tasks (2 sets of 15-30s or 8 reps/task 
       20 min/day) 
Measurement Timepoints: Baseline (pre-control 
period), pre-intervention (8 weeks), & post-
intervention (16 weeks) 
Results: CIPN (TNSc^, EORTC QLQ CIPN20^, 
NCSn.d.), Physical Function (6MWT^, CIPN-R-
ODS^), QOL (SF-36^), Balance (Swaymeter^), 














Baseline CIPN present 
(N = 21) 
Intervention: 12 weeks at home; 3-4 days/week; 90 
min/week (10-30 min/day) 
   Aerobic – light-moderate intensity (55-70% HRmax) 
   Strength – 3 sets of 10 reps; light-moderate 
      intensity (RPE 11-14) 
   Balance – For those with severe CIPN or balance 
      issues only 
Measurement Timepoints: Baseline, 12 weeks (post-
intervention), & 24 weeks  
Results: CIPN (FACT/GOG-NTXn.d.); Physical 
Function (30 s sit-to-stand test^, SF-36^), QOL 
(FACT-O^); Balance (Single-leg balance test^); 
Fitness (10 rep max test^, submaximal aerobic 
capacity testn.d.); Physical Activity Behavior 
(IPAQ^); Fatigue (SPHERE^); Other measures 









Mixed chemo typesa 
Unclear baseline CIPN 
presence 
(N = 61) 
Intervention: 36 weeks in clinic; 2 days/week 
   Aerobic – 20-60 min/week (10-30 min/day); 
      vigorous intensity (60-80% HRmax) 
   Strength – 4 tasks (5 min/day); vigorous intensity 
      (max force for 1 minute) 
   Balance – 4 tasks (3 sets of 20 s  10 min/day) 
 
Measurement Timepoints: Baseline (pre-chemo); 12, 
24, & 36 weeks 
Results: CIPN (Vibration sensitivity^), Pain (QLQ-
C30 pain itemn.d.), QOL (QLQ-C30n.d.), Balance 










Baseline CIPN present 
(N = 30) 
Intervention: 8 weeks in clinic; 2 days/week 
   Aerobic – 20 min/week (10 min/day); moderate 
      intensity (60-70% HRmax) 
   Strength – 5 tasks (2 sets of 8-12 reps  20 
      min/day); moderate intensity (60-80% 1RM) 
   Balance – 4 tasks (15 min/day)  
Control: Waitlist 
 
Measurement Timepoints: Baseline, post-
intervention (8 weeks), & 12 weeks 
Results: CIPN (FACT/GOG-TOI^, NTX^); Balance 
(Gleichgewichtstest^); Strength (hypothetical 
1RM^); Endurance (6MWTn.d.) 
Clark (2012) Yoga 4-arm RT 
Platinums 
Established CIPN 
(N = 26) 
Intervention: 6 weeks in clinic; group-based  
   Yoga - 60 min/week (60 min/day, 1 day/week); 
       low intensity 
Comparison: Reiki or meditation 
Control: Education 
Measurement Timepoints: Baseline & 6 weeks 
Results: CIPN (FACT/GOG-Ntxn.d.), QOL 
(FACT/GOG-Ntxn.d., BSIn.d., Mindful Attention 
Awareness Scalen.d.) 
Abbreviations. ^, significant result in favor of the intervention; v, significant result in opposition of the intervention; n.d., no difference in the outcome; 6MWT, Six Minute Walk 
Test; 1RM, one repetition max; BBS, Berg Balance Scale; BR23, Breast Cancer Module; BSI, Brief Symptom Inventory; CIPN, chemotherapy-induced peripheral neuropathy; 
CIPN20, chemotherapy-induced peripheral neuropathy module; CIPNAT, CIPN Assessment Tool; CIPN-R-ODS, CIPN Rasch Built Overall Disability Score; EORTC, European 
Organisation for Research and Treatment of Cancer; FACT, Functional Assessment of Cancer Therapies; FACT-O, FACT Ovarian Cancer module; GOG-Ntx, Gynecologic 
Oncology Group Neurotoxicity Scale; IPAQ, International Physical Activity Questionnaire; LC-13, lung cancer module; LE, lower-extremity; max, maximum; MFI, 
Multidimensional Fatigue Inventory; mTNS©, Modified Total Neuropathy Score; NCS, nerve conduction studies; NR, not reported; NRS, Numerical Rating Scale 0-10; PSQI, 
Pittsburgh Sleep Quality Index, PN, peripheral neuropathy; rep, repetitions; PRO, patient-reported outcome; QE, quasi-experiment; QLQ-C30, Quality of Life survey; QOL, 
quality of life; RCT, randomized controlled trial; RPE, rating of perceived exertion; RT, randomized trial; SF-36, Medical Outcome Study Short Form 36; SPHERE, Somatic and 
Psychological Health Report questionnaire; Sx, symptoms; TNSc, Total Neuropathy Score-Clinical; TOI, Trial of Outcome Index. 





Table II.2 presents the critical appraisal results of the studies’ risks of scientific bias. 
CIPN was the primary outcome in five studies (Dhawan et al. 2019; McCrary et al. 2019; 
Streckmann et al. 2018; Wonders 2014; Zimmer et al. 2018). All but 2 studies (McCrary et al. 
2019; Streckmann et al. 2018) had a high risk of bias. The first study rated to have a moderate 
risk of bias by McCrary et al. (2019) tested an aerobic+strength+balance training intervention. 
The second “moderate-risk” study by Streckmann et al. (2018) tested a sensorimotor (balance) 
training intervention. The strengths of these “moderate-risk” studies included employment of 
both clinical and patient-reported outcome (PRO) measures to assess CIPN as the primary 
outcome and enrollment of individuals who had established clinically- and patient report-
confirmed chronic CIPN. Despite small sample sizes (N = 40 split into 4 groups (Streckmann et 
al. 2018), and N = 29 (McCrary et al. 2019)), both studies found significant CIPN benefits. 
However, both the McCrary et al. (2019) and Streckmann et al. (2018) studies had 
significant limitations. The McCrary et al. QE study lacked report of the qualification and 
blinding of the individual who performed the clinical CIPN assessments (McCrary et al. 2019). 
The Streckmann et al. study lacked report of inter-rater reliability for the CIPN clinical 
assessments (Streckmann et al. 2018). Instead of using a validated measure like the Total 
Neuropathy Score (TNS©) (Guido Cavaletti et al. 2006; Chaudhry et al. 1994; Cornblath et al. 
1999), clinical signs of CIPN (e.g., tendon reflexes) were evaluated separately without clear use 
of an established, reproducible, grading rubric (Streckmann et al. 2018). Finally, their PRO 
neuropathic pain (PainDETECT) data is likely unreliable due to missing data (likely from 





Table II.2  
Risk of Scientific Bias of the Studies 
























+ -- N/A + + N/A ? + + -- + Mod 
Streckmann (2018) 
 
          + + + -- + + + + + + + Mod 
Zimmer (2018) 
 
+ + + + + + -- + + + + Highe 
Dhawan (2019) 
 
+ + + + + -- ? -- + + + High 
Wonders (2014) 
 
+ -- N/A ? + N/A -- -- + -- ? High 
Clark (2012) 
 
-- + + -- + + ? + + + + Highe 
Courneya (2013; 2014) 
 
  -- + + + -- + -- -- + + + High 
Fernandes (2016) 
 
-- -- N/A -- + N/A -- + ? ? -- High 
Henke (2014) 
 
-- + + -- -- -- ? -- -- -- + High 
Kleckner (2018) 
 
-- + + + + + -- -- + ? + High 
Mizrahi (2015) 
 
-- -- N/A -- -- N/A -- + -- -- + High 
Streckmann (2014) 
 
          -- + + -- -- + + + + + + High 
Vollmers (2018) -- + + ? + -- ? + + -- + High 
Abbreviations. +, criteria met; --, criteria not met; ?, unclear whether the criteria was met; CIPN, chemotherapy-induced peripheral neuropathy; COI, conflict of interest; ITT, 
intention-to-treat analysis; Mod, moderate; PRO, patient-reported outcome; RCT, randomized controlled trial. 
aThe study had to meet this criteria to be categorized “low” risk of bias;  
bThe study had to meet this criteria to be categorized “mod” risk of bias. 
cAll participants had and/or were at risk for developing CIPN; patients with other types of peripheral neuropathy and/or who were receiving other neurotoxic drugs were 
excluded; and no potential critical selection bias (e.g., enrollment rate ≥50%; all accessible eligible patients were offered the chance to participate (e.g., no physician referrals of 
just the “pleasant” or ”compliant” patients); no significant differences between participants who enrolled and did not enroll in, or were analyzed vs. withdrew from the study). 
dStudies needed to report assessor blinding to be considered moderate; and assessor and interventionist blinding to be considered low risk of bias. Lack of assessor blinding was 
disregarded if the CIPN outcome was a PRO. 





Most other studies lacked assessor blinding (Clark, Cortese-Jimenez, and Cohen 2012; 
Courneya et al. 2013; Courneya, McKenzie, et al. 2014; Dhawan et al. 2019; Fernandes and 
Kumar 2016; Henke et al. 2014; Kleckner et al. 2018; McCrary et al. 2019; Mizrahi et al. 2015; 
Vollmers et al. 2018; Wonders 2014; Zimmer et al. 2018) and sufficient power (Clark, Cortese-
Jimenez, and Cohen 2012; Fernandes and Kumar 2016; Henke et al. 2014; Mizrahi et al. 2015; 
Streckmann et al. 2018; Streckmann, Kneis, et al. 2014; Vollmers et al. 2018; Wonders 2014). 
Few studies utilized either a strong PRO (Clark, Cortese-Jimenez, and Cohen 2012; Vollmers et 
al. 2018; Zimmer et al. 2018) or clinical assessment (Fernandes and Kumar 2016) CIPN 
measure; even fewer used both a strong PRO and clinical assessment CIPN measure (Dhawan et 
al. 2019; McCrary et al. 2019; Streckmann et al. 2018). No studies of CIPN as a 
secondary/exploratory outcome reported error rate adjustment to avoid the risk of statistical 
fishing bias (Clark, Cortese-Jimenez, and Cohen 2012; Courneya et al. 2013; Courneya, 
McKenzie, et al. 2014; Fernandes and Kumar 2016; Henke et al. 2014; Kleckner et al. 2018; 
Mizrahi et al. 2015; Streckmann, Kneis, et al. 2014; Vollmers et al. 2018). All 13 studies lacked 
control for potential confounding factors, including peripheral neuropathy-related comorbidities 
(e.g., diabetes, peripheral arterial disease, and vitamin B deficiency); heterogeneity of the sample 
in CIPN presence, severity, and stability at baseline; chemotherapy status, regimen, and duration; 
and other psychological mediators/moderators (e.g., mood). Further, all the studies lacked report 
of or control for the participants’ intervention adherence and/or outside exercise/physical activity. 
Sample Characteristics 
The study sample sizes referenced above ranged from 21 to 355 participants. Average 
participant age was 55.6 (range = 18- 81) years (n = 12); BMI, 25.62 kg/m2 (n = 7); and percent 





generally below average. Study participants had stage I to IV (mostly breast) cancer; and had 
received (Clark, Cortese-Jimenez, and Cohen 2012; Fernandes and Kumar 2016; McCrary et al. 
2019; Streckmann et al. 2018) or were actively receiving (Courneya et al. 2013; Dhawan et al. 
2019; Henke et al. 2014; Kleckner et al. 2018; Mizrahi et al. 2015; Streckmann, Kneis, et al. 
2014; Vollmers et al. 2018; Wonders 2014; Zimmer et al. 2018) primarily taxane- (Courneya et 
al. 2013; Courneya, McKenzie, et al. 2014; Dhawan et al. 2019; Vollmers et al. 2018; Wonders 
2014) or platinum-based (Clark, Cortese-Jimenez, and Cohen 2012; Henke et al. 2014; Zimmer 
et al. 2018), or mixed types of chemotherapy (Kleckner et al. 2018; McCrary et al. 2019; Mizrahi 
et al. 2015; Streckmann et al. 2018; Streckmann, Kneis, et al. 2014). Few studies focused on one 
type of cancer and chemotherapy (Courneya et al. 2013; Courneya, McKenzie, et al. 2014; 
Henke et al. 2014; Mizrahi et al. 2015; Streckmann, Kneis, et al. 2014; Vollmers et al. 2018; 
Zimmer et al. 2018). Baseline CIPN was chronic and moderate-severe (n = 4) (Clark, Cortese-
Jimenez, and Cohen 2012; Fernandes and Kumar 2016; McCrary et al. 2019; Streckmann et al. 
2018), absent/mild (n = 3) (Courneya et al. 2013; Courneya, McKenzie, et al. 2014; Kleckner et 
al. 2018; Vollmers et al. 2018), or mixed/acute/unclearly specified (n = 5) (Dhawan et al. 2019; 
Henke et al. 2014; Mizrahi et al. 2015; Streckmann, Kneis, et al. 2014; Wonders 2014; Zimmer 
et al. 2018).  
Exercise Interventions 
Six different types of  exercise were tested in the 13 studies: yoga (Clark, Cortese-
Jimenez, and Cohen 2012), and exercise with aerobic (n = 7) (Courneya et al. 2013; Courneya, 
McKenzie, et al. 2014; Henke et al. 2014; Kleckner et al. 2018; McCrary et al. 2019; Mizrahi et 
al. 2015; Streckmann, Kneis, et al. 2014; Wonders 2014; Zimmer et al. 2018), strength (n = 9) 





Kleckner et al. 2018; McCrary et al. 2019; Mizrahi et al. 2015; Streckmann, Kneis, et al. 2014; 
Vollmers et al. 2018; Wonders 2014; Zimmer et al. 2018), and balance (n = 7) training 
components (Dhawan et al. 2019; Fernandes and Kumar 2016; McCrary et al. 2019; Mizrahi et 
al. 2015; Streckmann et al. 2018; Streckmann, Kneis, et al. 2014; Vollmers et al. 2018; Zimmer 
et al. 2018). The interventions in all but three—one yoga (Clark, Cortese-Jimenez, and Cohen 
2012), and two balance training alone (Fernandes and Kumar 2016; Streckmann et al. 2018)—
studies were multimodal: varied combinations of aerobic, strength, and balance training. 
Aerobic+strength (Courneya et al. 2013; Courneya, McKenzie, et al. 2014; Henke et al. 2014; 
Kleckner et al. 2018; Wonders 2014), and aerobic+strength+balance (McCrary et al. 2019; 
Mizrahi et al. 2015; Streckmann, Kneis, et al. 2014; Zimmer et al. 2018) exercises were the most 
common interventions.  
Dosages. The mean exercise prescription characteristics included 107.61 (23-210) 
minutes per week, over 3.42 (1-7) days per week, for a duration of 11.68 (3-36) weeks. Seven 
interventions encouraged moderate- to vigorous-intensity (50%-80% heart rate 
maximum/reserve, 40%-75% VO2peak, or Borg rating of perceived exertion [RPE] of 13-15) 
exercise (Courneya et al. 2013; Courneya, McKenzie, et al. 2014; Henke et al. 2014; McCrary et 
al. 2019; Streckmann, Kneis, et al. 2014; Vollmers et al. 2018; Wonders 2014; Zimmer et al. 
2018). 
The most common aerobic exercise dosages prescribed were 20 to 30 minutes per session 
of moderate- to vigorous-intensity physical activity, two to five days per week. The total 
prescribed weekly doses (20-165 min per week) and durations (6-36 weeks) of the aerobic 
interventions varied. The strength training dosages ranged from 4 strength training tasks (3 sets 





(Kleckner et al. 2018) performed at light to moderate-intensity two to seven days per week 
(Courneya et al. 2013; Courneya, McKenzie, et al. 2014; Dhawan et al. 2019; Henke et al. 2014; 
Kleckner et al. 2018; McCrary et al. 2019; Streckmann, Kneis, et al. 2014; Vollmers et al. 2018; 
Wonders 2014; Zimmer et al. 2018). Balance training sessions were most commonly 10 to 12 
minutes in duration (Dhawan et al. 2019; Fernandes and Kumar 2016; Streckmann et al. 2018; 
Streckmann, Kneis, et al. 2014) and involved four (Dhawan et al. 2019; McCrary et al. 2019; 
Streckmann et al. 2018; Streckmann, Kneis, et al. 2014; Zimmer et al. 2018), 15- to 30-second 
(McCrary et al. 2019; Streckmann et al. 2018; Streckmann, Kneis, et al. 2014) balance training 
tasks repeated two to three times each (Fernandes and Kumar 2016; McCrary et al. 2019; 
Streckmann et al. 2018; Streckmann, Kneis, et al. 2014; Zimmer et al. 2018). 
Delivery setting. All but four studies (Dhawan et al. 2019; Kleckner et al. 2018; McCrary 
et al. 2019; Mizrahi et al. 2015) were conducted in a clinical setting. One intervention was 
delivered by group (Clark, Cortese-Jimenez, and Cohen 2012).  
Control Conditions 
 The most common control conditions were no exercise/usual care (Dhawan et al. 2019; 
Henke et al. 2014; Kleckner et al. 2018; Streckmann et al. 2018; Streckmann, Kneis, et al. 2014) 
or health education (Clark, Cortese-Jimenez, and Cohen 2012; Vollmers et al. 2018). One four-
arm study evaluated a balance training intervention compared to whole body vibration, no 
intervention, and age- and gender-matched healthy controls (Streckmann et al. 2018); and 
another four-arm study evaluated yoga compared to reiki, meditation, or health education (Clark, 
Cortese-Jimenez, and Cohen 2012). One three-arm study evaluated three exercise interventions 





Outcome Measures and Results  
Table II.3 contains a list of the most common outcome variables evaluated, the n that 
evaluated that outcome, and the percentage of studies that showed outcome improvement. 
Balance, fitness, and CIPN outcomes improved most consistently. Given the dichotomous 
quantification (improvement or no improvement) in the tables, two pre-posttest QE studies of 
individuals in active neurotoxic chemotherapy treatment without baseline CIPN were excluded, 
because the participants had no room for improvement (Courneya et al. 2013; Mizrahi et al. 
2015).  
Table II.3  
Outcomes Measured and Frequency of Positive Effects in the Studies 
 All Studies (N=11)a 
Outcome Variable Frequency (n) 
Positive Effectsb 
(n [%]) 
CIPN 11 9 (82) 
Pain 4 2 (50) 
Balance 6 6 (100) 
PF 3 2 (67) 
QOL 8 4 (50) 
Fitness 6 6 (100) 
Other symptomsc 3 2 (67) 
Abbreviations. CIPN, chemotherapy-induced peripheral neuropathy; PF, physical function; QOL, quality of life. 
aThe results from two pre-posttest quasi-experiments in individuals actively receiving neurotoxic chemotherapy could not be 
interpreted dichotomously, and thus, excluded from this table.40,44,45 
bA study was considered to have demonstrated positive effects if the intervention was statistically significantly (p ≤ .05) 
beneficial for the outcome pre-posttest or between groups. 
cOther symptom outcomes included fatigue, cognitive impairment, endocrine symptoms, and hemoptysis. 
 
CIPN outcomes. Table II.4 lists the n and percentage of studies that demonstrated 
statistically significant (p < .05) outcome improvement by sample characteristic. Five (83%) 
studies demonstrated clinically significant (≥ 30%) intervention group-favoring intergroup 
differences in PRO-surveyed (Dhawan et al. 2019; Henke et al. 2014; Kleckner et al. 2018; 
Zimmer et al. 2018) and clinically assessed CIPN (Streckmann, Kneis, et al. 2014) among 





(Henke et al. 2014; Kleckner et al. 2018; Zimmer et al. 2018). Clinically significant pre-post-
intervention CIPN improvements were also demonstrated, using clinical assessments (Fernandes 
and Kumar 2016; Streckmann et al. 2018) and PRO surveys (Dhawan et al. 2019; Streckmann et 
al. 2018) in patients with baseline CIPN (Dhawan et al. 2019; Fernandes and Kumar 2016; 
Streckmann et al. 2018). Although not clinically significant, two studies showed moderate 
statistically significant improvements in CIPN, measured by the TNS©-Clinical version (24.29% 
improvement; p = .001) (McCrary et al. 2019), European Organisation for Research and 
Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) CIPN20 module (27.17% 
improvement; p < .001) (McCrary et al. 2019), and Leeds assessment of neuropathic symptoms 
and signs (no effect size reported) (Wonders 2014). Nerve conduction studies—often considered 
a diagnostic tool for peripheral neuropathy—did not detect significant effects, even though 
clinical assessment and PRO surveys of CIPN did (Dhawan et al. 2019; McCrary et al. 2019; 
Streckmann et al. 2018). One study among individuals with baseline chronic CIPN, showed that 
clinically assessed CIPN values recovered to a level that matched healthy age- and gender-







Synthesis of Outcomes by Sample Characteristic (n = 11)a 
Population n Studies 




  CIPN Pain PF QOL Balance Fitness  
Chemotherapy Type  (n+ [%])b (n+/nmo [%])b Mean (n) 
   Taxane-primaryc 3 2 (67) 1/1 (100) 0/1 2/3 (67) 1/1 (100) 2/2 (100) 67.5 (n=1) 89.4 (n=3) 
   Platinums 3 2 (67) 1/1 (100) 1/1 (100) 0/2 1/1 (100) 2/2 (100) 88.3 (n=1) 71.7 (n=3) 
   Mixed or Not 
Reported 
5 5 (100) 0/2 1/1 (100) 2/3 (67) 4/4 (100) 2/2 (100) 75 (n=3) 89 (n=4) 
Chemotherapy Status          
   Active 7 6 (86) 2/3 (67) 1/2 (50) 3/5 (60) 3/3 (100) 5/5 (100) 74.5 (n=4) 83.8 (n=7) 
   Completed 4 3 (75) 0/1 1/1 (100) 1/3 (33) 3/3 (100) 1/1 (100) 83.1 (n=1) 84.2 (n=3) 
CIPN Status at 
Baseline 
         
   Little-None 2 1 (50) -- -- 0/1 1/1 (100) 1/1 (100) 77 (n=1) 84.1 (n=2) 
   Some with acute CIPN 5 4 (100) 1/2 (50) 1/2 (50) 2/3 (67) 2/2 (100) 4/4 (100) 76.7 (n=2) 81.8 (n=4) 
   Established moderate- 
      severe CIPN 
4 3 (75) 0/1 1/1 (100) 1/3 (33) 3/3 (100) 1/1 (100) 83.1 (n=1) 84.2 (n=3) 
Sample Sizes          
   < 30 4 3 (75) 1/1 (100) 2/2 (100) 1/3 (33) 2/2 (100) 2/2 (100) 83.1 (n=1) 72.7 (n=3) 
   30-50 5 4 (80) 1/2 (50) 0/1 2/4 (50) 3/3 (100) 3/3 (100) 77.9 (n=2) 89.1 (n=5) 
   > 50 2 2 (100) 0/1 -- 1/1 (100) 1/1 (100) 1/1 (100) 71 (n=2) 87.8 (n=2) 
Abbreviations. --, no study measured the specified outcome; CIPN, chemotherapy-induced peripheral neuropathy; PA, physical activity; PF, physical function; QOL, quality of 
life. 
aThe results from two pre-posttest quasi-experiments in individuals actively receiving neurotoxic chemotherapy could not be interpreted dichotomously, and thus, excluded from 
this table.40,44,45 
b(n+/nmo [%]) = n positive studies over n studies that measured the specified outcome. 





Among individuals actively receiving chemotherapy, those with acute baseline CIPN 
showed no progression (Mizrahi et al. 2015; Zimmer et al. 2018) or significant improvement of 
CIPN (p < .05) (Dhawan et al. 2019; Wonders 2014); but those with no baseline CIPN 
demonstrated significant development/worsening of CIPN over time (Courneya et al. 2013; 
Henke et al. 2014; Kleckner et al. 2018). Regardless of baseline CIPN status, intergroup 
outcomes were often better in the intervention than the control groups in individuals receiving 
chemotherapy (Dhawan et al. 2019; Henke et al. 2014; Kleckner et al. 2018; Streckmann, Kneis, 
et al. 2014; Zimmer et al. 2018). 
 Table II.5 lists the n and percentage of studies that demonstrated statistically significant 
outcome improvement by exercise intervention characteristic. Statistically significant CIPN 
benefits were found in all studies of home-based interventions (Dhawan et al. 2019; Kleckner et 
al. 2018; McCrary et al. 2019); and those with an aerobic exercise component (Henke et al. 
2014; McCrary et al. 2019; Streckmann, Kneis, et al. 2014; Vollmers et al. 2018; Wonders 2014; 
Zimmer et al. 2018), dosages, ≥ 100 minutes per week of exercise (Dhawan et al. 2019; Kleckner 
et al. 2018; McCrary et al. 2019; Streckmann, Kneis, et al. 2014; Zimmer et al. 2018), and/or 
durations of eight to 12 weeks (Dhawan et al. 2019; Henke et al. 2014; McCrary et al. 2019; 
Wonders 2014; Zimmer et al. 2018). All interventions with only balance training led to large 
clinically significant improvements in established CIPN (Fernandes and Kumar 2016; 
Streckmann et al. 2018). However, some studies of clinic-based interventions (Fernandes and 
Kumar 2016; Henke et al. 2014; Streckmann et al. 2018; Streckmann, Kneis, et al. 2014; 
Wonders 2014; Zimmer et al. 2018); and those of doses less than 100 (as low as 22.66) minutes 
per week also demonstrated statistically significant CIPN benefits (Fernandes and Kumar 2016; 





three weeks (Fernandes and Kumar 2016) and aerobic+strength training for as low as six weeks 
in duration resulted in statistically significant CIPN benefits (Kleckner et al. 2018).  
Focusing on the eight aerobic intervention studies, moderate-large intergroup (Henke et 
al. 2014; Kleckner et al. 2018; Streckmann, Kneis, et al. 2014; Zimmer et al. 2018) and small 
pre-posttest (McCrary et al. 2019; Zimmer et al. 2018) CIPN benefits—measured by PRO 
(Henke et al. 2014; Kleckner et al. 2018; McCrary et al. 2019; Wonders 2014; Zimmer et al. 
2018) and clinical assessments (McCrary et al. 2019; Streckmann, Kneis, et al. 2014)—were 
demonstrated among patients mostly in active treatment with various neurotoxic chemotherapy 
types (Henke et al. 2014; Kleckner et al. 2018; Streckmann, Kneis, et al. 2014; Wonders 2014; 
Zimmer et al. 2018). The interventions that led to large intervention-favoring CIPN benefits 
(40%-141% difference between groups) all were of moderate-vigorous intensity (55%-70% of 
heart rate reserve or 60%-80% of heart rate maximum). The one home, step-count prescription-
based intervention led to moderate intervention-favoring CIPN benefits (34% difference) 
between groups (Kleckner et al. 2018). Various doses (20-60 minutes per week; 8-30 minutes per 
day), frequencies (2-5 days per week), and durations (6-36 weeks) of aerobic exercise led to 
moderate-large clinically significant benefits. No studies tested (in comparison to a control 
condition) an aerobic exercise dose greater than 60 minutes per week. Of note, one study that had 
no control condition found no differences in FACT-Taxane-measured CIPN outcomes between 
prescriptions of 25 to 30 minutes and 50 to 60 minutes per day of vigorous-intensity aerobic 
exercise three days per week throughout chemotherapy (over 16-32 weeks) (Courneya et al. 






Synthesis of the Outcomes by Exercise Intervention Characteristic (n = 11)a 
Exercise  n Papers Positive Effects Adherence Rate Completion Rate 






Typec  (n+ [%])b (n+/nmo [%])b Mean (n) 
   Aerobic Component 6 6 (100) 1/2 (50) 2/3 (67) 3/4 (75) 3/3 (100) 5/5 (100) 78.8 (n=3) 84.49 (n=5) 
   Strength Component 8 7 (88) 2/3 (67) 2/3 (67) 4/6 (67) 4/4 (100) 6/6 (100) 76 (n=4) 83.6 (n=7) 
   Balance Component 7 6 (86) 1/3 (33) 1/1 (100) 3/5 (20) 6/6 (100) 4/4 (100) 80.3 (n=5) 87.7 (n=6) 
   Yoga 1 0 -- -- 0/1 -- -- -- 72 (n=1) 
   Balance Alone 2 2 (100) 0/1 -- 0/1 2/2 (100) -- -- 97.5 (n=1) 
   Aerobic+Strength 3 3 (100) 1/1 (100) 1/2 (50) 1/2 (50) -- 2/2 (100) -- 78.2 (n=2) 
   Strength+Balance 2 1 (50) 1/1 (100) -- 1/2 (50) 1/1 (100) 1/1 (100) 67.5 (n=1) 87.4 (n=2) 
   Aerobic+Strength+Balance    3 3 (100) 0/1 1/1 (100) 2/2 (100) 3/3 (100) 3/3 (100) 78.8 (n=3) 84.6 (n=3) 
Durationd          
   < 8 weeks 4 3/4 (75) 0/1 -- 0/2 2/2 (100) -- -- 84.9 (n=2) 
   8-12 weeks 5 5 (100) 2/2 (100) 2/3 (67) 3/4 (75) 2/2 (100) 4/4 (100) 79.6 (n=3) 82.1 (n=5) 
   > 12 weeks 2 1/2 (50) 0/1 -- 1/2 (50) 2/2 (100) 2/2 (100) 65 (n=1) 87.4 (n=2) 
Per Week Dose (min/week) 
  
       
   < 100 min/week 5 4 (80) 1/2 (50) 1/2 (75) 1/4 (25) 2/2 (100) 2/2 (100) -- 81.5 (n=4) 
   100-120 min/week 2 2 (100) 0/1 -- 1/1 (100) 2/2 (100) 2/2 (100) 76.7 (n=2) 85.5 (n=2) 
   > 120 min/week 3 3 (100) 1/1 (100) 1/1 (100) 2/2 (100) 1/1 (100) 1/1 (100) 75.9 (n=3) 86.2 (n=3) 
   Not Reported 1 0 -- -- 0/1 1/1 (100) 1/1 (100) -- 83.7 (n=1) 
Frequency          
   1-2 days/week 6 4 (67) 0/2 0/1 2/5 (40) 4/4 (100) 4/4 (100) 76.7 (n=2) 86.3 (n=6) 
   ≥ 3 days/week 5 5 (100) 2/2 (100) 2/2 (100) 2/3 (67) 2/2 (100) 2/2 (100) 75.9 (n=3) 80.4 (n=4) 
Intensity          
   Light 5 4 (80) 1/2 (50) -- 1/3 (33) 2/2 (100) -- 72.3 (n=2) 86.3 (n=4) 
   Moderate-Vigorous 6 5 (83) 1/2 (50) 2/3 (67) 3/5 (60) 4/4 (100) 6/6 (100) 78.8 (n=3) 82.3 (n=6) 
Setting          
   Home 2 2 (100) 1/1 (100) -- 1/1 (100) -- -- 72.3 (n=2) 87.8 (n=2) 
   Clinic 7 6 (86)  1/3 (33) 1/2 (50) 2/6 (33) 5/5 (100) 5/5 (100) 76.7 (n=2) 84.8 (n=6) 
   Both Home/Clinic 1 1 (100) -- 1/1 (100) 1/1 (100) 1/1 (100) 1/1 (100) 83.1 (n=1) 82.9 (n=1) 
Abbreviations. --, no study measured the specified outcome; CIPN, chemotherapy-induced peripheral neuropathy; PF, physical function. 
aThe results from two pre-posttest quasi-experiments in individuals actively receiving neurotoxic chemotherapy could not be interpreted dichotomously, and thus, excluded from 
this table.40,44,45 
bn+/nmo [%]) = n positive studies over n studies that measured the specified outcome. 
cOne 3-arm study tested and therefore is counted as both an aerobic alone and strength alone intervention study. 





Finally, the two studies with a moderate risk of bias showed small-moderate (19%-35%) 
statistically significant pre-post-posttest benefits. Specifically, aerobic+strength+balance and 
solely balance training alleviated established moderate-severe clinical signs and symptoms of 
CIPN, measured by the TNSc© and CIPN20 (McCrary et al. 2019), and deep tendon reflexes 
and vibration sensibility (Streckmann et al. 2018). Specifically the QE study (N = 29) suggested 
that 8 weeks of individualized combined home- and clinic-based moderate-vigorous 
aerobic+strength+balance training (60 minutes per day, 3 days per week) may alleviate CIPN, 
and improve physical function, balance, and QOL in individuals with breast, colorectal, ovarian, 
and other cancers who have completed paclitaxel, oxaliplatin, or other types of neurotoxic 
chemotherapy treatment (McCrary et al. 2019). The 4-arm RCT (N = 40) showed that six weeks 
of clinic-based sensorimotor training (2 days per week; < 30 minutes per week) may effectively 
treat chronic CIPN in individuals one to five years post-taxane- platinum-, or vinca alkaloid-
treatment; it may restore tendon reflexes and vibration sensibility to normal levels exhibited by 
age- and gender-matched healthy controls. Brief sensorimotor training may also improve balance 
and subjective CIPN; however, a higher dose may be required to induce significant benefit.  
Other key outcomes. Balance and fitness improved significantly in all the studies, 
regardless of exercise type, dosage, or setting, but pain, physical function, and QOL 
improvement varied. Higher weekly doses (> 100 minutes) and frequencies (≥ 3 days) resulted in 
more consistent holistic outcome benefits. 
Long-term outcomes. Two studies reported long-term follow-up one month (Zimmer et 
al. 2018) and 3 months (Mizrahi et al. 2015) post-intervention completion. Eight weeks of clinic-
based moderate-vigorous aerobic+strength+balance training (60 minutes twice weekly) led to 





one-month follow-up in colorectal cancer survivors receiving oxaliplatin; the control group 
simultaneously exhibited declines in all the outcomes (Zimmer et al. 2018). The other study did 
not provide meaningful long-term follow-up results because it lacked intent-to-treat analysis and 
only had three-month follow-up data on 12 (40%) participants who complied with the 
intervention and had no medical complications (Mizrahi et al. 2015).  
Adherence and completion rates. Eleven studies reported outcome assessment 
completion rates ranging from 70% (Mizrahi et al. 2015) to 99% (Courneya et al. 2013; 
Courneya, McKenzie, et al. 2014). Seven studies reported adherence rates (65% (Streckmann, 
Kneis, et al. 2014)-88.3% (Zimmer et al. 2018)), defined as the percent of intervention sessions 
attended or time completed (Courneya et al. 2013; Courneya, McKenzie, et al. 2014; McCrary et 
al. 2019; Zimmer et al. 2018); or percent of participants who met a specified exercise 
dose/criteria (Dhawan et al. 2019; Kleckner et al. 2018; Mizrahi et al. 2015; Streckmann, Kneis, 
et al. 2014). Participants adhered to 64 to 120 (SDs = 17-39) minutes per week of moderate-
vigorous intensity aerobic exercise (65.2%-68.4% VO2peak) in a clinic-supervised setting 
(Courneya et al. 2013; Courneya, McKenzie, et al. 2014) and 196 (SD = 138) minutes per week 
of aerobic+strength+balance exercise self-reported in a home-based setting (Mizrahi et al. 2015). 
Participants averaged 4,820 steps per day in another home-based aerobic+strength training study 
(Kleckner et al. 2018). These adherence levels were all obtained from patients in active 
chemotherapy treatment. 
The studies with the lowest adherence rates were conducted in individuals actively 
receiving treatment (Dhawan et al. 2019; Kleckner et al. 2018; Mizrahi et al. 2015; Streckmann, 
Kneis, et al. 2014); two studies also had high standards for their definition of adherence: percent 





(Dhawan et al. 2019). The studies with the lowest completion rates evaluated low 
dosage/intensity interventions and small sample sizes (Clark, Cortese-Jimenez, and Cohen 2012; 
Henke et al. 2014; Mizrahi et al. 2015), lacked rigor (Clark, Cortese-Jimenez, and Cohen 2012; 
Mizrahi et al. 2015), and/or were conducted in stage III to IV cancer survivors receiving 
treatment (Henke et al. 2014; Mizrahi et al. 2015). The primary reasons reported by participants 
for study discontinuation included loss of interest/unknown reasons (20%-100%), medical 
complications (11%-100%), noncompliance (5%-59%), death (11%-35%), and time concerns 
(33%). One study reported that three (33%) of the patients who withdrew did so due to 
chemotherapy side effects (Mizrahi et al. 2015). No other patterns were found between the 
intervention characteristics and adherence or completion rates. 
The studies with an adherence and completion rate ≥ 80% (Courneya et al. 2013; 
Courneya, McKenzie, et al. 2014; McCrary et al. 2019; Zimmer et al. 2018) tested clinic-based 
aerobic, balance, and multimodal training interventions performed two to three days per week. 
The intervention and sample characteristics were otherwise heterogenous in these studies.  
Enrollment rates. On average, 53.16% (range = 33%-76.3%) of patients enrolled out of 
the 233 (range = 48-728) mean patients approached for the studies (Courneya et al. 2013; 
Courneya, McKenzie, et al. 2014; Dhawan et al. 2019; Kleckner et al. 2018; McCrary et al. 
2019; Mizrahi et al. 2015; Streckmann, Kneis, et al. 2014; Vollmers et al. 2018). Recruitment 
occurred over a mean period of 28.89 (range = 6-84) months and most often in clinics or 
hospital settings (Courneya et al. 2013; Courneya, McKenzie, et al. 2014; Dhawan et al. 2019; 
Henke et al. 2014; Kleckner et al. 2018; McCrary et al. 2019; Mizrahi et al. 2015; Streckmann, 
Kneis, et al. 2014; Vollmers et al. 2018; Zimmer et al. 2018). The oncologists usually referred 





recruit patients pre- and/or shortly after chemotherapy initiation (Courneya et al. 2013; 
Courneya, McKenzie, et al. 2014; Kleckner et al. 2018; Streckmann, Kneis, et al. 2014; Vollmers 
et al. 2018). However, the 2 studies with the highest enrollment rates (63% (Mizrahi et al. 2015) 
and 76.3% (Dhawan et al. 2019)) recruited participants midway through chemotherapy 
treatment. The top reasons for declining participation (and the % of patients who cited the 
reason) included lack of interest or response (15%-100%), living too far away/transportation 
issues (11%-54%; highest in supervised intervention studies), time concerns (22%-28%), and 
medical complications (6%-28%). One study reported that 6.02% of patients refused 
participation due to chemotherapy side effects (Courneya et al. 2013; Courneya, McKenzie, et al. 
2014). 
Adverse effects. No exercise adverse effects were found (Courneya et al. 2013; Courneya, 
McKenzie, et al. 2014; Dhawan et al. 2019; Mizrahi et al. 2015; Streckmann et al. 2018; 
Streckmann, Kneis, et al. 2014; Zimmer et al. 2018). However, nearly half of the studies lacked 
report about adverse effects. 
Discussion 
This integrative review identified 13 clinical trials that reported the effects of an exercise 
or physical therapy intervention on CIPN and other key outcomes. The following key findings 
emerged:  
 All the studies had a moderate-high risk of bias and were conducted in adults.  
 CIPN, balance, and fitness improved consistently after the exercise interventions. 
 All the aerobic exercise-containing interventions led to significant CIPN benefits; 





 Adherence, completion, and enrollment rates were the lowest among patients who were 
just starting chemotherapy treatment.  
 The samples and intervention types, dosages, and delivery settings were otherwise highly 
heterogeneous.  
These findings are consistent with prior systematic reviews of exercise interventions 
among patients with CIPN (Brayall et al. 2018; Duregon et al. 2018; Jung, Rein, and Fuchs 
2018). The general consensus is that exercise may lead to improvements in balance, fitness, and 
CIPN among adults with and/or at risk for CIPN; however, the evidence is limited in abundance 
and quality. Further, the current studies have been too heterogeneous to identify the most 
effective exercise prescriptions to target CIPN (Brayall et al. 2018). One review highlighted the 
importance of balance training for reducing CIPN but ultimately proposed that moderate-
intensity aerobic+strength+balance training (2-5 days per week; ≤ 60 minutes per session) for at 
least 36 weeks may be most beneficial for individuals receiving neurotoxic chemotherapy 
(Duregon et al. 2018).  
 This integrative review supports the value of combined aerobic+strength+balance 
training (≥ 100 minutes; ≥ 3 days per week) for individuals with CIPN (Dhawan et al. 2019; 
Kleckner et al. 2018; McCrary et al. 2019; Streckmann, Kneis, et al. 2014; Zimmer et al. 2018); 
however, this review found that interventions eight to 12 weeks in duration led to the most 
consistent (Dhawan et al. 2019; Henke et al. 2014; McCrary et al. 2019; Wonders 2014; Zimmer 
et al. 2018) and potentially sustainable CIPN benefits (Zimmer et al. 2018).  
Further, this review’s numerical evidence suggests that aerobic exercise is a key modality 
to reduce CIPN (Henke et al. 2014; Kleckner et al. 2018; McCrary et al. 2019; Streckmann, 





chemotherapy treatment (Henke et al. 2014; Kleckner et al. 2018; Streckmann, Kneis, et al. 
2014; Wonders 2014; Zimmer et al. 2018). Various aerobic exercise doses (20-60 minutes per 
week; 8-30 minutes per day), frequencies (2-5 days per week), intensities (Borg RPE 11-15; 
40%-80% VO2peak, HRmax, or HRreserve), and durations (6-36 weeks) were beneficial. However, no 
studies have tested the effects of aerobic exercise alone and/or in doses ≥ 60 minutes per week on 
CIPN, compared to control. 
Overall, few studies have tested unimodal, national guideline prescription-compliant, and 
home- and group-based exercise interventions for CIPN. Sole aerobic exercise and balance 
training interventions appear most promising for CIPN, but no studies have evaluated their 
individual long-term effects on acute, chronic, and painful CIPN at various dosages. Finally, only 
three studies tested a home-based intervention—all of which showed improved CIPN outcomes 
(Dhawan et al. 2019; Kleckner et al. 2018; Mizrahi et al. 2015)—and one study tested a group-
based intervention (yoga) (Clark, Cortese-Jimenez, and Cohen 2012).  
Patterns between adherence, completion, and enrollment rates; and CIPN outcomes and 
sample characteristics were difficult to identify. Seven studies reported variable exercise 
adherence rates (65%-88.3%) based on variable definitions of adherence (Courneya et al. 2013; 
Courneya, McKenzie, et al. 2014; Dhawan et al. 2019; Kleckner et al. 2018; McCrary et al. 
2019; Mizrahi et al. 2015; Streckmann, Kneis, et al. 2014; Zimmer et al. 2018); 6 studies 
reported adverse effects data.(Courneya et al. 2013; Courneya, McKenzie, et al. 2014; Dhawan et 
al. 2019; Mizrahi et al. 2015; Streckmann et al. 2018; Streckmann, Kneis, et al. 2014; Zimmer et 
al. 2018) No studies comprehensively described the recruitment process (e.g., timing, location, 
and medium); however, the studies that recruited patients before and/or just after beginning 





of interest/personal reasons, living far away/transportation issues especially in supervised 
intervention studies, and time concerns were also common reasons for declining participation. 
Few studies employed strong CIPN assessment methods. No studies rigorously controlled for 
peripheral neuropathy-related comorbidities (e.g., diabetes); potential mediating or moderating 
psychological confounders (e.g., mood); intervention adherence; outside physical activity (in 
non-home-physical activity-based interventions); and sample heterogeneity in baseline CIPN 
presence, severity, and stability, and chemotherapy status, regimen, and duration. Lastly, few 
studies reported key participant characteristics (e.g., baseline BMI, physical activity level, and 
motivational traits) that could have biased participant enrollment, completion, and benefit from 
the exercise interventions. 
Limitations  
Definitive conclusions about the most effective intervention types and dosages cannot be 
drawn from this review, because a small number of studies with moderate-high risk of bias have 
been published, and the tested interventions were highly heterogeneous. These review findings 
can only be used to inform future studies among adults, given that no studies in this review had 
evaluated pediatric populations. Additionally, the study samples may not fully represent the 
population of patients with or at risk for CIPN, because some study samples were mixed and 
included some participants who were and some that were not receiving/had not received any 
neurotoxic chemotherapy. For example, some participants in the Courneya et al. (2013) study 
received non-neurotoxic regimens (e.g., Adriamycin and Doxorubicin) and some received 
paclitaxel or other neurotoxic chemotherapies. Finally, one author primarily reviewed and 
synthesized the literature; however, the co-authors were consulted to develop the eligibility 





Conclusions and Recommendations for Further Research  
Considering the findings and limitations of this review along with prior systematic 
reviews of exercise for CIPN, the following can be concluded: 
 Exercise, particularly aerobic exercise and balance training are promising preventive 
interventions and treatments for CIPN and should be further investigated individually. 
 Higher quality studies are needed to provide more definitive results on the effects of 
specific exercise types, dosages, and delivery methods on specific types of CIPN. 
 Studies are needed to evaluate the effects of exercise on CIPN among children. 
No cures or preventive interventions for CIPN have been found.(Hershman et al. 2014; 
Majithia et al. 2016) Yet, preliminary empirical evidence suggests that exercise may be effective 
in preventing and treating CIPN. Thus, research is needed to evaluate the mechanisms that 
mediate the protective or treatment effects of specific exercise types—first focusing on aerobic 
and balance training—on CIPN in homogeneous samples. Homogeneous samples would consist 
of individuals receiving a uniform neurotoxic drug class, dose, and schedule who participate in 
the study at a similar time in relation to chemotherapy treatment. For example, influence from 
coasting effects may be avoided by enrolling all participants at least 6 months after they have 
completed neurotoxic chemotherapy treatment. Prior studies have also lacked control (through 
eligibility criteria or statistics) for potential confounding factors: baseline peripheral neuropathy 
severity and related comorbidities, use of medications intended to reduce peripheral neuropathy 
(e.g., duloxetine), cumulative chemotherapy dose received, and outside physical activity levels.  
Secondly, studies are needed to evaluate the feasibility of specific exercise prescriptions 
in patients with or at risk for developing CIPN. Report of participants’ baseline BMI, physical 





best individualized exercise prescriptions for specific populations. Further, studies are needed to 
evaluate the interactions among the exercise prescription; participant adherence; changes in 
outside physical activity and lifestyle; and CIPN outcomes. Finally, future studies should test and 
compare the efficacy and feasibility (e.g., cost/labor effectiveness) of home- and group-based 
interventions versus standard individually supervised, in-clinic interventions.   
Implications for Practice  
CIPN is among the most common, debilitating, and treatment-resistant side effects of 
neurotoxic chemotherapy. However, a growing body of evidence has shown that appropriately 
prescribed exercise is safe, feasible, and a potentially effective intervention for patients with 
CIPN (Courneya 2014; Courneya et al. 2003; Henke et al. 2014; Streckmann, Kneis, et al. 2014; 
Streckmann, Zopf, et al. 2014). Various exercise types and dosages and increased physical 
activity have demonstrated broad benefits at every stage of cancer survivorship (Courneya, 
McKenzie, et al. 2014; Fernandes and Kumar 2016; Henke et al. 2014; Streckmann, Kneis, et al. 
2014; Zimmer et al. 2018); however, identifying exercise prescriptions to utilize as non-
pharmacological symptom treatment requires rigorous research. This review highlights the 
importance of critically evaluating the literature before using the findings. Ultimately, the 
practice implications that can be drawn from the current studies of exercise for CIPN is limited, 
because all but two studies had critical limitations. 
However, nurses can encourage and educate cancer survivors about the safety and 
importance (particularly in bolstering balance and fitness, and possibly alleviating symptoms) of 
exercise throughout cancer survivorship. Patients in active chemotherapy treatment with baseline 
CIPN and poorer functional status may require additional support to promote adherence to 
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The Effects of Exercise on Chemotherapy-Induced Peripheral Neuropathy 
 
Chemotherapy-induced peripheral neuropathy (CIPN) is a prevalent side effect of 
neurotoxic chemotherapy that can lead to ongoing discomfort and functional impairments during 
and after the completion of cancer treatment. Broadly, about 60% of individuals with various 
types of cancer develop CIPN from frontline neurotoxic chemotherapies, such as platinum 
compounds, taxanes, vinca alkaloids, proteasome inhibitors, antiangiogenesis agents, 
epothilones, ifosfamide and gemcitabine. Some types of neurotoxic chemotherapy such as 
oxaliplatin—a standard platinum-based chemotherapy for invasive gastrointestinal (GI) cancer—
can cause CIPN in 85% to 95% of individuals (Andre et al., 2004; Argyriou, Bruna, Marmiroli, 
& Cavaletti, 2012; Argyriou et al., 2013; Beijers et al., 2015; Ventzel, Madsen, et al., 2016).  
The acute manifestations of oxaliplatin-induced peripheral neuropathy (OIPN) include 
cramps, tingling, and cold sensitivity in the face, throat, and bilateral hands and feet (Drott et al., 
2019). Additionally, patients may exhibit pre-clinical signs of OIPN including loss of deep 
tendon reflexes and proprioception. As OIPN progresses, patients may begin to report cumulative 
OIPN symptoms: persistent numbness, neuropathic pain, and weakness in the bilateral hands and 
feet that progress up the extremities. Autonomic OIPN signs (e.g., orthostatic hypotension and 
constipation) are uncommon (Carozzi, Canta, & Chiorazzi, 2015; Dermitzakis et al., 2016; 
Giannoccaro et al., 2011; Nazir et al., 2017; Simon, Danso, Alberico, Basch, & Bennett, 2017; 





cancer survivors without OIPN due to impaired proprioception, balance, and strength 
(Bao et al., 2016; Kolb et al., 2016; Winters-Stone et al., 2017). Cancer survivors with OIPN also 
report difficulty with simple tasks, such as typing, grasping items from the refrigerator, and 
buttoning a shirt. These impairments can be distressing and reduce individuals’ quality of life 
(QOL) and ability to function in their usual roles (Exposito Vizcaino, Casanova-Molla, Escoda, 
Galan, & Miro, 2018; Monfort et al., 2016; Speck et al., 2012; Tofthagen, 2010b, 2010a; 
Tofthagen, McAllister, & McMillan, 2011; Zanville et al., 2016).  
Although most individuals develop some degree of OIPN during oxaliplatin treatment, 
the individuals at the highest risk for developing persistent and severe OIPN include those with 
baseline peripheral neuropathy (e.g., diabetic neuropathy) (de la Morena Barrio et al., 2015; 
Hershman et al., 2016; Kawakami et al., 2012; Saad, Tafani, Psimaras, & Ricard, 2014; Seretny 
et al., 2014) and a history of prior cancer treatment (Argyriou et al., 2012; Lewis et al., 2015; 
Velasco et al., 2010). Additionally, higher oxaliplatin cumulative dose is the dominant direct 
predictor of OIPN chronicity and severity (Argyriou et al., 2012; Beijers et al., 2015; Miltenburg 
& Boogerd, 2014; Seretny et al., 2014; Velasco et al., 2014; Ventzel, Jensen, Jensen, Jensen, & 
Finnerup, 2016). With each cycle of chemotherapy, acute OIPN becomes more severe and the 
risk of chronic OIPN increases (Argyriou et al., 2012, 2013; Beijers et al., 2015; Krishnan & 
Park, 2014; Loprinzi et al., 2014; Miltenburg & Boogerd, 2014; Pachman et al., 2015, 2016; 
Seretny et al., 2014; Velasco et al., 2014; Ventzel, Jensen, et al., 2016; Ventzel, Madsen, et al., 
2016). Other risk factors for OIPN include co-administration of other neurotoxic drugs and 
malnutrition (Staff & Windebank, 2014); obesity (Cox-Martin et al., 2017; Shahriari-Ahmadi, 
Fahimi, Payandeh, & Sadeghi, 2015; Song et al., 2017); older age (Cox-Martin et al., 2017; 





lifestyle behaviors, including physical inactivity, smoking, and alcohol use disorder (Brydoy et 
al., 2009; Greenlee et al., 2017; Mols et al., 2015; Saad et al., 2014; Seretny et al., 2014). 
No preventative therapies for OIPN are known; the primary treatment for OIPN is 
oxaliplatin dosage reduction or cessation. However, burgeoning evidence suggests that exercise 
may help to reduce OIPN (Dhawan, Andrews, Kumar, Wadhwa, & Shukla, 2019; Fernandes & 
Kumar, 2016; Henke et al., 2014; Kleckner et al., 2018; McCrary et al., 2019; Streckmann et al., 
2014, 2018; Wonders, 2014; Zimmer et al., 2018). Three randomized controlled trials (RCT) 
(Henke et al., 2014; Streckmann et al., 2014; Zimmer et al., 2018) and two quasi-experiments 
(McCrary et al., 2019; Wonders, 2014) suggest that aerobic exercise may be key in both 
preventing and treating OIPN. Specifically, the most abundant evidence supports that in-clinic 
and home-based moderate to vigorous aerobic exercise (50%-70% of maximum heart rate; 10 to 
30 minutes per day, two to three days per week, over eight to 12 weeks) combined with strength 
and/or balance training, may reduce OIPN during and after completing chemotherapy treatment 
(Henke et al., 2014; McCrary et al., 2019; Streckmann et al., 2014; Wonders, 2014; Zimmer et 
al., 2018). One secondary data analysis of an RCT also showed that a six-week home-based light 
step-count prescribed physical activity (PA) and elastic band strength training intervention led to 
better CIPN outcomes among individuals in active taxane and platinum-based chemotherapy 
treatment (Kleckner et al., 2018).  
Aerobic exercise may target and reduce OIPN through multiple mechanisms. Some 
evidence suggests that oxaliplatin primarily causes OIPN by pooling around and inducing 
oxidative stress, inflammation, and apoptosis of vulnerable peripheral nerves. Aerobic exercise 
may reduce OIPN (i.e., neurotoxicity) by improving blood circulation and reducing oxaliplatin 





oxidative stress and inflammation (Azizbeigi, Azarbayjani, Atashak, & Stannard, 2015; Chang, 
Chang, Hwang, & Chen, 2015; Di Cesare Mannelli, Zanardelli, Failli, & Ghelardini, 2012; 
Gomez-Cabrera, Salvador-Pascual, Cabo, Ferrando, & Vina, 2015; L. W. Jones et al., 2014; 
Karimi & Roshan, 2013; Park et al., 2013; Schaun et al., 2011; Tofthagen, Visovsky, & Hopgood, 
2013; Zhou, Liu, Yang, Mi, & Ye, 2016). Finally, aerobic exercise may relieve symptom distress 
associated with OIPN by bolstering mood (Courneya, 2014; Thraen-Borowski, Trentham-Dietz, 
Edwards, Koltyn, & Colbert, 2013) and reducing co-occurring symptoms such as fatigue, 
insomnia, pain, anxiety, and depression (Berger, 2010; Binkley et al., 2012; El-Shami et al., 
2015; Knoerl, Chornoby, & Smith, 2018, 2019; Mols et al., 2013; Pachman, Barton, Swetz, & 
Loprinzi, 2012; Skerman, Yates, & Battistutta, 2012).  
Altogether, the studies that have evaluated the effects of exercise on OIPN and other 
types of CIPN have had critical limitations: most commonly small sample sizes, heterogeneous 
samples of mixed CIPN types, and lack of strong CIPN measures and control for CIPN-
influencing factors. Few studies have evaluated home-based exercise, and no studies isolated 
aerobic exercise to evaluate its unique impact on one type of CIPN such as OIPN. 
Purpose and Design 
The purpose of this pilot study was to explore the efficacy of eight weeks of home-based 
moderate-intensity aerobic exercise (i.e., brisk walking) for OIPN in GI cancer survivors 
receiving active neurotoxic treatment. Specifically, the aims of this dual-site, prospective, 
randomized, controlled, pilot study were to evaluate the effect of an eight-week home-based 
brisk walking (the “MI-Walk”) intervention, on 1) OIPN severity and 2) QOL at eight weeks, 
compared to PA education alone in oxaliplatin-receiving GI cancer survivors. The primary 





than patients in control group at eight weeks, controlling for received oxaliplatin dose and 
baseline sensory OIPN. Motor OIPN severity, global QOL, and individual QOL domains (i.e., 
physical and emotional function) were explored as secondary outcomes. Additionally, mood was 
explored as a covariate in the models. Finally, dose response—association between moderate to 
vigorous PA (MVPA) and the outcomes—were explored. 
Methods 
 Sixty adults (at least 18 years of age) with stage II-IV colon, rectal, colorectal, pancreatic, 
ileal, and esophageal cancers were recruited to the study at their second cycle of FOLFOX or 
FOLFIRINOX (two oxaliplatin-based chemotherapy regimens). Convenience sampling was used 
to identify participants that met the additional following eligibility criteria, based on their 
electronic medical records, and medical oncologist- and self-report. The institutional review 
board at both recruitment sites approved the study and all participants gave informed consent. 
Inclusion Criteria 
Participants were eligible for the study if they were 1) scheduled to receive at least 6 
cycles of FOLFOX or FOLFIRINOX, 2) had a Karnofsky Performance Status ≥ 80% or an 
Eastern Cooperative Oncology Group (ECOG) Status zero to one; and 6) voluntarily consented 
to participate in all intervention components. 
Exclusion Criteria 
Individuals were excluded if they had 1) exercise- or mobility-limiting cardiovascular, 
pulmonary, musculoskeletal, or psychological disease, 2) a major surgical procedure scheduled 
during the eight-week study time period, 3) self-reported pre-existing peripheral neuropathy 
(potentially due to diabetes, central nervous system malignancy, vitamin deficiency, heredity, 





and 5) a prognosis of less than three months. Baseline peripheral neuropathy was screened by in-
person interview (e.g., “do you have numbness or tingling in your hands or feet?”) and using the 
primary outcome measure (CIPN20 survey); participants with a CIPN20 sensory subscale score 
≥ 25 (“a little” sensory neuropathy on the transformed scale) were considered ineligible due to 
baseline peripheral neuropathy and were excluded from the analysis. Pregnancy and inability to 
read or speak English were additional exclusion criteria. 
Intervention and Control Condition 
 Participants were stratified by diabetes status and recruitment site then randomized in a 
1:1 ratio to receive either the PA education control condition or the eight-week MI-Walk 
Intervention. The same interventionist (the first author) provided the education and guided 
participants through the MI-Walk Intervention. The control group at each site solely received the 
Physical Activity and the Cancer Patient pamphlet (American Cancer Society, 2014) and verbal 
reinforcement of safety precautions surrounding, tips for maintaining, and the benefits and 
recommended levels of PA during and after cancer treatment. Telephone follow-up (to assess for 
adverse events) occurred at one, two, four, and six weeks. 
The MI-Walk Intervention. In addition to the PA education, participants in the 
intervention group received a tailored progressive walking plan, three motivational enhancement 
therapy (MET) sessions, and tools described below to encourage home-based aerobic walking. 
The progressive walking plan goal by eight weeks was for participants to meet or exceed the 
national aerobic PA guidelines: at least 150 minutes of MVPA per week (American Cancer 
Society, 2014; Schmitz et al., 2010; U.S. Department of Health and Human Services, 2018). 





per week, at moderate intensity defined as Borg rating of perceived exertion between 12 and 14 
(Borg, 1998).  
The MET sessions—motivational interviewing and worksheets to write exercise goals 
and barrier-addressing “if-then implementation intention” statements—occurred in-person at 
intervention initiation and by telephone two and four weeks later. The “if-then implementation 
intention” statement worksheet encouraged participants to identify their major exercise barrier(s) 
and create a plan to address it/them. For example, if a participant’s major barrier was forgetting 
to walk, their intention statement could be “if it is six PM on Saturday, then I will walk for 10 
minutes.”  
The intervention group participants also received additional tools, including a Fitbit 
Charge 2, tailored progressive walking plan, exercise diary, progress summary at two and four 
weeks, supplemental cancer treatment and exercise educational pamphlet, and written patient 
testimony about staying physically active during oxaliplatin treatment. Additionally, the 
intervention participants were added to an email group and invited to weekly group walking 
events with the other intervention group participants. They received one weekly scripted 
motivational message and were encouraged to engage in email discussion.  
Measurement 
 Participants completed the outcome measure surveys electronically on a tablet at the 
baseline and eight-week timepoints. Baseline assessments occurred at the participants’ second 
infusion visit. The eight weeks assessments occurred at the sixth infusion visit or whichever visit 
coincided with the eight-week timepoint. A one-week leeway was permitted in cases when a 
chemotherapy visit was re-scheduled. All assessments occurred at least two weeks after the prior 





participants at eight weeks; the interventionist provided the eight-week surveys to 25% of the 
participants due to limited personnel.  
 OIPN. The European Organisation for the Research and Treatment of Cancer (EORTC) 
Quality of Life Questionnaire (QLQ)-Chemotherapy-Induced Peripheral Neuropathy 20-item 
supplement (CIPN20) (Postma et al., 2005) was used to measure the primary outcome. It is a 
patient-reported outcome that assesses three domains of CIPN symptoms: sensory (9 items), 
motor (8 items) and autonomic function (3 items). Each item was rated on a scale from 1 (“not at 
all”) to 4 (“very much”). The mean of each subscale score was linearly transformed to a 0 to 100 
scale (higher scores represented worse CIPN severity). Evidence supports the internal 
consistency reliability among the sensory (Cronbach’s α coefficient = 0.82-0.88), motor (α 
coefficient = 0.73-0.88), and autonomic (α = 0.76-0.78) items (Lavoie Smith et al., 2013; Postma 
et al., 2005). Factor analysis has supported the construct validity of the sensory and motor 
subscales (Lavoie Smith et al., 2013). Excellent content validity has been demonstrated by 
cognitive interviews with patients, and review by five oncology practitioners and scientists (CVI 
= 0.80) (Smith et al., 2017). The CIPN20 has demonstrated responsiveness to change (cohen’s d 
range = 0.32-0.69) (Smith et al., 2018) in the context of chronic stable CIPN (Alberti et al., 
2014; Cavaletti et al., 2013; Knoerl et al., 2017; Lavoie Smith et al., 2013; Postma et al., 2005; 
Smith et al., 2018). Finally, the electronic tool has demonstrated excellent mode equivalence 
with the paper-pencil CIPN20 (ICC range >0.91) (Knoerl et al., 2017). 
 QOL. The EORTC QLQ-Core 30-item (C30) survey was used to assess QOL. It is a 30-
item patient-reported measure of cancer-specific QOL. The EORTC QLQ-C30 contains five 
multi-item functional scales measuring physical (5 items) and emotional function (4 items); and 





pain (2-item), and nausea and vomiting (2-item) symptom and global health/QOL scale (2 
items); and several individual symptom items. Participants rated the degree to which each item 
applied to them during the past week using a four-point Likert scale (1, not at all; 4, very much). 
The average of the item scores gives a raw subscale score, and all raw subscale and single-item 
scores are transformed to a 0 to 100 scale. Higher scores indicate that a concept applies more 
strongly to an individual. For example, a higher score on the emotional functioning scale 
indicates higher emotional functioning, but a higher symptom score indicates more severe 
symptoms. The EORTC QLQ-C30 and its individual subscales have demonstrated strong internal 
consistency reliability (α = 0.74-0.85); and group-contrasting validity (p ≤ .02; grouped by 
ECOG performance status) globally in adults receiving cancer treatment (Aaronson et al., 1993; 
Cankurtaran et al., 2007; Li, Lin, Qiu, Gao, & Xu, 2014; Nicklasson & Bergman, 2007; 
Niezgoda & Pater, 1993; Osoba et al., 1994; Ringdal & Ringdal, 1993; Sherman et al., 2000). 
Evidence supports its convergent validity with other common QOL (e.g., the 36-Item Short Form 
Health Survey) and mood (e.g., Hospital Anxiety and Depression Scale) measures (r = .24-.77) 
(Cankurtaran et al., 2007; Li et al., 2014; Ringdal & Ringdal, 1993; Rodrigues et al., 2017; 
Sherman et al., 2000; Snyder et al., 2014).  
Fitbit-measured physical activity. In the MI-Walk group, the Fitbit Charge 2 was used to 
measure PA trends over the eight weeks. Total (light to vigorous) PA and MVPA were quantified 
as the minutes of PA performed at or above 1.1 and 3 metabolic equivalent of tasks, respectively 
(American Cancer Society, 2014; Fitbit, 2019; U.S. Department of Health and Human Services, 
2018). Step count per day was also collected.  
Intervention participants continuously wore the Fitbit over the eight weeks. The device 





Charge models have demonstrated step count-based test-retest reliability (ICC = 0.92-0.96) and 
criterion-related validity in older adults in controlled lab settings (ICC = 0.90-0.95) (Burton et 
al., 2018). Some evidence suggests convergent validity of Fitbit Charge 2 step count, sedentary 
time, and MVPA measurements with symptom burden (r = .17-.52) (Low et al., 2017) and 
functional status (r = .63-.69), and predictive validity in relation to favorable cancer survival and 
reduced adverse events among cancer survivors (OR = 0.21-0.48) (Gresham et al., 2018). The 
Fitbit Charge models have demonstrated convergent validity with other commercial and 
research-grade PA monitors but tend to overestimate energy expenditure (Bai, Hibbing, Mantis, 
& Welk, 2018; Brooke et al., 2017; Feehan et al., 2018; Nazari, MacDermid, Sinden, Richardson, 
& Tang, 2019; Tedesco et al., 2019; Thomson et al., 2019). 
Self-reported physical activity. The Physical Activity Scale for the Elderly (PASE) 
(Washburn, McAuley, Katula, Mihalko, & Boileau, 1999; Washburn, Smith, Jette, & Janney, 
1993) was used to compare total PA levels between the intervention and control groups. 
Confounding bias was suspected if the control group’s PASE scores increased significantly from 
baseline to eight weeks and were equal or higher than the intervention group’s scores at eight 
weeks. 
The PASE is a 28-item self-report measure of total PA (leisure time, household, and 
occupational activities) performed over the past seven days. It contains six four-point Likert 
scale items that measure the frequency of (0, never; 3, often) and usual session duration spent (0, 
less than 1 hour; 3, more than 4 hours) performing various activities: occupational walking and 
standing, muscle strength exercises, leisure-time walking, and light to strenuous sports. Six items 
measure engagement (1, yes; 0, no) in household activities: house/lawn/yard care and repairs and 





scoring manual. Before summation, the raw item scores were multiplied by pre-determined 
weights that were originally obtained from the published principal components analysis 
(Physiopedia contributors, 2019; Washburn et al., 1999, 1993).   
The PASE has demonstrated good content (CVI = 0.91) and face validity (Su, Lee, Yeh, 
Kao, & Lin, 2014), and adequate test-retest reliability (ICC = 0.67-0.90) (Dinger, Oman, Taylor, 
Vesely, & Able, 2004; Forsen et al., 2010; Washburn et al., 1993). Convergent validity has been 
supported by its associations with various performance status measures (r = .36-.59), the six-
minute walk test (r = .40), and EORTC QLQ-C30-measured physical function and global QOL (r 
= .57) (Granger, Parry, & Denehy, 2015). Adequate criterion-related validity has been suggested 
by its correlations with the ActiGraph and pedometers (r = .50-.68) (Granger, Parry, & Denehy, 
2015; Su, Lee, Yeh, Kao, & Lin, 2014). Finally, the PASE has shown capability of detecting 
decreases in PA throughout lung cancer treatment (ES = .23-.24; p ≤ .023) (Granger et al., 2015).  
Motivational interviewing fidelity. The fidelity/integrity of the MET was assessed using 
the Motivational Interviewing Treatment Integrity Code (Moyers et al., 2016). An external MET 
expert used the tool to review and code three MET sessions at the beginning, middle, and end of 
the study (three to five months apart)..  
Oxaliplatin dose. The cumulative oxaliplatin dose (mg/m2) was abstracted from the 
electronic medical record. Oxaliplatin dose was evaluated primarily as a continuous dose but also 
as a dichotomous variable (0, no dose reduction; 1, dose reduction).  
Demographic characteristics. Participants self-reported their age, race, gender, and 
marital and employment status. They also verbally rated their confidence on a 0 to 10 scale in 
their ability to increase their aerobic exercise over the next eight weeks. Cancer type and stage, 





electronic medical record. The principal investigator obtained participants’ lists of prescribed 
analgesic, anti-epileptic, and neuroprotectant medications from the electronic medical record and 
asked the participants in-person to confirm the dosages that they were regularly taking. 
Demographic characteristics that significantly differed between groups (p < .05) were explored 
as covariates in the analysis of the effects of the intervention on the outcomes. 
Power Analysis 
Reasonable parameter estimates for this power analysis were obtained from a secondary 
data analysis of the effects of a six-week home-based PA and strength training intervention on 0 
to 10 numeric rating scale-measured numbness and tingling in individuals initiating platinum 
(oxaliplatin-like) treatment (Kleckner et al., 2018). The power analysis was conducted assuming 
that the observed magnitude of effect would be similar between the Kleckner et al. and present 
study, despite differing outcome measures. The present study was estimated to have an 85.9% 
power to detect significant differences in OIPN scores, assuming a one-tailed α of .05, n of 24 
per group, linear increase in OIPN throughout oxaliplatin treatment (Pachman et al., 2015, 2016; 
Ventzel, Jensen, et al., 2016; Zimmerman et al., 2016), baseline numeric rating scale mean of 
0.46, and projected inter-group difference in means of 1.86 at eight weeks and non-homogeneity 
of variance (SDs = 1.53 and 0.90).  
Statistical Analysis 
 Statistical analyses were performed using the STATA version 15.0 statistical software 
(StataCorp, 2017). The normality of the standardized residuals for each outcome variable were 
assessed using spread-level residual and quantile-quantile plots, and histograms and centrality 
and dispersion statistics. Homoskedasticity was verified using the White and Breusch-Pagan tests 





was used to evaluate the normality of the distribution of residuals for each model. If the Shapiro-
Wilk test was significant (p ≤ .05), indicating possible violations to normality, the standardized 
residuals of each model were assessed. Outliers with a standardized residual ≥ 3 were considered 
overly influential and removed from analysis of the specified model, and model diagnostics were 
re-evaluated after removing them. Finally, lack of multicollinearity was determined based on 
variance inflation factors < 4.  
Differences in the baseline sample characteristics and concomitant treatment changes 
between the intervention and control group were evaluated using two-sided independent t-tests 
and Fisher’s exact and chi-square tests.Linear mixed model regression was conducted to evaluate 
changes in self-reported PA over time between groups. 
Missing data. Table III.1 tabulates the patterns and amount of missing data for each 
variable. Qualitative researcher observations were also considered in assessing the reasons for 
each missing value. Imputation was only performed on the data assumed to be missing at 
random. All the outcome variables (e.g., OIPN and QOL) had complete data at baseline but 
missing data—all assumed to be missing at random—from 6 (11% ) of participants at the eight-
week timepoint. About 14% of the Fitbit data was missing, presumably “at random.” Self-
reported PA was missing for 11% of cases at baseline and 16% of cases at eight weeks but was 
not imputed due to the small sample size and limited imputation model variable capacity. The 
missing data pattern was mixed and/or arbitrary. 
All dichotomous variables were coded 0 (no) and 1 (yes) and all factor variables were 
encoded into numeric variables. The missing Fitbit data for the control group participants were 





imputed for the control group participants. No calculated variables required passive imputation, 
because participants responded to all or none of the items in each subscale. 
Table III.1 
Missing Values 
Variable Missing at Eight Weeks 
 n %a 
Sensory OIPN 6 10.53 
Motor OIPN 6 10.53 
Oxaliplatin Dose 6 10.53 
QOL 6 10.53 
Physical Function 6 10.53 
Emotional Function 6 10.53 
Fitbit mean MVPA 4 13.79 
Abbreviations. MVPA, moderate to vigorous physical activity; OIPN, oxaliplatin- 
induced peripheral neuropathy; QOL, quality of life 
aPercent of subjects who did not provide a response for the listed item. 
Multiple imputation. Multiple imputation and linear regression were used to address the 
aims by modified intent-to-treat analysis. Specifically, multivariate imputation by chained 
equations (MICE) with predictive mean matching was conducted based on group, age, gender, 
oxaliplatin dose, Fitbit-measured MVPA, and baseline and eight-week OIPN, global QOL, 
physical, role, and emotional function. The MICE-predictive mean matching method was chosen 
because multiple continuous variables with skewed residual distributions required semi-
parametric imputation. Additionally, predictive mean matching was used due to the small sample 
size and potentially insufficient amount of observed data to restrict the imputations and avoid 
imputing data outside of a reasonable range. To maximize model convergence, 200 iterations of 
imputation were performed. 
Several multiple imputation diagnostic methods were used before analyzing the aims to 
check the imputed data for unexpected values and obvious deviations from the original observed 





using cumulative plots. Means and variances of each imputed variable were also calculated and 
compared to the observed data. Finally, the results of complete case analysis (with listwise 
deletion) on the observed data was compared to the study results obtained from regression on the 
imputed data. Reasonable similarity in the estimates obtained from the observed versus imputed 
data were verified prior to proceeding with analysis of the aims.  
Analysis of the aims. Linear regression was used to address the aims. Robust 
regression—a very conservative alternative to linear regression—was used if the adequacy of the 
model fit, normality of residuals, and homogeneity of variances were questionable after 
evaluating the standardized residuals and removing outliers. Group assignment (the intervention) 
was the primary independent variable in each model. The first regression model evaluated eight-
week sensory OIPN as the outcome and included baseline OIPN and oxaliplatin dose received by 
eight weeks as additional covariates. Mood and inter-group differing demographic covariates 
were added secondarily as exploratory covariates. The same covariates were used to model the 
eight-week motor OIPN outcome. Eight-week global QOL and physical and emotional function 
were each modeled separately; these models included baseline QOL/function and eight-week 
sensory OIPN severity as covariates.  
Descriptive statistics of groups are presented as means with standard deviations (𝑋±SD) 
for continuously scaled and n (%) for categorical data. The b estimates for effects (𝑋∆ for 
dichotomous variables), along with 95% confidence intervals (CIs) are used to evaluate and 
report effect magnitudes. Significance was determined by a two-tailed α ≤ .05 (a CI that did not 
contain zero) and pre-specified clinical significance cut-offs: a 30% difference in mean scores 
between groups was considered clinically significant (Dworkin et al., 2005; Farrar, Young, 






Figure III.1 demonstrates the flow of participants through the study. Sixty (62%) of 97 
screened individuals enrolled in the study. The individuals who enrolled reported significantly 
fewer comorbidities (𝑋 = 0.78; SD = 0.88; range = 0-3) than participants who declined 
participation (𝑋 = 1.12; SD = 0.48; range = 0-3), (𝑋 -𝑋 = 0.34; 95% CI -0.67, -0.01; p = .01). 
The patients who enrolled versus declined were otherwise similar.  
Of the 57 eligible enrolled participants, six individuals withdrew from the study (87% 
completion rate) due to major surgery (n = 1), medical complications (n = 2), perceived 
excessive study time requirement (n = 2), and lack of follow-up (n = 1). The participants who 
completed the study were significantly younger (𝑋 = 57.00; SD = 10.81; range = 19-75 years) 
than the participants who withdrew (𝑋 = 66.33; SD = 3.56; range = 61-72 years), (𝑋 -𝑋 = 9.33; 
95% CI -18.28, -0.39; p = .03). 
Sample Characteristics 
Table III.2 provides a summary of the baseline characterist ics of the participants. The 
sample included subjects with stage II-IV mainly colon and/or rectal (67%) or pancreatic cancers 
(31%). Most participants were male (63%), white (91%), and married (79%), and had the 
optimal ECOG functional status (77%). Nearly half the participants were former (42%) or 
current (7%) smokers. A higher proportion of males were randomized to the intervention than the 
control group (p = .01). All participants were receiving their first-ever oxaliplatin-based 
chemotherapy regimen; however, one participant (who reported no baseline peripheral 
neuropathy) had previously received paclitaxel for breast cancer. Twenty-three (41%) of the 
participants were taking at least one analgesic medication at baseline; 10 of these participants 





Figure III.1  
Recruitment Flowchart A 
 
 
Abbreviations. ECOG, Eastern Cooperative Oncology Group functional status score; ITT, 
intention to treat analysis; PN, peripheral neuropathy. 
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Baseline peripheral neuropathy and QOL. Table III.2 also includes the baseline self-
reported peripheral neuropathy scores, which were similar between the intervention and control 
group participants. At baseline, one participant gave a CIPN20 score (> 25) that indicated “a 
little” baseline motor peripheral neuropathy; and nine (16%) of patients had an autonomic 
peripheral neuropathy CIPN20 score > 25 at baseline. No between-group differences were found 
in QOL and the functional subscales at baseline. 
Table III.2 
Baseline Characteristics  





 N = 57 n = 29 n = 28   
 n (%) 𝒙𝟐 p 
Male Gender 36 (63) 23 (79%) 13 (46) 6.62 .01* 
Race 
   White 
   Black 















   Married 
   Separated/Divorced 
   Widowed 


















   High School or Less 
   Some College 
   Bachelors Degree 


















   Full-time 
   Part-time 
   Retired 
   Not employed 





















   Never smoked 
   Former smoker 















   Colon 
   Rectal/Colorectal 
   Pancreatic 






















   II 
   III 
   IV 


















   0 











Number of comorbidities 
   0 
   1 














Number of pain medications 
   0 
   1 
   2-3 

















      
 𝑿 (SD) 𝑋 -𝑋  p 
Age 57.88 (10.68) 56.79 (11.72) 59.00 (9.58) -2.21 .44 
BMI 25.61 (3.96) 25.01 (3.73) 26.23 (4.16) -1.23 .25 
Oxaliplatin dose (mg/m2) 
   Baseline 
















Sensory PN 6.30 (6.93) 6.39 (6.33) 6.22 (7.61) 0.17 .93 
   Tingling F/H 16.96 (17.95) 17.24 (16.95) 16.67 (19.25) 0.57 .91 
   Tingling T/F 88.77 (16.09) 8.05 (14.52) 9.52 (17.82) -1.48 .73 
   Numbness F/H 9.36 (15.11) 9.20 (15.16) 9.52 (15.33) -0.33 .94 
   Numbness T/F 5.85 (12.79) 4.60 (11.70) 7.14 (13.93) -2.55 .46 
   NP F/H 3.51 (10.32) 3.45 (10.33) 3.57 (10.50) -0.12 .96 
   NP T/F 1.75 (7.51) 2.30 (8.60) 1.19 (6.30) 1.11 .58 
Motor PN 3.62 (6.93) 3.61 (5.19) 3.64 (8.47) -0.02 .99 
Autonomic PN 10.72 (14.84) 10.73 (14.08) 10.71 (15.85) 0.01 >.99 
QOL total score 69.30 (20.48) 72.41 (17.69) 66.07 (22.90) 6.34 .25 
Physical function 92.16 (12.35) 92.64 (12.39) 91.67 (12.52) 0.98 .77 
Mood / Emotional function 85.82 (12.09) 85.34 (12.13) 86.31 (12.26) -0.96 .77 
Self-reported PA (n= 51) 112.45 (91.79) 128.04 (120.14) 96.24 (44.50) 31.80 .22 
Abbreviations. BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; F/H, fingers and hands; NP, neuropathic 
pain; PA, physical activity; PN, peripheral neuropathy; QOL, quality of life; SD, standard deviation; T/F, toes and feet 
Physical Activity Trends 
Per the Fitbit, the MI-Walk Intervention participants’ (n = 25) minutes of MVPA per 
week increased significantly (b = 17.39; 95% CI 1.38, 33.40; p = .03) and total PA per day 
increased significantly over the eight weeks (b = 7.80; 95% CI 2.31, 13.29; p = .01). The 
increase in mean daily step count over time was not statistically significant (b = 157.98; 95% CI 





Group comparison. The self-reported PA (PASE) scores were no different between the 
intervention and control groups at baseline (n = 51) and eight weeks (n = 48); the mean (SD) 
scores were 96.24 (44.50) in the control and 128.04 (120.14) in the intervention group at baseline 
and 144.17 (64.76) in the control and 156.67 (101.79) in the intervention group at eight weeks. A 
significant increase in self-reported PA from baseline to eight weeks was observed in the full 
sample (b = 44.85; 95% CI 12.57, 77.12; p = .01). On average, the intervention group’s self-
reported PA score was 33.07 points higher (95% CI -16.27, 82.41; p = .18) but their pre-posttest 
increase in PA was 24.02 points lower (95% CI -69.88, 21.83; p = .30) than those of the control 
group.  
Motivational Interviewing Fidelity 
Based on external expert review, the interventionist met basic motivational interviewing 
proficiency but missed key opportunities to strengthen participants' motivation for increasing 
their amount of aerobic exercise. The mean global Motivational Interviewing Treatment Integrity 
ratings were 3.67 (range = 3-4) for cultivating change talk, 3.67 (range = 3-5) for softening 
sustain talk, 4.33 (range = 4-5) for partnership, and 4.67 (range = 4-5) for expressing empathy. 
OIPN Outcomes  
OIPN severity between groups. Table III.3 shows the mean OIPN severities at the eight-
week time point. Significant baseline to eight-week increases were found in the total sample’s 
OIPN sensory (𝑋∆ = 5.17; 95% CI 2.44, 7.91; p < .01) and motor symptoms (𝑋∆ = 3.41; 95% CI 
1.44, 6.26; p = .01). Specific sensory changes included an increase in tingling in the toes and feet 
(𝑋∆ =  10.18; 95% CI 3.01, 17.35; p < .01) and fingers and hands (𝑋∆ =  20.95; 95% CI 12.72, 
29.18; p < .01). At eight weeks, the mean sensory OIPN scores were 13% lower (not significant) 





significant). Overall, the mean severities of all the OIPN symptoms were below the CIPN20 cut-
off score of 25 (“a little” OIPN, based on the 0-100 transformed scale; 𝑋 = 11.76; SD = 10.57), 
except for the tingling in the fingers and hands at eight weeks (𝑋 = 37.91; SD = 24.96). 
Table III.3  
Mean OIPN Severities at the Eight-Week Time point (N = 57) 
Eight-Week OIPN Group Intergroup 
 Intervention (n = 29) Control (n = 28) 𝑿∆ [         95% CI          ] 
 𝑿 (SD)    
Sensory 10.70 (0.31) 12.28 (0.44) 1.59 -3.85 7.03 
Motor 8.38 (0.32) 6.54 (0.35) -1.84 -6.56 2.89 
Tingling F/H 37.10 (0.88) 38.23 (0.97) 1.13 -12.04 14.29 
Tingling T/F 17.33 (19.53) 20.51 (23.24) 3.18 -8.93 15.28 
Numbness F/H 13.33 (16.67) 16.67 (27.08) 3.33 -9.38 16.05 
Numbness T/F 8 (14.53) 12.82 (23.24) 4.82 -6.14 15.78 
NP F/H 4.33 (12.47) 11.54 (20.96) 6.21 -3.55 15.96 
NP T/F 2.67 (9.23) 2.56 (9.06) -0.10 -5.25 5.04 
Abbreviations. CI, confidence interval; F/H, fingers and hands; NP, neuropathic pain; OIPN, oxaliplatin-induced peripheral 
neuropathy; SD, standard deviation; T/F, toes and feet. 
 
Statistical models. Table III.4 shows the OIPN outcome statistical models (n = 56-57; one 
outlier was removed from the motor OIPN models). The intervention had no significant effect on 
sensory OIPN at eight weeks (𝑋∆ = -0.01; 95% CI -4.32, 4.31; p > .99), controlling for baseline 
peripheral neuropathy and oxaliplatin dose received. Mood and gender were added individually 
as exploratory factors. Poorer mood was significantly associated with more severe sensory OIPN 
at eight weeks (b = -0.15; 95% CI -0.27, -0.01; p < .01). Female gender was associated with an 
average 4.54 unit increase in eight-week sensory OIPN, adjusting for the other covariates in the 
model (95% CI -0.08, 9.17; p = .05). Altogether, the mood and gender covariate models each 
accounted for 33% and 31% of the variance in eight-week sensory OIPN, respectively (p < .01).   
Regarding motor OIPN, the intervention did not significantly affect motor OIPN at eight 
weeks (𝑋∆ = 2.39; 95% CI -1.04, 5.82; p = .17), controlling baseline motor neuropathy and 





increased estimated effect (𝑋∆) of the intervention on motor OIPN at eight weeks. The model 
including female gender as a covariate (𝑋∆ = 2.38; 95% CI –1.56, 6.32) accounted for 33% of the 
variance in eight-week motor OIPN (p = .01).  
Concomitant medication dosage changes from baseline to eight weeks were minimal and 
did not differ between groups; participants’ dosages decreased in 11 (21%), increased in eight 
(15%), and did not change in 33 (63%) participants by eight weeks. 
Table III.4  
Results of the OIPN Outcome ITT Analyses 
Outcome b [     95% CI    ] RVI FMI RE R2 p-valuea 
Sensory OIPN (n = 57) 
       
Base model 
     Intervention 
     Baseline sensory OIPN 
     Oxaliplatin dose 
 
-0.01 
   0.59* 
   0.05* 
 
 -4.32 
  0.23 



















     Intervention 
     Baseline sensory OIPN 
     Oxaliplatin dose 
     Mood 
 
 0.27 
   0.50* 




  0.13 






















.33 < .01* 
Gender model 
   Intervention 
   Baseline sensory OIPN 
   Oxaliplatin dose 




   0.49* 
   0.06* 
 4.54 
 
  -3.02 
   0.15 
 0.02 






















Motor OIPN (n = 56)         
Base model 
     Intervention 
     Baseline motor OIPN 
     Oxaliplatin dose 
 
2.39 
  0.53* 
  0.04* 
 
 -1.04 
  0.12 



















     Intervention 
     Baseline motor OIPN 
     Oxaliplatin dose  
     Genderb 
 
 3.01 





























Abbreviations. CI, confidence interval; FMI, fraction of missing information; ITT, intention to treat; OIPN, oxaliplatin-induced 
peripheral neuropathy; PA, physical activity; QOL, quality of life; RE, relative efficiency; RVI, relative variance increase. 
aThe p-value refers to the statistical significance of the full regression model. 
bMales were coded as 0 and females were coded with a 1. 






Table III.5 shows the QOL statistical models. The intervention did not significantly affect 
eight-week Global QOL and physical and emotional function outcomes. Baseline QOL/function 
were significant covariates in their respective models. Further, eight-week sensory OIPN was a 
statistically significant covariate in the emotional function outcome model  (b = -0.36; 95% CI -
0.70, -0.03; p = .03). Exploratory analysis showed that improved mood was significantly 
associated with improved QOL (b = 0.51; 95% CI 0.15, 0.87; p = .01). Exploring further, female 
gender was factored in the models and associated with an 11.00 unit decrease (95% CI -22.19, 
0.20; p = .05) in QOL and an 8.21 unit decrease in physical function at eight weeks (95% CI -
15.8, -0.57; p = .05), controlling for the intervention, baseline QOL/physical function, and eight-
week sensory OIPN. 
Table III.5  
Results of the QOL Outcome ITT Analyses 
Outcome b [     95% CI    ] RVI FMI RE R2 p-valuea 
QOL (n = 57) 
       
Base model 
     Intervention 
     Baseline QOL 
     Eight-week sensory OIPN 
 
-1.43 




    0.37 

















.38 < .01* 
Mood model 
     Intervention 
     Baseline QOL 
     Eight-week sensory OIPN 
     Mood 
 
 0.25 




   -8.87 
    0.21 
   -0.64 























     Intervention 
     Baseline QOL 
     Eight-week sensory OIPN 
     Genderb 
 
-4.53 





    0.32 























Physical Function (n = 57) 
        
Base model 
     Intervention 
     Baseline physical function 































     Intervention 
     Baseline physical function 
     Eight-week sensory OIPN 
     Genderb 
 





  -6.43 
  -0.01 























Emotional Function (n = 56) 
        
     Intervention 
     Baseline emotional function 
     Eight-week sensory OIPN 
1.01 
  0.54* 
 -0.36* 
 -5.79 















Abbreviations. CI, confidence interval; FMI, fraction of missing information; ITT, intention to treat; OIPN, oxaliplatin-induced 
peripheral neuropathy; PA, physical activity; QOL, quality of life; RE, relative efficiency; RVI, relative variance increase. 
aThe p-value refers to the statistical significance of the full regression model. 
bMales were coded as 0 and females were coded with a 1. 
*, significant two-sided difference (p < .05). 
Dose Reponse 
Table III.6 provides the results just within the intervention group (n = 29) of the imputed 
mixed effects models that evaluate the effects of MVPA, total PA, and step count on the 
outcomes. Total PA minutes and step count per day had no effect on the outcomes. However, 
MVPA minutes per week had a small beneficial effect on the outcomes though not statistically 
significant.  
MVPA and OIPN. Data trends showed that just within the intervention group, mean 
minutes of MVPA over the eight weeks could lead to less sensory OIPN (b = -0.02; 95% CI -
0.03, 0.00; p = .06), controlling for baseline OIPN and eight-week oxaliplatin dose. The model 
accounted for 32% of the variance in sensory OIPN at eight weeks (p = .04). Trends also showed 
that mean minutes of MVPA over the eight weeks could lead to higher QOL (b = 0.04; 95% CI -
0.00, 0.07; p = .07), controlling for baseline QOL and eight-week OIPN severity. The model 
accounted for 47% of the variance in QOL at eight weeks (p < .01). Mood and gender were not 





Table III.6  
Effects of MVPA, Step Count, and Total PA on the Ouctomes (n = 29) 
Outcome   b [       95% CI      ] RVI FMI RE R2 p-valuea 
Sensory OIPN        
Model 1  
     MVPA (min/week) 
     Baseline sensory OIPN 







-0.03      0.00b 
 0.14      1.17 















Model 2  
     Total PA (min/day) 
     Baseline sensory OIPN 







-0.06      0.06 
-0.02      1.07 















Model 3  
     Steps per day 
     Baseline sensory OIPN 







 -0.00      0.00 
  0.03      1.08 















Motor OIPN        
Model 1 
     MVPA (min/week) 
     Baseline motor OIPN 







-0.03       0.01 
-0.27       1.29 
















     Total PA (min/day) 
     Baseline motor OIPN 







-0.03       0.07 
 0.01       1.38 
















     Steps per day 
     Baseline motor OIPN 







-0.00      0.00 
-0.27      1.32 














QOL        
Model 1 
     MVPA (min/week) 
     Baseline motor OIPN 







-0.00      0.07 
 0.17      0.95 
















     Total PA (min/day) 
     Baseline QOL 







-0.14      0.14 
 0.05      1.01 
















     Steps per day 
     Baseline QOL 







-0.00      0.00 
-0.01      0.89 


















Physical Function        
Model 1 
     MVPA (min/week) 
     Baseline physical function 







 -0.01      0.05 
0.49      1.38 














.61 < .01* 
Model 2 
     Total PA (min/day) 
     Baseline physical function 







-0.09      0.09 
 0.45      1.33 













.48 < .01* 
Model 3 
     Steps per day 
     Baseline physical function 







 -0.00     0.00 
  0.48     1.35 














.64 < .01* 
Emotional Function        
Model 1 
     MVPA (min/week) 
     Baseline emotional function 







-0.01      0.06 
 0.23      1.31 
















     Total PA (min/day) 
     Baseline emotional function 







-0.10      0.17 
 0.09      1.54 















     Steps per day 
     Baseline emotional function 







-0.00      0.00 
 0.16      1.26 














Abbreviations. CI, confidence interval; FMI, fraction of missing information; MVPA, moderate to vigorous physical activity; 
OIPN, oxaliplatin-induced peripheral neuropathy; PA, physical activity; QOL, quality of life; RE, relative efficiency; RVI, 
relative variance increase. 
*, Significant two-sided difference (p < .05). 
aThe p-value refers to the statistical significance of the full regression model. 








 This pilot study revealed that the MI-Walk Intervention was no more or less effective 
than PA education alone in reducing OIPN severity and improving QOL and function by the 
eight-week study endpoint (10 weeks into oxaliplatin-based treatment) among GI cancer 
survivors. Sensory and motor OIPN symptoms significantly increased from baseline to eight-
weeks but remained mild in severity at the eight-week time point. Tingling in the fingers and 
hands was most prevalent and demonstrated the greatest increase from baseline to the eight-week 
time point. Exploratory analysis showed that female gender and engagement in fewer minutes of 
MVPA per week may be additional factors associated with more severe eight-week sensory 
OIPN severity and worse QOL. Ultimately, self-reported PA level was similar between groups at 
and had significantly increased from baseline in the control group by eight weeks, suggesting 
potential bias and a lack of assay sensitivity.. 
No other studies to date have evaluated a comprehensive motivational enhancement 
therapy- and home-based eight-week aerobic walking intervention, compared to PA education 
alone, to reduce OIPN. However, several studies have tested home-based aerobic exercise 
interventions among individuals receiving neurotoxic chemotherapy treatment and provide 
insight on the effects of various interventions on MVPA levels, and CIPN and QOL outcomes. 
Confounding bias due to a lack of difference in PA levels between groups has been a prevalent 
problem in prior exercise trials among patients receiving cancer treatment (Furmaniak, Menig, & 
Markes, 2016). For example, some studies have shown equal increases in self-reported PA levels 
and/or fitness between control group participants who received weekly to every other week 
telephone follow-up alone and intervention participants who received a tailored MVPA 





have shown efficacy of a simple exercise prescription from an oncologist in improving PA levels. 
Although increasing exercise in cancer survivors is theorized as a complex behavior that requires 
complex interventions like the MI-Walk Intervention, the current study suggests PA education 
with telephone follow-up every two weeks could be equally effective. Some evidence also 
suggests PA education and weekly to every two week-follow-up by a nurse, oncologist, or 
trained therapist may be sufficient to promote the optimal short-term increases in MVPA among 
patients receiving active cancer treatment (Cadmus et al., 2009; Griffith et al., 2009; Hawkes et 
al., 2013; L. W. Jones, Courneya, Fairey, & Mackey, 2004; Mock et al., 2005; Swenson, Nissen, 
& Henly, 2010).  
The observed small increases in OIPN in the current study match the literature that 
suggests aerobic exercise may blunt but not completely prevent the development of acute CIPN. 
However, the mean sensory OIPN severities observed in both groups at eight weeks may have 
been less severe than the average sensory OIPN severities (CIPN20 sensory scores) that have 
previously been observed at the sixth cycle of oxaliplatin (M = 12-15) (Loprinzi et al., 2014; 
Pachman et al., 2015, 2016; Zimmerman et al., 2016). The observed mean motor OIPN severity 
in this study did not appear lower than the averages observed previously (Pachman et al., 2015, 
2016). Reduction but not complete prevention of CIPN was also observed in other aerobic 
exercise-containing intervention trials among patients who were just starting active neurotoxic 
chemotherapy treatment and had no baseline peripheral neuropathy (Courneya et al., 2013, 2014; 
Henke et al., 2014; Kleckner et al., 2018; Streckmann et al., 2014). However, the studies were 
not designed to evaluate CIPN as the primary outcome and lacked optimal measurement and 
evaluation of the intervention effect on long term CIPN persistence. Specifically, the CIPN 





on a general peripheral neuropathy on the EORTC QLQ-lung cancer 13 module to measure 
CIPN (Henke et al., 2014). Another study evaluated taxane- and platinum-based CIPN, using a 
zero to 10 numeric rating scale of numbness/tingling and hot/cold sensation that had not been 
previously tested for reliability and validity (Kleckner et al., 2018).  
The finding that tingling in the fingers and hands was the most severe and bothersome 
mirrors the results of other studies that suggest tingling in the fingers, hands, toes, and feet are 
the earliest and most severe cumulative OIPN symptoms (Barton et al., 2011; Grothey et al., 
2011; Loprinzi et al., 2014; Pachman et al., 2015, 2016; Ventzel, Jensen, et al., 2016; 
Zimmerman et al., 2016). Another recent study also showed tingling in the fingers and hands 
may interfere the most with daily activities (Drott et al., 2019). Thus, tingling in the fingers and 
hands should be a primary focus of subsequent studies in patients receiving oxaliplatin. 
The optimal intensity of PA (i.e., step counts and light to vigorous PA versus MVPA) to 
target CIPN is unclear. The current study showed trends of associations between more Fitbit-
measured minutes of MVPA and less severe OIPN and improved QOL and function at eight 
weeks. Other evidence also suggests that home-based aerobic exercise-containing interventions 
could lead to reduced CIPN (McCrary et al., 2019), and improved physical function and QOL 
(McCrary et al., 2019; Mizrahi et al., 2015). Specifically, one quasi-experiment found reductions 
in sensory CIPN signs and symptoms (per the CIPN20 and Total Neuropathy Score) and 
improved physical function and overall QOL after an eight-week home- and clinic-based aerobic, 
strength, and balance training intervention among individuals with baseline chronic CIPN 
(McCrary et al., 2019). Another RCT suggested the benefits of light-intensity PA for CIPN. 
Specifically, the study showed better sensory CIPN outcomes (per 0-10 numeric rating scale) 





six-week home- and step count-based PA and elastic band strength training intervention 
compared to the no exercise control group (Kleckner et al., 2018).   
The pathophysiology of OIPN and the potential mechanisms that could mediate the 
influence of aerobic exercise on OIPN is still under investigation. Some evidence suggests that 
aerobic exercise may decrease OIPN primarily by bolstering blood circulation and reducing 
oxidative stress and neuronal apoptosis (Azizbeigi et al., 2015; Chang et al., 2015; Di Cesare 
Mannelli et al., 2012; Gomez-Cabrera et al., 2015; L. W. Jones et al., 2014; Karimi & Roshan, 
2013; Park et al., 2013; Schaun et al., 2011; Tofthagen et al., 2013; Zhou et al., 2016). Aerobic 
exercise may also reduce OIPN by decreasing inflammation (Chen, Tzeng, Lin, Hung, & Wang, 
2014; S. B. Jones et al., 2013; Rogers et al., 2013; Schmidt et al., 2016; Yoon, Thakur, Isham, 
Fayad, & Chattopadhyay, 2015), and improving neuronal metabolism, homeostasis (Dobson, 
McMillan, & Li, 2014; Marcelino et al., 2013; Marques-Aleixo, Oliveira, Moreira, Magalhaes, & 
Ascensao, 2012), and coordination/regulation of firing and inhibition (Taube & Gollhofer, 2010; 
Taube, Gruber, et al., 2007; Taube, Kullmann, et al., 2007). The release of endogenous opioids 
(Kim, Byun, & Choi, 2015; Stagg et al., 2011), pain-inhibiting neurotransmitters (Bobinski et al., 
2015; Kami, Taguchi Ms, Tajima, & Senba, 2016), and neurotrophic factors (Detloff, Smith, 
Quiros Molina, Ganzer, & Houle, 2014; Molteni, Zheng, Ying, Gomez-Pinilla, & Twiss, 2004; 
Seo et al., 2009; Zhou et al., 2016) are well-known effects of aerobic exercise that may moderate 
OIPN severity. Finally, aerobic exercise may help to reduce symptom and psychological distress 
that are known to cluster and interact with OIPN (e.g., fatigue, anxiety, and depression) (Cramp 
& Byron-Daniel, 2012; Furmaniak et al., 2016; Mishra, Scherer, Snyder, Geigle, & Gotay, 2015; 





2011) and bolster coping, mood, and positive lifestyle behaviors (Courneya, 2014; Lynch, Cerin, 
Owen, Hawkes, & Aitken, 2008; Peddle, Au, & Courneya, 2008; Thraen-Borowski et al., 2013). 
Exploratory findings of the current study noted that mood and female gender may 
independently be potential predictors of poorer OIPN and QOL outcomes in participants of an 
exercise intervention study. A prior study has demonstrated that higher baseline mood may 
predict better response to CIPN treatments, such as duloxetine—the only currently endorsed drug 
to treat established CIPN (Smith et al., 2017). Additionally, OIPN may cluster and interact with 
anxiety and depression; and influence QOL and function (Knoerl, Chornoby, & Smith, 2018, 
2019; Mols et al., 2013; Skerman, Yates, & Battistutta, 2012). Mood may have also indirectly 
influenced the outcomes: aerobic exercise has frequently shown associations with improved 
mood and QOL (Ekkekakis, Parfitt, & Petruzzello, 2011; Hawkes et al., 2013; Henriksson, 
Arving, Johansson, Igelstrom, & Nordin, 2016; Mas et al., 2015) and potentially lower symptom 
burden (Low et al., 2017).  
A similar home-based PA trial also showed that males responded and had better CIPN 
outcomes (Kleckner et al., 2018). The findings in the current study that gender effects only 
influenced physical but not emotional function suggest that several physiological differences are 
likely responsible for mediating or moderating the effects of aerobic exercise on OIPN. Gender-
based differences in the cardiovascular, musculoskeletal, metabolic, immune, and 
neuroendocrine system adaptation to exercise training may alter and blunt the effects of aerobic 
exercise on OIPN. For example, prominent differences in the cardiovascular and pulmonary 
systems and their response to aerobic exercise include decreased lung capacity (Talaminos 
Barroso, Marquez Martin, Roa Romero, & Ortega Ruiz, 2018; Townsend, Miller, & Prakash, 





to men (Barnes & Fu, 2018; Kouvari, Yannakoulia, Souliotis, & Panagiotakos, 2018). Further, 
women may have increased pain sensitivity (Kowalczyk et al., 2010; Maurer, Lissounov, 
Knezevic, Candido, & Knezevic, 2016; Popescu, LeResche, Truelove, & Drangsholt, 2010), and 
greater activation of the amygdala, hypothalamus, and stress response to noxious stimuli than 
men (Jancke, 2018). Additional evidence is also emerging related to the effects of sex steroid 
hormones on gene expression, neurotransmitters, neurodegeneration, and inflammatory 
responses (Forger, Strahan, & Castillo-Ruiz, 2016; Kohman, Bhattacharya, Wojcik, & Rhodes, 
2013; McCarthy, Nugent, & Lenz, 2017; McCarthy, Pickett, VanRyzin, & Kight, 2015; Popescu 
et al., 2010; Villa, Della Torre, & Maggi, 2019). 
Limitations 
 The results of this study may only be applicable to younger, white, GI cancer survivors 
with few to no comorbidities. The small sample size may have limited the power to detect 
significant changes in the outcomes, and the convenience sampling method may have biased the 
results. Further, inadequate assay sensitivity—"the ability of a trial to distinguish an effective 
from an ineffective treatment” (Food and Drug Administration & HHS, 2001)—may have 
contributed to the current study’s inability to detect significant results (Dworkin et al., 2012). 
Specifically, the timing of outcome measurement may have been premature in the study. Sensory 
and motor OIPN severities were still mild in severity at the eight-week time point (coinciding 
with the sixth infusion). Additionally, acute OIPN fluctuates; thus, recommendations suggest 
repeated pain measurements to obtain an adequately reliable response that could maximize the 
study’s ability to detect significant differences (Heapy et al., 2014). 
Additionally, total PA level could not be evaluated as a covariate in the analyses due to 





received an ActiGraph GT9X Link and scripted instructions to wear it during the day even when 
napping or resting; yet, several participants did not wear the ActiGraph on days when they were 
physically inactive. Other participants lost their ActiGraphs while walking outside. Ultimately, 
over half of the ActiGraph data were missing, presumably not at random. The high risk of 
confounding bias due to the observed increase in self-reported PA among the control group 
participants inhibited the study’s evaluation of whether the mild eight-week OIPN levels were 
due to the efficacy of the interventions/higher levels.   
Additionally, the first author recruited participants, conducted the MI-Walk Intervention, 
and provided the PA education to the control group participants. The first author could have 
unintentionally provided motivational interviewing to both groups of participants during the 
intervention orientation and follow-up phone calls. Further, inadequate participant blinding could 
have led to compensatory rivalry bias and placebo effects, particularly because the PA education 
reviewed the broad health- and cancer treatment-related benefits of exercise. 
Conclusions 
The results of this study are inconclusive regarding the efficacy of home-based aerobic 
walking for OIPN due to limited assay sensitivity. The MI-Walk Intervention was no more 
effective than PA education alone at improving self-reported PA levels. Further consideration is 
needed regarding the most effective home-based aerobic exercise intervention components to 
maximize MVPA among individuals receiving neurotoxic chemotherapy and appropriate control 
conditions. 
Future directions. Further study of the effects of home-based aerobic exercise on OIPN 





receive separate interventions. The control condition, if education-based, should focus on broad 
health or other education other than PA.   
In future studies, the CIPN outcome measures should be specific to the type of neurotoxic 
chemotherapy. For example, this study found that tingling in the fingers and hands was the most 
severe symptom of OIPN; thus, investigators of OIPN outcomes may want to evaluate tingling of 
the fingers and hands as one of their primary measures. The utilization of both patient-reported 
measures and clinical assessment of OIPN would also strengthen the studies. Finally, future 
studies should evaluate mediators and moderators of the effects of aerobic exercise on OIPN 
development and QOL. For example, future studies could evaluate gender as a moderator of the 
effects of aerobic exercise on sensory OIPN, and studies could evaluate mood as a mediator of 
the effects of aerobic exercise on QOL and fatigue.  
Ultimately, the goal is for future trials to contribute toward developing the most optimal 
exercise prescriptions for maximizing MVPA, QOL, and function, and reducing cancer treatment 
side effects, including OIPN. Currently, the focus must still be on establishing or refuting the 
efficacy of aerobic exercise for OIPN and understanding the intervention’s mediating mechanism 
of actions. If shown effective, the science should aim to uncover the optimal type, dosage, and 
delivery of exercise for OIPN and other types of CIPN, as well as the most accessible, 







Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., … de Haes, J. 
C. (1993). The European Organization for Research and Treatment of Cancer QLQ-C30: 
A quality-of-life instrument for use in international clinical trials in oncology. Journal of 
the National Cancer Institute, 85(5), 365–376. 
Alberti, P., Rossi, E., Cornblath, D. R., Merkies, I. S. J., Postma, T. J., Frigeni, B., … Cavaletti, 
G. (2014). Physician-assessed and patient-reported outcome measures in chemotherapy-
induced sensory peripheral neurotoxicity: Two sides of the same coin. Annals of 
Oncology, 25(1), 257–264. https://doi.org/10.1093/annonc/mdt409 
American Cancer Society. (2014). Physical Activity and the Cancer Patient. Retrieved February 
3, 2017, from https://www.cancer.org/treatment/survivorship-during-and-after-
treatment/staying-active/physical-activity-and-the-cancer-patient.html%0D 
Andre, T., Boni, C., Mounedji-Boudiaf, L., Navarro, M., Tabernero, J., Hickish, T., … de 
Gramont, A. (2004). Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for 
colon cancer. The New England Journal of Medicine, 350(23), 2343–2351. 
https://doi.org/10.1056/NEJMoa032709 
Argyriou, A. A., Bruna, J., Marmiroli, P., & Cavaletti, G. (2012). Chemotherapy-induced 
peripheral neurotoxicity (CIPN): An update. Critical Reviews in Oncology/Hematology, 
82(1), 51–77. https://doi.org/10.1016/j.critrevonc.2011.04.012 
Argyriou, A. A., Cavaletti, G., Briani, C., Velasco, R., Bruna, J., Campagnolo, M., … Kalofonos, 
H. P. (2013). Clinical pattern and associations of oxaliplatin acute neurotoxicity: A 




Azizbeigi, K., Azarbayjani, M. A., Atashak, S., & Stannard, S. R. (2015). Effect of moderate and 
high resistance training intensity on indices of inflammatory and oxidative stress. 






Bai, Y., Hibbing, P., Mantis, C., & Welk, G. J. (2018). Comparative evaluation of heart rate-
based monitors: Apple Watch vs Fitbit Charge HR. Journal of Sports Sciences, 36(15), 
1734–1741. https://doi.org/10.1080/02640414.2017.1412235 
Bao, T., Basal, C., Seluzicki, C., Li, S. Q., Seidman, A. D., & Mao, J. J. (2016). Long-term 
chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, 
risk factors, and fall risk. Breast Cancer Research and Treatment, 159(2), 327–333. 
https://doi.org/10.1007/s10549-016-3939-0 
Barnes, J. N., & Fu, Q. (2018). Sex-Specific Ventricular and Vascular Adaptations to Exercise 
BT  - Sex-Specific Analysis of Cardiovascular Function. In P. L. M. Kerkhof & V. M. 
Miller (Eds.) (pp. 329–346). Cham: Springer International Publishing. 
https://doi.org/10.1007/978-3-319-77932-4_21 
Barton, D. L., Wos, E. J., Qin, R., Mattar, B. I., Green, N. B., Lanier, K. S., … Loprinzi, C. L. 
(2011). A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-
induced peripheral neuropathy: NCCTG trial N06CA. Supportive Care in Cancer, 19(6), 
833–841. https://doi.org/10.1007/s00520-010-0911-0 
Beijers, A. J. M., Mols, F., Tjan-Heijnen, V. C. G., Faber, C. G., van de Poll-Franse, L. V, & 
Vreugdenhil, G. (2015). Peripheral neuropathy in colorectal cancer survivors: The 
influence of oxaliplatin administration. Results from the population-based PROFILES 
registry. Acta Oncologica, 54(4), 463–469. 
https://doi.org/10.3109/0284186X.2014.980912 
Berger, A. M. A. M. (2010). Fatigue and other variables during adjuvant chemotherapy for colon 
and rectal cancer. Oncology Nursing Forum, 37(6), E359–E369. 
https://doi.org/10.1188/10.ONF.E359-E369 
Binkley, J. M., Harris, S. R., Levangie, P. K., Pearl, M., Guglielmino, J., Kraus, V., & Rowden, 
D. (2012). Patient perspectives on breast cancer treatment side effects and the prospective 
surveillance model for physical rehabilitation for women with breast cancer. Cancer, 
118(8 Suppl), 2207–2216. https://doi.org/10.1002/cncr.27469 
Bobinski, F., Ferreira, T. A. A., Cordova, M. M., Dombrowski, P. A., da Cunha, C., Santo, C. C. 
do E., … Santos, A. R. S. (2015). Role of brainstem serotonin in analgesia produced by 
low-intensity exercise on neuropathic pain after sciatic nerve injury in mice. Pain, 





Borg, G. (1998). Borg’s perceived exertion and pain scales. Borg’s perceived exertion and pain 
scales. Champaign, IL, US: Human Kinetics. 
Breusch, T., & Pagan, A. (1979). A simple test for heteroscedasticity and random coefficient 
variation. Econometrica, 47, 1287–1294. 
Brooke, S. M., An, H.-S., Kang, S.-K., Noble, J. M., Berg, K. E., & Lee, J.-M. (2017). 
Concurrent Validity of Wearable Activity Trackers Under Free-Living Conditions. 
Journal of Strength and Conditioning Research, 31(4), 1097–1106. 
https://doi.org/10.1519/JSC.0000000000001571 
Brydoy, M., Oldenburg, J., Klepp, O., Bremnes, R. M., Wist, E. A., Wentzel-Larsen, T., … Fossa, 
S. D. (2009). Observational study of prevalence of long-term Raynaud-like phenomena 
and neurological side effects in testicular cancer survivors. Journal of the National 
Cancer Institute, 101(24), 1682–1695. https://doi.org/10.1093/jnci/djp413 
Burton, E., Hill, K. D., Lautenschlager, N. T., Thogersen-Ntoumani, C., Lewin, G., Boyle, E., & 
Howie, E. (2018). Reliability and validity of two fitness tracker devices in the laboratory 
and home environment for older community-dwelling people. BMC Geriatrics, 18(1), 
103. https://doi.org/10.1186/s12877-018-0793-4 
Cadmus, L. A., Salovey, P., Yu, H., Chung, G., Kasl, S., & Irwin, M. L. (2009). Exercise and 
quality of life during and after treatment for breast cancer: Results of two randomized 
controlled trials. Psycho-Oncology, 18(4), 343–352. https://doi.org/10.1002/pon.1525 
Cankurtaran, E. S., Ozalp, E., Soygur, H., Ozer, S., Akbiyik, D. I., & Bottomley, A. (2008). 
Understanding the reliability and validity of the EORTC QLQ-C30 in Turkish cancer 
patients. European Journal of Cancer Care, 17(1), 98–104. 
https://doi.org/10.1111/j.1365-2354.2007.00827.x 
Carozzi, V. A., Canta, A., & Chiorazzi, A. (2015). Chemotherapy-induced peripheral neuropathy: 
What do we know about mechanisms? Neuroscience Letters, 596, 90–107. 
https://doi.org/10.1016/j.neulet.2014.10.014 
Cavaletti, G., Cornblath, D. R., Merkies, I. S. J., Postma, T. J., Rossi, E., Frigeni, B., … Pessino, 
A. (2013). The chemotherapy-induced peripheral neuropathy outcome measures 
standardization study: From consensus to the first validity and reliability findings. Annals 





Chang, C.-F., Chang, C.-C., Hwang, S.-L., & Chen, M.-Y. (2015). Effects of Buerger exercise 
combined health-promoting program on peripheral neurovasculopathy among community 
residents at high risk for diabetic foot ulceration. Worldviews on Evidence-Based 
Nursing, 12(3), 145–153. https://doi.org/10.1111/wvn.12091 
Chen, Y.-W., Tzeng, J.-I., Lin, M.-F., Hung, C.-H., & Wang, J.-J. (2014). Forced treadmill 
running suppresses postincisional pain and inhibits upregulation of substance P and 
cytokines in rat dorsal root ganglion. The Journal of Pain, 15(8), 827–834. 
https://doi.org/10.1016/j.jpain.2014.04.010 
Courneya, K. S. (2014). A multicenter randomized trial of the effects of exercise dose and type 
on psychosocial distress in breast cancer patients undergoing chemotherapy. Cancer 
Epidemiology, Biomarkers & Prevention, 23(5), 857–864. https://doi.org/10.1158/1055-
9965.EPI-13-1163 
Courneya, K. S., Friedenreich, C. M., Quinney, H. A., Fields, A. L. A., Jones, L. W., & Fairey, A. 
S. (2004). Predictors of adherence and contamination in a randomized trial of exercise in 
colorectal cancer survivors. Psycho-Oncology, 13(12), 857–866. 
https://doi.org/10.1002/pon.802 
Courneya, K. S., McKenzie, D. C., Mackey, J. R., Gelmon, K., Friedenreich, C. M., Yasui, Y., … 
Segal, R. J. (2013). Effects of exercise dose and type during breast cancer chemotherapy: 
Multicenter randomized trial. Journal of the National Cancer Institute, 105(23), 1821–
1832. https://doi.org/10.1093/jnci/djt297 
Courneya, K. S., McKenzie, D. C., Mackey, J. R., Gelmon, K., Friedenreich, C. M., Yasui, Y., … 
Segal, R. J. (2014). Subgroup effects in a randomised trial of different types and doses of 
exercise during breast cancer chemotherapy. British Journal of Cancer, 111(9), 1718–
1725. https://doi.org/10.1038/bjc.2014.466 
Cox-Martin, E., Trahan, L. H., Cox, M. G., Dougherty, P. M., Lai, E. A., & Novy, D. M. (2017). 
Disease burden and pain in obese cancer patients with chemotherapy-induced peripheral 
neuropathy. Supportive Care in Cancer, 25(6), 1873–1879. 
https://doi.org/10.1007/s00520-017-3571-5 
Cramp, F., & Byron-Daniel, J. (2012). Exercise for the management of cancer-related fatigue in 






de la Morena Barrio, P., Conesa, M. A. V., Gonzalez-Billalabeitia, E., Urrego, E., Garcia-Garre, 
E., Garcia-Martinez, E., … de la Pena, F. A. (2015). Delayed recovery and increased 
severity of Paclitaxel-induced peripheral neuropathy in patients with diabetes. JNCCN, 
13(4), 417–423. 
Dermitzakis, E. V, Kimiskidis, V. K., Lazaridis, G., Alexopoulou, Z., Timotheadou, E., 
Papanikolaou, A., … Fountzilas, G. (2016). The impact of paclitaxel and carboplatin 
chemotherapy on the autonomous nervous system of patients with ovarian cancer. BMC 
Neurology, 16(1), 190. https://doi.org/10.1186/s12883-016-0710-4 
Detloff, M. R., Smith, E. J., Quiros Molina, D., Ganzer, P. D., & Houle, J. D. (2014). Acute 
exercise prevents the development of neuropathic pain and the sprouting of  non-
peptidergic (GDNF- and artemin-responsive) c-fibers after spinal cord injury. 
Experimental Neurology, 255, 38–48. https://doi.org/10.1016/j.expneurol.2014.02.013 
Dhawan, S., Andrews, R., Kumar, L., Wadhwa, S., & Shukla, G. (2019). A randomized 
controlled trial to assess the effectiveness of muscle strengthening and balancing 
exercises on chemotherapy-induced peripheral neuropathic pain and quality of life among 
cancer patients. Cancer Nursing. https://doi.org/10.1097/NCC.0000000000000693 
Di Cesare Mannelli, L., Zanardelli, M., Failli, P., & Ghelardini, C. (2012). Oxaliplatin-induced 
neuropathy: Oxidative stress as pathological mechanism. Protective effect of silibinin. 
The Journal of Pain, 13(3), 276–284. https://doi.org/10.1016/j.jpain.2011.11.009 
Dinger, M. K., Oman, R. F., Taylor, E. L., Vesely, S. K., & Able, J. (2004). Stability and 
convergent validity of the Physical Activity Scale for the Elderly  (PASE). The Journal of 
Sports Medicine and Physical Fitness, 44(2), 186–192. 
Dobson, J. L., McMillan, J., & Li, L. (2014). Benefits of exercise intervention in reducing 
neuropathic pain. Frontiers in Cellular Neuroscience, 8, 102. 
https://doi.org/10.3389/fncel.2014.00102 
Drott, J., Fomichov, V., Starkhammar, H., Borjeson, S., Kjellgren, K., & Bertero, C. (2019). 
Oxaliplatin-induced neurotoxic side effects and their impact on daily activities: A 






Dworkin, R. H., Turk, D. C., Farrar, J. T., Haythornthwaite, J. A., Jensen, M. P., Katz, N. P., … 
Witter, J. (2005). Core outcome measures for chronic pain clinical trials: IMMPACT 
recommendations. Pain, 113(1–2), 9–19. https://doi.org/10.1016/j.pain.2004.09.012 
Dworkin, R. H., Turk, D. C., Peirce-Sandner, S., Burke, L. B., Farrar, J. T., Gilron, I., … Ziegler, 
D. (2012). Considerations for improving assay sensitivity in chronic pain clinical trials: 
IMMPACT recommendations. Pain, 153(6), 1148–1158. 
https://doi.org/10.1016/j.pain.2012.03.003 
Ekkekakis, P., Parfitt, G., & Petruzzello, S. J. (2011). The pleasure and displeasure people feel 
when they exercise at different intensities: Decennial update and progress towards a 
tripartite rationale for exercise intensity prescription. Sports Medicine, 41(8), 641–671. 
https://doi.org/10.2165/11590680-000000000-00000 
El-Shami, K., Oeffinger, K. C., Erb, N. L., Willis, A., Bretsch, J. K., Pratt-Chapman, M. L., … 
Cowens-Alvarado, R. L. (2015). American Cancer Society colorectal cancer survivorship 
care guidelines. CA Cancer Journal for Clinicians, 65(6), 427–455. 
https://doi.org/10.3322/caac.21286 
Exposito Vizcaino, S., Casanova-Molla, J., Escoda, L., Galan, S., & Miro, J. (2018). Neuropathic 
pain in cancer patients treated with bortezomib. Neurologia, 33(1), 28–34. 
https://doi.org/10.1016/j.nrl.2016.05.008 
Farrar, J. T., Young, J. P. J., LaMoreaux, L., Werth, J. L., & Poole, R. M. (2001). Clinical 
importance of changes in chronic pain intensity measured on an 11-point  numerical pain 
rating scale. Pain, 94(2), 149–158. 
Feehan, L. M., Geldman, J., Sayre, E. C., Park, C., Ezzat, A. M., Yoo, J. Y., … Li, L. C. (2018). 
Accuracy of Fitbit devices: Systematic review and narrative syntheses of quantitative 
data. JMIR MHealth and UHealth, 6(8), e10527–e10527. https://doi.org/10.2196/10527 
Fernandes, J., & Kumar, S. (2016). Effect of lower limb closed kinematic chain exercises on 
balance in patients with chemotherapy-induced peripheral neuropathy: A pilot study. 
International Journal of Rehabilitation Research. 
https://doi.org/10.1097/MRR.0000000000000196 






Food and Drug Administration, & HHS. (2001). International Conference on Harmonisation. 
E10: Choice of control groups and related issues in clinical trials. Federal Register, 
66(93), 24390–24391. Retrieved from https://www.govinfo.gov/content/pkg/FR-2001-05-
14/pdf/01-12026.pdf 
Forger, N. G., Strahan, A. J., & Castillo-Ruiz, A. (2016). Cellular and molecular mechanisms of 
sexual differentiation in the mammalian nervous system. Frontiers in 
Neuroendocrinology, 40, 67–86. https://doi.org/10.1016/j.yfrne.2016.01.001 
Forsen, L., Loland, N. W., Vuillemin, A., Chinapaw, M. J. M., van Poppel, M. N. M., Mokkink, 
L. B., … Terwee, C. B. (2010). Self-administered physical activity questionnaires for the 
elderly: A systematic review of measurement properties. Sports Medicine, 40(7), 601–
623. https://doi.org/10.2165/11531350-000000000-00000 
Furmaniak, A. C., Menig, M., & Markes, M. H. (2016). Exercise for women receiving adjuvant 
therapy for breast cancer. Cochrane Database of Systematic Reviews, 2016(9). 
https://doi.org/10.1002/14651858.CD005001.pub3 
Giannoccaro, M. P., Donadio, V., Gomis Perez, C., Borsini, W., Di Stasi, V., & Liguori, R. (2011, 
April). Somatic and autonomic small fiber neuropathy induced by bortezomib therapy: 
An immunofluorescence study. Neurological Sciences. Italy. 
https://doi.org/10.1007/s10072-010-0475-2 
Gomez-Cabrera, M. C., Salvador-Pascual, A., Cabo, H., Ferrando, B., & Vina, J. (2015). Redox 
modulation of mitochondriogenesis in exercise. Does antioxidant supplementation blunt 
the benefits of exercise training? Free Radical Biology & Medicine, 86, 37–46. 
https://doi.org/10.1016/j.freeradbiomed.2015.04.006 
Granger, C. L., Parry, S. M., & Denehy, L. (2015). The self-reported Physical Activity Scale for 
the Elderly (PASE) is a valid and clinically applicable measure in lung cancer. Supportive 
Care in Cancer, 23(11), 3211–3218. https://doi.org/10.1007/s00520-015-2707-8 
Greenlee, H., Hershman, D. L., Shi, Z., Kwan, M. L., Ergas, I. J., Roh, J. M., & Kushi, L. H. 
(2017). BMI, lifestyle factors and taxane-induced neuropathy in breast cancer patients: 






Gresham, G., Hendifar, A. E., Spiegel, B., Neeman, E., Tuli, R., Rimel, B. J., … Shinde, A. M. 
(2018). Wearable activity monitors to assess performance status and predict clinical 
outcomes in advanced cancer patients. Npj Digital Medicine, 1(1), 27. 
Griffith, K., Wenzel, J., Shang, J., Thompson, C., Stewart, K., & Mock, V. (2009). Impact of a 
walking intervention on cardiorespiratory fitness, self-reported physical function, and 
pain in patients undergoing treatment for solid tumors. Cancer, 115(20), 4874–4884. 
https://doi.org/10.1002/cncr.24551 
Grothey, A., Nikcevich, D. A., Sloan, J. A., Kugler, J. W., Silberstein, P. T., Dentchev, T., … 
Loprinzi, C. L. (2011). Intravenous calcium and magnesium for oxaliplatin-induced 
sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. Journal of Clinical 
Oncology, 29(4), 421–427. https://doi.org/10.1200/JCO.2010.31.5911 
Hawkes, A. L., Chambers, S. K., Pakenham, K. I., Patrao, T. A., Baade, P. D., Lynch, B. M., … 
Courneya, K. S. (2013). Effects of a telephone-delivered multiple health behavior change 
intervention (CanChange) on health and behavioral outcomes in survivors of colorectal 
cancer: A randomized controlled trial. Journal of Clinical Oncology, 31(18), 2313–2321. 
https://doi.org/10.1200/JCO.2012.45.5873 
Heapy, A., Dziura, J., Buta, E., Goulet, J., Kulas, J. F., & Kerns, R. D. (2014). Using multiple 
daily pain ratings to improve reliability and assay sensitivity: how many is enough? The 
Journal of Pain : Official Journal of the American Pain Society, 15(12), 1360–1365. 
https://doi.org/10.1016/j.jpain.2014.09.012 
Henke, C. C., Cabri, J., Fricke, L., Pankow, W., Kandilakis, G., Feyer, P. C., & de Wit, M. 
(2014). Strength and endurance training in the treatment of lung cancer patients in stages 
IIIA/IIIB/IV. Supportive Care in Cancer, 22(1), 95–101. https://doi.org/10.1007/s00520-
013-1925-1 
Henriksson, A., Arving, C., Johansson, B., Igelstrom, H., & Nordin, K. (2016). Perceived barriers 
to and facilitators of being physically active during adjuvant cancer treatment. Patient 
Education and Counseling, 99(7), 1220–1226. https://doi.org/10.1016/j.pec.2016.01.019 
Hershman, D. L., Till, C., Wright, J. D., Awad, D., Ramsey, S. D., Barlow, W. E., … Unger, J. 
(2016). Comorbidities and risk of chemotherapy-induced peripheral neuropathy among 
participants 65 years or older in southwest oncology group clinical trials. Journal of 





Jancke, L. (2018). Sex/gender differences in cognition, neurophysiology, and neuroanatomy 
[version 1; peer review: 3 approved]. F1000Research, 7(805). 
https://doi.org/10.12688/f1000research.13917.1 
Jones, L. W., Courneya, K. S., Fairey, A. S., & Mackey, J. R. (2004). Effects of an oncologist’s 
recommendation to exercise on self-reported exercise behavior in newly diagnosed breast 
cancer survivors: A single-blind, randomized controlled trial. Annals of Behavioral 
Medicine, 28(2), 105–113. https://doi.org/10.1207/s15324796abm2802_5 
Jones, L. W., Hornsby, W. E., Freedland, S. J., Lane, A., West, M. J., Moul, J. W., … Eves, N. D. 
(2014). Effects of nonlinear aerobic training on erectile dysfunction and cardiovascular 
function following radical prostatectomy for clinically localized prostate cancer. 
European Urology, 65(5), 852–855. https://doi.org/10.1016/j.eururo.2013.11.009 
Jones, S. B., Thomas, G. A., Hesselsweet, S. D., Alvarez-Reeves, M., Yu, H., & Irwin, M. L. 
(2013). Effect of exercise on markers of inflammation in breast cancer survivors: The 
Yale exercise and survivorship study. Cancer Prevention Research, 6(2), 109–118. 
https://doi.org/10.1158/1940-6207.CAPR-12-0278 
Kami, K., Taguchi Ms, S., Tajima, F., & Senba, E. (2016). Improvements in impaired GABA and 
GAD65/67 production in the spinal dorsal horn contribute to exercise-induced 
hypoalgesia in a mouse model of neuropathic pain. Molecular Pain, 12. 
https://doi.org/10.1177/1744806916629059 
Karimi, N., & Roshan, V. D. (2013). Change in adiponectin and oxidative stress after modifiable 
lifestyle interventions in breast cancer cases. Asian Pacific Journal of Cancer Prevention, 
14(5), 2845–2850. 
Kawakami, K., Tunoda, T., Takiguchi, T., Shibata, K., Ohtani, T., Kizu, J., … Taguchi, K. (2012). 
Factors exacerbating peripheral neuropathy induced by paclitaxel plus carboplatin in non-
small cell lung cancer. Oncology Research, 20(4), 179–185. 
Kerckhove, N., Collin, A., Conde, S., Chaleteix, C., Pezet, D., & Balayssac, D. (2017). Long-
term effects, pathophysiological mechanisms, and risk factors of chemotherapy-induced 
peripheral neuropathies: A comprehensive literature review. Frontiers in Pharmacology, 





Kim, Y.-J., Byun, J.-H., & Choi, I.-S. (2015). Effect of exercise on micro-opioid receptor 
expression in the rostral ventromedial medulla in neuropathic pain rat model. Annals of 
Rehabilitation Medicine, 39(3), 331–339. https://doi.org/10.5535/arm.2015.39.3.331 
Kleckner, I. R., Kamen, C., Gewandter, J. S., Mohile, N. A., Heckler, C. E., Culakova, E., … 
Musian, K. M. (2018). Effects of exercise during chemotherapy on chemotherapy-
induced peripheral neuropathy: A multicenter, randomized controlled trial. Supportive 
Care in Cancer, 26(4), 1019–1028. https://doi.org/10.1007/s00520-017-4013-0 
Knoerl, R., Chornoby, Z., & Smith, E. M. L. (2018). Estimating the frequency, severity, and 
clustering of SPADE symptoms in chronic painful chemotherapy-induced peripheral 
neuropathy. Pain Management Nursing, 19(4), 354–365. 
https://doi.org/10.1016/j.pmn.2018.01.001 
Knoerl, R., Chornoby, Z., & Smith, E. M. L. (2019). Corrigendum to ‘Estimating the frequency, 
severity, and clustering of SPADE symptoms in chronic painful chemotherapy-induced 
peripheral neuropathy’ Pain Management Nursing 2018;19(4):354-365. Pain 
Management Nursing, 20(1), 88. https://doi.org/10.1016/j.pmn.2018.12.010 
Knoerl, R., Gray, E., Stricker, C., Mitchell, S. A., Kippe, K., Smith, G., … Lavoie Smith, E. M. 
(2017). Electronic versus paper-pencil methods for assessing chemotherapy-induced 
peripheral neuropathy. Supportive Care in Cancer. https://doi.org/10.1007/s00520-017-
3764-y 
Kohman, R. A., Bhattacharya, T. K., Wojcik, E., & Rhodes, J. S. (2013). Exercise reduces 
activation of microglia isolated from hippocampus and brain of aged mice. Journal of 
Neuroinflammation, 10(1), 885. https://doi.org/10.1186/1742-2094-10-114 
Kolb, N. A., Smith, A. G., Singleton, J. R., Beck, S. L., Stoddard, G. J., Brown, S., & Mooney, 
K. (2016). The association of chemotherapy-induced peripheral neuropathy symptoms 
and the risk of falling. JAMA Neurology, 73(7), 860–866. 
https://doi.org/10.1001/jamaneurol.2016.0383 
Kouvari, M., Yannakoulia, M., Souliotis, K., & Panagiotakos, D. B. (2018). Challenges in sex- 
and gender-centered prevention and management of cardiovascular disease: Implications 






Kowalczyk, W. J., Sullivan, M. A., Evans, S. M., Bisaga, A. M., Vosburg, S. K., & Comer, S. D. 
(2010). Sex differences and hormonal influences on response to mechanical pressure pain 
in humans. The Journal of Pain, 11(4), 330–342. 
Krishnan, A. V, & Park, S. B. (2014). Chemotherapy-induced peripheral neuropathy: The end of 
the beginning? Journal of Neurology, Neurosurgery & Psychiatry, 85(4), 359. 
https://doi.org/10.1136/jnnp-2013-305600 
Lavoie Smith, E. M., Barton, D. L., Qin, R., Steen, P. D., Aaronson, N. K., & Loprinzi, C. L. 
(2013). Assessing patient-reported peripheral neuropathy: The reliability and validity of 
the European Organization for Research and Treatment of Cancer QLQ-CIPN20 
Questionnaire. Quality of Life Research, 22(10), 2787–2799. 
https://doi.org/10.1007/s11136-013-0379-8 
Lewis, M. A., Zhao, F., Jones, D., Loprinzi, C. L., Brell, J., Weiss, M., & Fisch, M. J. (2015). 
Neuropathic symptoms and their risk factors in medical oncology outpatients with 
colorectal vs. breast, lung, or prostate cancer: Results from a prospective multicenter 
study. Journal of Pain and Symptom Management, 49(6), 1016–1024. 
https://doi.org/10.1016/j.jpainsymman.2014.11.300 
Li, Q., Lin, Y., Qiu, Y., Gao, B., & Xu, Y. (2014). The assessment of health-related quality of life 
and related factors in Chinese elderly patients undergoing chemotherapy for advanced 
cancer: A cross-sectional study. European Journal of Oncology Nursing, 18(4), 425–435. 
https://doi.org/10.1016/j.ejon.2014.03.005 
Loprinzi, C. L., Qin, R., Dakhil, S. R., Fehrenbacher, L., Flynn, K. A., Atherton, P., … Grothey, 
A. (2014). Phase III randomized, placebo-controlled, double-blind study of intravenous 
calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity 
(N08CB/Alliance). Journal of Clinical Oncology, 32(10), 997–1005. 
https://doi.org/10.1200/JCO.2013.52.0536 
Low, C. A., Dey, A. K., Ferreira, D., Kamarck, T., Sun, W., Bae, S., & Doryab, A. (2017). 
Estimation of symptom severity during chemotherapy from passively sensed data: 
Exploratory study. J Med Internet Res, 19(12), e420. https://doi.org/10.2196/jmir.9046 
Lynch, B. M., Cerin, E., Owen, N., Hawkes, A. L., & Aitken, J. F. (2008). Prospective 





Journal of Clinical Oncology, 26(27), 4480–4487. 
https://doi.org/10.1200/JCO.2007.15.7917 
Marcelino, T. B., Longoni, A., Kudo, K. Y., Stone, V., Rech, A., de Assis, A. M., … Matte, C. 
(2013). Evidences that maternal swimming exercise improves antioxidant defenses and 
induces mitochondrial biogenesis in the brain of young Wistar rats. Neuroscience, 246, 
28–39. https://doi.org/10.1016/j.neuroscience.2013.04.043 
Marques-Aleixo, I., Oliveira, P. J., Moreira, P. I., Magalhaes, J., & Ascensao, A. (2012). Physical 
exercise as a possible strategy for brain protection: Evidence from mitochondrial-
mediated mechanisms. Progress in Neurobiology, 99(2), 149–162. 
https://doi.org/10.1016/j.pneurobio.2012.08.002 
Mas, S., Quantin, X., & Ninot, G. (2015). Barriers to, and facilitators of physical activity in 
patients receiving chemotherapy for lung cancer: An exploratory study. Journal of 
Palliative Care, 31(2), 89–96. Retrieved from 
https://www.scopus.com/inward/record.uri?eid=2-s2.0-
84937859700&partnerID=40&md5=660e8d75227723bc158f1c91cb3aa42e 
Maurer, A. J., Lissounov, A., Knezevic, I., Candido, K. D., & Knezevic, N. N. (2016). Pain and 
sex hormones: A review of current understanding. Pain Management, 6(3), 285–296. 
https://doi.org/10.2217/pmt-2015-0002 
McCarthy, M. M., Nugent, B. M., & Lenz, K. M. (2017). Neuroimmunology and 
neuroepigenetics in the establishment of sex differences in the brain. Nature Reviews. 
Neuroscience, 18(8), 471–484. https://doi.org/10.1038/nrn.2017.61 
McCarthy, M. M., Pickett, L. A., VanRyzin, J. W., & Kight, K. E. (2015). Surprising origins of 
sex differences in the brain. Hormones and Behavior, 76, 3–10. 
https://doi.org/10.1016/j.yhbeh.2015.04.013 
McCrary, J. M., Goldstein, D., Sandler, C. X., Barry, B. K., Marthick, M., Timmins, H. C., … 
Park, S. B. (2019). Exercise-based rehabilitation for cancer survivors with chemotherapy-
induced peripheral neuropathy. Supportive Care in Cancer. 
https://doi.org/10.1007/s00520-019-04680-w 
Miltenburg, N. C., & Boogerd, W. (2014). Chemotherapy-induced neuropathy: A comprehensive 






Mishra, S. I., Scherer, R. W., Snyder, C., Geigle, P., & Gotay, C. (2015). The effectiveness of 
exercise interventions for improving health-related quality of life from diagnosis through 
active cancer treatment. Oncology Nursing Forum, 42(1), E33–E53. 
https://doi.org/10.1188/15.ONF.E33-E53 
Mizrahi, D., Broderick, C., Friedlander, M., Ryan, M., Harrison, M., Pumpa, K., & Naumann, F. 
(2015). An exercise intervention during chemotherapy for women with recurrent ovarian 
cancer: A feasibility study. International Journal of Gynecological Cancer, 25(6), 985–
992. https://doi.org/10.1097/IGC.0000000000000460 
Mock, V., Frangakis, C., Davidson, N. E., Ropka, M. E., Pickett, M., Poniatowski, B., … 
McCorkle, R. (2005). Exercise manages fatigue during breast cancer treatment: A 
randomized controlled trial. Psycho-Oncology, 14(6), 464–477. 
https://doi.org/10.1002/pon.863 
Mols, F., Beijers, A. J. M., Vreugdenhil, G., Verhulst, A., Schep, G., & Husson, O. (2015). 
Chemotherapy-induced peripheral neuropathy, physical activity and health-related quality 
of life among colorectal cancer survivors from the PROFILES registry. Journal of 
Cancer Survivorship, 9(3), 512–522. https://doi.org/10.1007/s11764-015-0427-1 
Mols, F., Beijers, T., Lemmens, V., van den Hurk, C. J., Vreugdenhil, G., & van de Poll-Franse, 
L. V. (2013). Chemotherapy-induced neuropathy and its association with quality of life 
among 2- to 11-year colorectal cancer survivors: Results from the population-based 
PROFILES registry. Journal of Clinical Oncology, 31(21), 2699–2707. 
https://doi.org/10.1200/JCO.2013.49.1514 
Molteni, R., Zheng, J.-Q., Ying, Z., Gomez-Pinilla, F., & Twiss, J. L. (2004). Voluntary exercise 
increases axonal regeneration from sensory neurons. Proceedings of the National 
Academy of Sciences of the United States of America, 101(22), 8473–8478. 
https://doi.org/10.1073/pnas.0401443101 
Monfort, S. M., Pan, X., Patrick, R., Singaravelu, J., Loprinzi, C. L., Lustberg, M. B., & 
Chaudhari, A. M. W. (2016). Natural history of postural instability in breast cancer 
patients treated with taxane-based chemotherapy: A pilot study. Gait & Posture, 48, 237–
242. https://doi.org/10.1016/j.gaitpost.2016.06.011 
Morielli, A. R., Usmani, N., Boule, N. G., Tankel, K., Severin, D., Nijjar, T., … Courneya, K. S. 





intervention in patients with rectal cancer during and after neoadjuvant 
chemoradiotherapy. Oncology Nursing Forum, 43(3), 352–362. 
https://doi.org/10.1188/16.ONF.352-362 
Nazari, G., MacDermid, J. C., Sinden, K. E., Richardson, J., & Tang, A. (2019). Inter-instrument 
reliability and agreement of Fitbit Charge measurements of heart rate and activity at rest, 
during the Modified Canadian Aerobic Fitness Test, and in recovery. Physiotherapy 
Canada, 71(3), 197–206. https://doi.org/10.3138/ptc.2018-25 
Nazir, H. F., AlFutaisi, A., Zacharia, M., Elshinawy, M., Mevada, S. T., Alrawas, A., … Wali, Y. 
(2017). Vincristine-induced neuropathy in pediatric patients with acute lymphoblastic 
leukemia in Oman: Frequent autonomic and more severe cranial nerve involvement. 
Pediatric Blood & Cancer, 64(12), e26677. https://doi.org/10.1002/pbc.26677 
Nicklasson, M., & Bergman, B. (2007). Validity, reliability and clinical relevance of EORTC 
QLQ-C30 and LC13 in patients with chest malignancies in a palliative setting. Quality of 
Life Research, 16(6), 1019–1028. https://doi.org/10.1007/s11136-007-9210-8 
Niezgoda, H. E., & Pater, J. L. (1993). A validation study of the domains of the core EORTC 
Quality of Life Questionnaire. Quality of Life Research, 2(5), 319–325. Retrieved from 
http://www.jstor.org.proxy.lib.umich.edu/stable/4034756 
Osoba, D., Zee, B., Pater, J., Warr, D., Kaizer, L., & Latreille, J. (1994). Psychometric properties 
and responsiveness of the EORTC quality of Life Questionnaire (QLQ-C30) in patients 
with breast, ovarian and lung cancer. Quality of Life Research, 3(5), 353–364. 
Pachman, D. R., Barton, D. L., Swetz, K. M., & Loprinzi, C. L. (2012). Troublesome symptoms 
in cancer survivors: Fatigue, insomnia, neuropathy, and pain. Journal of Clinical 
Oncology, 30(30), 3687–3696. https://doi.org/10.1200/JCO.2012.41.7238 
Pachman, D. R., Qin, R., Seisler, D. K., Smith, E. M. L., Beutler, A. S., Ta, L. E., … Loprinzi, C. 
L. (2015). Clinical course of oxaliplatin-induced neuropathy: Results from the 
randomized phase III trial N08CB (Alliance). Journal of Clinical Oncology, 33(30), 
3416–3422. https://doi.org/10.1200/JCO.2014.58.8533 
Pachman, D. R., Qin, R., Seisler, D., Smith, E. M. L., Kaggal, S., Novotny, P., … Loprinzi, C. L. 
(2016). Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance 






Park, J.-H., Miyashita, M., Takahashi, M., Kawanishi, N., Bae, S.-R., Kim, H.-S., … Nakamura, 
Y. (2013). Effects of low-volume walking programme and vitamin E supplementation on 
oxidative damage and health-related variables in healthy older adults. Nutrition & 
Metabolism, 10(1), 38. https://doi.org/10.1186/1743-7075-10-38 
Peddle, C. J., Au, H.-J., & Courneya, K. S. (2008). Associations between exercise, quality of life, 
and fatigue in colorectal cancer survivors. Diseases of the Colon and Rectum, 51(8), 
1242–1248. https://doi.org/10.1007/s10350-008-9324-2 
Physiopedia contributors. (2019). Physical Activity Scale for the Elderly (PASE). Retrieved 
November 24, 2019, from https://www.physio-
pedia.com/index.php?title=Physical_Activity_Scale_for_the_Elderly_(PASE)&oldid=22
5006 
Popescu, A., LeResche, L., Truelove, E. L., & Drangsholt, M. T. (2010). Gender differences in 
pain modulation by diffuse noxious inhibitory controls: A systematic review. Pain, 
150(2), 309–318. 
Postma, T. J., Aaronson, N. K., Heimans, J. J., Muller, M. J., Hildebrand, J. G., Delattre, J. Y., … 
Lucey, R. (2005). The development of an EORTC quality of life questionnaire to assess 
chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. European Journal of 
Cancer (Oxford, England : 1990), 41(8), 1135–1139. 
https://doi.org/10.1016/j.ejca.2005.02.012 
Ringdal, G. I., & Ringdal, K. (1993). Testing the EORTC Quality of Life Questionnaire on 
cancer patients with heterogeneous diagnoses. Quality of Life Research, 2(2), 129–140. 
Retrieved from http://www.jstor.org.proxy.lib.umich.edu/stable/4034394 
Rodrigues, K. C., Toledo, R. A., Coutinho, F. L., Nunes, A. B., Maciel, R. M., Hoff, A. O., … 
Lourenço, D. M. J. (2017). Assessment of depression, anxiety, quality of life, and coping 
in long-standing multiple endocrine neoplasia type 2 patients. Thyroid, 27(5), 693–706. 
https://doi.org/10.1089/thy.2016.0148 
Rogers, L. Q., Fogleman, A., Trammell, R., Hopkins-Price, P., Vicari, S., Rao, K., … Hoelzer, K. 
(2013). Effects of a physical activity behavior change intervention on inflammation and 
related health outcomes in breast cancer survivors: Pilot randomized trial. Integrative 





Saad, M., Tafani, C., Psimaras, D., & Ricard, D. (2014). Chemotherapy-induced peripheral 
neuropathy in the adult. Current Opinion in Oncology, 26(6), 634–641. 
https://doi.org/10.1097/CCO.0000000000000139 
Schaun, M. I., Dipp, T., Rossato, J. da S., Wilhelm, E. N., Pinto, R., Rech, A., … Reischak-
Oliveira, A. (2011). The effects of periodized concurrent and aerobic training on 
oxidative stress parameters, endothelial function and immune response in sedentary male 
individuals of middle age. Cell Biochemistry and Function, 29(7), 534–542. 
https://doi.org/10.1002/cbf.1781 
Schmidt, M. E., Meynkohn, A., Habermann, N., Wiskemann, J., Oelmann, J., Hof, H., … Ulrich, 
C. M. (2016). Resistance exercise and inflammation in breast cancer patients undergoing 
adjuvant radiation therapy: Mediation analysis from a randomized, controlled 
intervention trial. International Journal of Radiation Oncology, Biology, Physics, 94(2), 
329–337. https://doi.org/10.1016/j.ijrobp.2015.10.058 
Schmitz, K. H., Courneya, K. S., Matthews, C., Demark-Wahnefried, W., Galvao, D. A., Pinto, 
B. M., … Schwartz, A. L. (2010). American College of Sports Medicine roundtable on 
exercise guidelines for cancer  survivors. Medicine and Science in Sports and Exercise, 
42(7), 1409–1426. https://doi.org/10.1249/MSS.0b013e3181e0c112 
Seo, T. B., Oh, M.-J., You, B.-G., Kwon, K.-B., Chang, I.-A., Yoon, J.-H., … Namgung, U. 
(2009). ERK1/2-mediated Schwann cell proliferation in the regenerating sciatic nerve by 
treadmill training. Journal of Neurotrauma, 26(10), 1733–1744. 
https://doi.org/10.1089/neu.2008.0711 
Seretny, M., Currie, G. L., Sena, E. S., Ramnarine, S., Grant, R., MacLeod, M. R., … Fallon, M. 
(2014). Incidence, prevalence, and predictors of chemotherapy-induced peripheral 
neuropathy: A systematic review and meta-analysis. Pain, 155(12), 2461–2470. 
https://doi.org/10.1016/j.pain.2014.09.020 
Shahriari-Ahmadi, A., Fahimi, A., Payandeh, M., & Sadeghi, M. (2015). Prevalence of 
oxaliplatin-induced chronic neuropathy and influencing factors in patients with colorectal 
cancer in Iran. Asian Pacific Journal of Cancer Prevention, 16(17), 7603–7606. 
Sherman, A. C., Simonton, S., Adams, D. C., Vural, E., Owens, B., & Hanna, E. (2000). 
Assessing quality of life in patients with head and neck cancer: cross-validation of the 





Head and Neck module (QLQ-H&N35). Archives of Otolaryngology--Head & Neck 
Surgery, 126(4), 459–467. 
Simon, N. B., Danso, M. A., Alberico, T. A., Basch, E., & Bennett, A. V. (2017). The prevalence 
and pattern of chemotherapy-induced peripheral neuropathy among women with breast 
cancer receiving care in a large community oncology practice. Quality of Life Research. 
https://doi.org/10.1007/s11136-017-1635-0 
Skerman, H. M., Yates, P. M., & Battistutta, D. (2012). Cancer-related symptom clusters for 
symptom management in outpatients after commencing adjuvant chemotherapy, at 6 
months, and 12 months. Supportive Care in Cancer, 20(1), 95–105. 
https://doi.org/10.1007/s00520-010-1070-z 
Smith, E. M. L., Haupt, R., Kelly IV, J. P., Lee, D., Kanzawa-Lee, G., Knoerl, R., … Donohoe, 
C. (2017). The content validity of a chemotherapy-induced peripheral neuropathy patient-
reported outcome measure. Oncology Nursing Forum, 44(5), 580–588. 
https://doi.org/10.1188/17.ONF.580-588 
Smith, E. M. L., Knoerl, R., Yang, J. J., Kanzawa-Lee, G., Lee, D., & Bridges, C. (2018). In 
search of a gold standard patient-reported outcome measure for use in chemotherapy-
induced peripheral neuropathy clinical trials. Cancer Control, 25(1). 
https://doi.org/10.1177/1073274818756608 
Smith, E. M. L., Pang, H., Ye, C., Cirrincione, C., Fleishman, S., Paskett, E. D. D., … Shapiro, 
C. L. L. (2017). Predictors of duloxetine response in patients with oxaliplatin-induced 
painful chemotherapy-induced peripheral neuropathy (CIPN): A secondary analysis of 
randomised controlled trial - CALGB/alliance 170601. European Journal of Cancer 
Care, 26(2), e12421. https://doi.org/10.1111/ecc.12421 
Snyder, C. F., Herman, J. M., White, S. M., Luber, B. S., Blackford, A. L., Carducci, M. A., & 
Wu, A. W. (2014). When Using Patient-Reported Outcomes in Clinical Practice, the 
Measure Matters: A Randomized Controlled Trial. Journal of Oncology Practice, 10(5), 
e299–e306. https://doi.org/10.1200/JOP.2014.001413 
Song, S. J., Min, J., Suh, S. Y., Jung, S. H., Hahn, H. J., Im, S.-A., & Lee, J.-Y. (2017). Incidence 
of taxane-induced peripheral neuropathy receiving treatment and prescription patterns in 






Speck, R. M., DeMichele, A., Farrar, J. T., Hennessy, S., Mao, J. J., Stineman, M. G., & Barg, F. 
K. (2012). Scope of symptoms and self-management strategies for chemotherapy-induced 
peripheral neuropathy in breast cancer patients. Supportive Care in Cancer, 20(10), 
2433–2439. https://doi.org/10.1007/s00520-011-1365-8 
Staff, N. P., & Windebank, A. J. (2014). Peripheral neuropathy due to vitamin deficiency, toxins, 
and medications. Continuum: Lifelong Learning in Neurology, 20(5 Peripheral Nervous 
System Disorders), 1293–1306. https://doi.org/10.1212/01.CON.0000455880.06675.5a 
Stagg, N. J., Mata, H. P., Ibrahim, M. M., Henriksen, E. J., Porreca, F., Vanderah, T. W., & Philip 
Malan, T. J. (2011). Regular exercise reverses sensory hypersensitivity in a rat 
neuropathic pain model: Role of endogenous opioids. Anesthesiology, 114(4), 940–948. 
https://doi.org/10.1097/ALN.0b013e318210f880 
StataCorp. (2017). Stata Statistical Software: Release 15. College Station, TX: StataCorp LLC. 
Stratogianni, A., Tosch, M., Schlemmer, H., Weis, J., Katona, I., Isenmann, S., & Haensch, C. A. 
(2012). Bortezomib-induced severe autonomic neuropathy. Clinical Autonomic Research, 
22(4), 199–202. https://doi.org/10.1007/s10286-012-0164-8 
Streckmann, F., Kneis, S., Leifert, J. A., Baumann, F. T., Kleber, M., Ihorst, G., … Bertz, H. 
(2014). Exercise program improves therapy-related side-effects and quality of life in 
lymphoma patients undergoing therapy. Annals of Oncology, 25(2), 493–499. 
https://doi.org/10.1093/annonc/mdt568 
Streckmann, F., Lehmann, H. C., Balke, M., Schenk, A., Oberste, M., Heller, A., … Baumann, F. 
T. (2018). Sensorimotor training and whole-body vibration training have the potential to 
reduce motor and sensory symptoms of chemotherapy-induced peripheral neuropathy-A 
randomized controlled pilot trial. Supportive Care in Cancer. 
https://doi.org/10.1007/s00520-018-4531-4 
Su, C.-C., Lee, K.-D., Yeh, C.-H., Kao, C.-C., & Lin, C.-C. (2014). Measurement of physical 
activity in cancer survivors: A validity study. Journal of Cancer Survivorship : Research 
and Practice, 8(2), 205–212. https://doi.org/10.1007/s11764-013-0325-3 
Swenson, K. K., Nissen, M. J., & Henly, S. J. (2010). Physical activity in women receiving 
chemotherapy for breast cancer: Adherence to a walking intervention. Oncology Nursing 





Talaminos Barroso, A., Marquez Martin, E., Roa Romero, L. M., & Ortega Ruiz, F. (2018). 
Factors affecting lung function: A review of the literature. Archivos de 
Bronconeumologia, 54(6), 327–332. https://doi.org/10.1016/j.arbres.2018.01.030 
Taube, W., & Gollhofer, A. (2010). Control and training of posture and balance. In 
Neuromuscular Aspects of Sport Performance (pp. 254–269). 
https://doi.org/10.1002/9781444324822.ch14 
Taube, W., Gruber, M., Beck, S., Faist, M., Gollhofer, A., & Schubert, M. (2007). Cortical and 
spinal adaptations induced by balance training: Correlation between stance stability and 
corticospinal activation. Acta Physiologica, 189(4), 347–358. 
https://doi.org/10.1111/j.1365-201X.2007.01665.x 
Taube, W., Kullmann, N., Leukel, C., Kurz, O., Amtage, F., & Gollhofer, A. (2007). Differential 
reflex adaptations following sensorimotor and strength training in young elite athletes. 
International Journal of Sports Medicine, 28(12), 999–1005. https://doi.org/10.1055/s-
2007-964996 
Tedesco, S., Sica, M., Ancillao, A., Timmons, S., Barton, J., & O’Flynn, B. (2019). Validity 
evaluation of the Fitbit Charge2 and the Garmin vivosmart HR+ in free-living 
environments in an older adult cohort. JMIR MHealth and UHealth, 7(6), e13084–
e13084. https://doi.org/10.2196/13084 
Thomson, E. A., Nuss, K., Comstock, A., Reinwald, S., Blake, S., Pimentel, R. E., … Li, K. 
(2019). Heart rate measures from the Apple Watch, Fitbit Charge HR 2, and 
electrocardiogram across different exercise intensities. Journal of Sports Sciences, 
37(12), 1411–1419. https://doi.org/10.1080/02640414.2018.1560644 
Thraen-Borowski, K. M., Trentham-Dietz, A., Edwards, D. F., Koltyn, K. F., & Colbert, L. H. 
(2013). Dose-response relationships between physical activity, social participation, and 
health-related quality of life in colorectal cancer survivors. Journal of Cancer 
Survivorship: Research and Practice, 7(3), 369–378. https://doi.org/10.1007/s11764-013-
0277-7 
Tofthagen, C. S. (2010a). Patient perceptions associated with chemotherapy-induced peripheral 






Tofthagen, C. S. (2010b). Surviving chemotherapy for colon cancer and living with the 
consequences. Journal of Palliative Medicine, 13(11), 1389–1391. 
https://doi.org/10.1089/jpm.2010.0124 
Tofthagen, C. S., McAllister, R. D., & McMillan, S. C. (2011). Peripheral neuropathy in patients 
with colorectal cancer receiving oxaliplatin. Clinical Journal of Oncology Nursing, 15(2), 
182–188. https://doi.org/10.1188/11.CJON.182-188 
Tofthagen, C. S., Visovsky, C. M., & Hopgood, R. (2013). Chemotherapy-induced peripheral 
neuropathy: An algorithm to guide nursing management. Clinical Journal of Oncology 
Nursing, 17(2), 138–144. https://doi.org/10.1188/13.CJON.138-144 
Townsend, E. A., Miller, V. M., & Prakash, Y. S. (2012). Sex differences and sex steroids in lung 
health and disease. Endocrine Reviews, 33(1), 1–47. https://doi.org/10.1210/er.2010-0031 
U.S. Department of Health and Human Services. (2018). Physical Activity Guidelines for 
Americans, 2nd edition. Washington, DC, US. Retrieved from 
https://health.gov/paguidelines/second-
edition/pdf/Physical_Activity_Guidelines_2nd_edition.pdf 
Van Vulpen, J. K., Velthuis, M. J., Steins Bisschop, C. N., Travier, N., Van Den Buijs, B. J. W., 
Backx, F. J. G., … May, A. M. (2016). Effects of an exercise program in colon cancer 
patients undergoing chemotherapy. Medicine and Science in Sports and Exercise, 48(5), 
767–775. https://doi.org/10.1249/MSS.0000000000000855 
van Waart, H., Stuiver, M. M., van Harten, W. H., Geleijn, E., Kieffer, J. M., Buffart, L. M., … 
Aaronson, N. K. (2015). Effect of low-intensity physical activity and moderate- to high-
intensity physical exercise during adjuvant chemotherapy on physical fitness, fatigue, and 
chemotherapy completion rates: Results of the PACES randomized clinical trial. Journal 
of Clinical Oncology, 33(17), 1918–1927. https://doi.org/10.1200/JCO.2014.59.1081 
Velasco, R., Bruna, J., Briani, C., Argyriou, A. A., Cavaletti, G., Alberti, P., … Kalofonos, H. P. 
(2014). Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal 
cancer patients. Journal of Neurology, Neurosurgery, and Psychiatry, 85(4), 392–398. 
https://doi.org/10.1136/jnnp-2013-305334 
Velasco, R., Petit, J., Clapes, V., Verdu, E., Navarro, X., & Bruna, J. (2010). Neurological 





multiple myeloma patients. Journal of the Peripheral Nervous System, 15(1), 17–25. 
https://doi.org/10.1111/j.1529-8027.2010.00248.x 
Ventzel, L., Jensen, A. B., Jensen, A. R., Jensen, T. S., & Finnerup, N. B. (2016). Chemotherapy-
induced pain and neuropathy: A prospective study in patients treated with adjuvant 
oxaliplatin or docetaxel. Pain, 157(3), 560–568. 
https://doi.org/10.1097/j.pain.0000000000000404 
Ventzel, L., Madsen, C. S., Jensen, A. B., Jensen, A. R., Jensen, T. S., & Finnerup, N. B. (2016). 
Assessment of acute oxaliplatin‐induced cold allodynia: A pilot study. Acta Neurologica 
Scandinavica, 133(2), 152–155. https://doi.org/10.1111/ane.12443 
Villa, A., Della Torre, S., & Maggi, A. (2019). Sexual differentiation of microglia. Frontiers in 
Neuroendocrinology, 52, 156–164. 
https://doi.org/https://doi.org/10.1016/j.yfrne.2018.11.003 
Washburn, R. A., McAuley, E., Katula, J., Mihalko, S. L., & Boileau, R. A. (1999). The Physical 
Activity Scale for the Elderly (PASE): Evidence for validity. Journal of Clinical 
Epidemiology, 52(7), 643–651. 
Washburn, R. A., Smith, K. W., Jette, A. M., & Janney, C. A. (1993). The Physical Activity Scale 
for the Elderly (PASE): Development and evaluation. Journal of Clinical Epidemiology, 
46(2), 153–162. 
White, H. (1980). A heteroscedasticity consistent covariance matrix estimator and a direct test of 
heteroscedasticity. Econometrica, 48, 817–818. 
Winters-Stone, K. M., Horak, F., Jacobs, P. G., Trubowitz, P., Dieckmann, N. F., Stoyles, S., & 
Faithfull, S. (2017). Falls, functioning, and disability among women with persistent 
symptoms of chemotherapy-induced peripheral neuropathy. Journal of Clinical 
Oncology, 35(23), 2604–2612. https://doi.org/10.1200/JCO.2016.71.3552 
Wonders, K. Y. (2014). The effect of supervised exercise training on symptoms of chemotherapy-
induced peripheral neuropathy. Int J Phys Med Rehabil, 2(4), 1–5. 
Yang, C., Tsai, J., Huang, Y., & Lin, C. (2011). Effects of a home‐based walking program on 
perceived symptom and mood status in postoperative breast cancer women receiving 






Yoon, H., Thakur, V., Isham, D., Fayad, M., & Chattopadhyay, M. (2015). Moderate exercise 
training attenuates inflammatory mediators in DRG of Type 1 diabetic rats. Experimental 
Neurology, 267, 107–114. https://doi.org/10.1016/j.expneurol.2015.03.006 
Zanville, N. R., Nudelman, K. N. H., Smith, D. J., Von Ah, D., McDonald, B. C., Champion, V. 
L., & Saykin, A. J. (2016). Evaluating the impact of chemotherapy-induced peripheral 
neuropathy symptoms (CIPN-sx) on perceived ability to work in breast cancer survivors 
during the first year post-treatment. Supportive Care in Cancer, 24(11), 4779–4789. 
https://doi.org/10.1007/s00520-016-3329-5 
Zhou, W., Liu, G., Yang, S., Mi, B., & Ye, S. (2016). Low-intensity treadmill exercise promotes 
rat dorsal wound healing. Journal of Huazhong University of Science and Technology, 
36(1), 121–126. https://doi.org/10.1007/s11596-016-1553-3 
Zimmer, P., Trebing, S., Timmers-Trebing, U., Schenk, A., Paust, R., Bloch, W., … Baumann, F. 
T. (2018). Eight-week, multimodal exercise counteracts a progress of chemotherapy-
induced peripheral neuropathy and improves balance and strength in metastasized 
colorectal cancer patients: A randomized controlled trial. Supportive Care in Cancer, 
26(2), 615–624. https://doi.org/10.1007/s00520-017-3875-5 
Zimmerman, C., Atherton, P. J., Pachman, D., Seisler, D., Wagner-Johnston, N., Dakhil, S., … 
Loprinzi, C. L. (2016). MC11C4: A pilot randomized, placebo-controlled, double-blind 
study of venlafaxine to prevent oxaliplatin-induced neuropathy. Supportive Care in 







Home-Based Aerobic Exercise Feasibility in Oxaliplatin-Receiving Cancer Survivors 
 
Gastrointestinal (GI) cancer including colorectal, stomach, pancreatic, small bowel, and 
esophageal cancers are cumulatively the second most common type of cancer in the United 
States (American Cancer Society, 2019). Oxaliplatin-based chemotherapy regimens such as 
FOLFOX and FOLFIRINOX are mainstay treatments for invasive GI cancer. They have 
improved the length of survival for many patients but may cause significant long-term morbidity 
(André, Boni, & Navarro, 2009; Choi et al., 2019; Drott, Starkhammar, Kjellgren, & Bertero, 
2016; Meyers, Cosby, Quereshy, & Jonker, 2017). People who have received 
FOLFOX/FOLFIRINOX commonly report distress from symptoms, such as oxaliplatin- (i.e., 
chemotherapy-) induced peripheral neuropathy (OIPN) (Andre et al., 2004; Mols et al., 2013; S. 
B. Park et al., 2013; Ventzel et al., 2015), fatigue, loss of appetite, insomnia, anxiety, and 
depression (Berger, 2010; Binkley et al., 2012; El-Shami et al., 2015; Mols et al., 2013; 
Pachman, Barton, Swetz, & Loprinzi, 2012; Skerman, Yates, & Battistutta, 2012; Yamagishi, 
Morita, Miyashita, & Kimura, 2009). Many of these symptoms cluster and affect long-term 
quality of life (QOL), including physical, emotional, social, and role function (Drott et al., 2016; 
Ezendam et al., 2014; Hershman et al., 2011; Kidwell et al., 2012; Mols et al., 2013; Pietrangeli, 
Leandri, Terzoli, Jandolo, & Garufi, 2006; Tofthagen, Donovan, Morgan, Shibata, & Yeh, 2013). 





performing daily tasks such as climbing stairs and typing on a laptop (Bakitas, 2007; Drott et al., 
2016; Monfort et al., 2016; Speck et al., 2012; Tofthagen, 2010b, 2010a). Impaired function may 
lead to sedentary behavior (Carels, Coit, Young, & Berger, 2007; Dunton, Atienza, Castro, & 
King, 2009; Hawkes et al., 2013; Henriksson, Arving, Johansson, Igelstrom, & Nordin, 2016; 
Liao, Chou, Huh, Leventhal, & Dunton, 2016; Liao, Shonkoff, & Dunton, 2015; Mata et al., 
2012; Shang, Wenzel, Krumm, Griffith, & Stewart, 2012), worse balance and higher risk for falls 
(Bao et al., 2016; Kolb et al., 2016; Winters-Stone et al., 2017), and social isolation (Boehmke & 
Dickerson, 2005; Exposito Vizcaino, Casanova-Molla, Escoda, Galan, & Miro, 2018; Tofthagen, 
McAllister, & McMillan, 2011; Zanville et al., 2016). Thus, patients, families, and clinicians are 
faced with complex treatment decisions regarding the balance between preserving QOL and 
pursuing the most aggressive treatment to eradicate the cancer (Ko et al., 2019).  
Aerobic exercise has been shown to globally benefit cancer survivors’ length and quality 
of survival (American College of Sports Medicine, 2015; Baumann et al., 2015; Cadmus et al., 
2009; Cramp & Byron-Daniel, 2012; Galvão & Newton, 2005; Knols, Aaronson, Uebelhart, 
Fransen, & Aufdemkampe, 2005; Lotfi-Jam et al., 2008; Mishra, Scherer, Snyder, Geigle, & 
Gotay, 2015; Mock et al., 2005; Morielli et al., 2016; Pachman et al., 2012; Stevinson et al., 
2009; U.S. Department of Health and Human Services, 2018). Specifically, light-moderate-
intensity home-based exercise has led to improved cancer treatment response (Baumann et al., 
2015; Cadmus et al., 2009; Cramp & Byron-Daniel, 2012; Galvão & Newton, 2005; Knols et al., 
2005; Lotfi-Jam et al., 2008; Mishra et al., 2015; Mock et al., 2005; Morielli et al., 2016; 
Pachman et al., 2012; Stevinson et al., 2009); and reduced fatigue (Cramp & Byron-Daniel, 
2012; Mishra et al., 2015; Mock et al., 1994; Morielli et al., 2016; Schwartz, 2001; Van Vulpen 





(Irwin et al., 2015; Morielli et al., 2016), and sleep disturbance (Mishra et al., 2015; Speck, 
Courneya, Masse, Duval, & Schmitz, 2010). 
However, many cancer survivors report not receiving education about the benefits of 
exercise during cancer treatment (Fernandez et al., 2015). Over 60% of individuals receiving 
cancer treatment are insufficiently active (Baumann et al., 2015; Cramp & Byron-Daniel, 2012; 
Dodd et al., 2010; Dreicer et al., 2014; Fernandez et al., 2015; Mishra et al., 2015; Morielli et al., 
2016; Pachman et al., 2012). Individuals with colorectal cancer have previously demonstrated 
the lowest levels of physical activity (PA) and adherence in PA trials (48% to 76%) (Backman et 
al., 2014; Courneya et al., 2003; Griffith et al., 2009; Tofthagen, Visovsky, & Berry, 2012; van 
Waart et al., 2015) compared to other cancer populations such as individuals with breast cancer 
whose adherence rates were 72% to 77% (Blanchard, Courneya, & Stein, 2008; Courneya et al., 
2003; Courneya, Katzmarzyk, & Bacon, 2008; Mock et al., 2005; Peddle, Au, & Courneya, 
2008; Speed-Andrews et al., 2012; Tofthagen, Visovsky, Beckstead, Loy, & Eckelman, 2014; 
Yang, Tsai, Huang, & Lin, 2011). 
Barriers to Exercise 
Although cancer survivors generally view PA as important during cancer treatment 
(Chou, Lai, Lin, Liang, & Shun, 2017; Mikkelsen, Nielsen, Vinther, Lund, & Jarden, 2019), 
motivational supports may be needed to overcome barriers and maximize exercise adherence 
during cancer treatment. Common cross-culturally perceived exercise barriers in adults include 
lack of time (Mikkelsen et al., 2019), self-efficacy, motivation, energy, skill knowledge, 
sociocultural support/expectations (Mikkelsen et al., 2019), and safe and accessible exercise 
environments (Eyl et al., 2018; Horne & Tierney, 2012). Additionally, morbidities (Mikkelsen et 





weather, statuses of being employed and divorced (Eyl et al., 2018; van Putten et al., 2016), and 
negative exercise outcomes are common exercise barriers (Chou et al., 2017; Gho, Munro, Jones, 
& Steele, 2014; Horne & Tierney, 2012; Justine, Azizan, Hassan, Salleh, & Manaf, 2013; Leone 
& Ward, 2013; Tulloch et al., 2013). Further, individuals receiving cancer treatment may 
experience stronger barriers, due to chemotherapy treatment scheduling and side effects (e.g., 
fatigue, pain, diarrhea, depression (Chou et al., 2017; Fernandez et al., 2015; Kamath, 2012; 
Kang et al., 2014; Mikkelsen et al., 2019)), and fear of exercise injury (Kang et al., 2014; Mas, 
Quantin, & Ninot, 2015; Park et al., 2015; Rogers et al., 2005; Swenson, Nissen, & Henly, 2010; 
Zanville et al., 2016).  
Other factors that influence exercise intervention adherence. Various factors including 
acceptability of an intervention and interest in and confidence in one’s ability to exercise have 
been theorized to influence exercise adherence (Chou et al., 2017; Sekhon, Cartwright, & 
Francis, 2017). The definition of acceptability and its relationship with the concepts of 
adherence, interest, and confidence are still under debate. Acceptability has been operationalized 
as evaluating intervention enrollment, dropout, uptake, and adverse outcomes. Additionally, 
cognitive/emotional aspects of acceptability include satisfaction with, understanding of, and 
perceived burden and usefulness of the intervention (Sekhon et al., 2017). It may be bi-
directionally associated with intervention adherence (Chou et al., 2017). In a concept analysis of 
acceptability, confidence in one’s ability to perform the intervention was conceptualized as a 
construct of acceptability; thus, confidence may also be bi-directionally associated with 
adherence (Sekhon et al., 2017). Interest (equated with intention to perform the intervention) was 
stated to be separate from but related to acceptability (Sekhon et al., 2017). However, evidence 





be negatively influenced by confidence (Gho et al., 2014; Mikkelsen et al., 2019). The following 
section focuses more on the role of other key theoretical constructs associated with exercise 
adherence. 
Theoretical Approaches for Facilitating Exercise 
The Social Cognitive Theory (SCT) and Self-Determination Theory (SDT) were used to 
guide the development of the intervention for this study. They have demonstrated strong  
predictive validity: the SCT has been shown to predict up to 89% (Phillips & McAuley, 2013), 
and the SDT has predicted up to 29% of the variance in PA behavior in cancer survivors 
(Edmunds, Ntoumanis, & Duda, 2006; Milne, Wallman, Guilfoyle, Gordon, & Corneya, 2008; 
Peddle, Plotnikoff, Wild, Au, & Courneya, 2008; Wilson, Blanchard, Nehl, & Baker, 2006).  
Table IV.1 lists key constructs of the SCT and SDT, their definitions, and motivational 
techniques that have been used to support the defined constructs. Briefly, the SCT proposes that 
self-efficacy may directly and indirectly influence exercise behavior through the other SCT 
constructs: outcome expectations, perceived facilitators and impediments, and goals (Bandura, 
1986, 2004). The SDT proposes three basic psychological needs—competence (akin to self-
efficacy), autonomy, and relatedness—drive intrinsic (pleasure-driven) and extrinsic (external 
pressure or internal guilt-driven) motivation (Deci & Ryan, 1985; Ryan, 1995; Ryan & Deci, 
2000). Autonomous motivation may be a combination of intrinsic and extrinsic motivation, and 
involves identification and integration of the behavior’s importance with one’s own beliefs and 













One’s perceived ability to perform a specific 
task and overcome barriers to performing the 
task. 
 
Sources of self-efficacy: 
 -Mastery: prior personal task-specific 
   success 
 -Vicarious Experience: viewing the 
   successes of other role models 
   performing the task 
 -Verbal Persuasion: affirmation and 
   encouragement from a trusted source 
 -Physiological and Affective States: 
   interpretation of physiological and 
   affective barriers and indicators of 
   incapability 
Mastery: 
 -Heart rate monitors 
 -Exercise logs 
 -Progress summaries 
Vicarious Influences: 
 -Idolized exercise 
   partners or role 
   models 
Verbal Persuasion: 
 -Individual or group 
   counseling 
 -Encouragement from 
   a health provider, 
   family, or friends 
Physiological and Affective 
States: 
 -Educational booklets 
 
-Heart rate monitor 
-Exercise diaries 
-Progress summaries 
-Exercise testimonies from 
  prior colorectal cancer 
  survivors on oxaliplatin 
-In-person and telephone 
  motivational interviewing. 
-Email group 
-Weekly walking groups 
-PA and Cancer treatment- 
  specific educational 
  pamphlets 
Outcome 
Expectations 
Perceived material or psychological gains 
from or negative effects of a behavior. 
 




Perceived physical, social, or situational 







Goals Short or long-term goals 
 




Perceived internal volitional control over 
one’s behavior and outcomes.  
 -Autonomous motivation stems from 
   both a) inherent pleasure in the 
   behavior or the pursuit of 
   accomplishing the behavior, and b) 
   integration of the behavior’s 
   importance with one’s own values. 
 
-Motivational 
  interviewing 
Motivational interviewing 




-Weekly walking groups 
-Peer accountability phone 
  calls 
Note. Although many motivational techniques may target multiple constructs, the techniques are categorized under the 
construct that it may affect the most. The constructs and definitions are derived from the Social Cognitive Theory (Bandura 
1986, 2004), and the Self-Determination Theory (Deci and Ryan 1985; Ryan 1995; Ryan and Deci 2000). 








Ultimately, self-efficacy and autonomous motivation have consistently been identified as 
key and potentially synergistic behavioral predictors (Mosher et al., 2008; Pinto, Rabin, & 
Dunsiger, 2009; Rogers, 2008; Sweet, Fortier, Strachan, & Blanchard, 2017). Thus, the SCT and 
SDT provide a strong framework for developing interventions to promote exercise in adults, 
including those receiving cancer treatment. 
Based on the theoretical framework, the MI-Walk Intervention was developed for and 
pilot tested in this study. The MI-Walk Intervention was an eight-week of home- and 
motivational enhancement therapy (MET)-based brisk walking intervention developed to reduce 
OIPN among oxaliplatin-receiving GI cancer survivors.  
Purpose and Design 
The purpose of this pilot study was to explore the feasibility of the MI-Walk Intervention 
compared to PA education alone among GI cancer survivors starting at the second FOLFOX or 
FOLFIRINOX treatment cycle. The specific aims of this dual-site, prospective, randomized, 
controlled, pilot study were to describe the rates of and explore the relationships between patient 
characteristics and 1) enrollment in and attrition from the study, 2) acceptability of the MI-Walk 
Intervention, and 3) intervention adherence. Overall PA levels were also explored. 
Methods 
A detailed description of the study methods are provided in another manuscript 
(Kanzawa-Lee et al., 2019, unpublished). Briefly, 60 adults, age 18 years or older, with stage II-
IV GI cancers were recruited to the study between May 14, 2018 and April 22, 2019 from an 
NCI-designated comprehensive cancer center and neighboring community cancer center. The 
participants were also screened based on the following key eligibility criteria: 1) scheduled to 





(ECOG) Status of zero to one, and 3) a prognosis greater than three months; and no 4) exercise- 
or mobility-limiting disease, 5) major surgery scheduled during the eight-week study time 
period, or 6) self-reported pre-existing peripheral neuropathy. Participants were also excluded if 
they were pregnant or unable to read or speak English.  
The institutional review boards at both study sites reviewed and approved the study. All 
pre-screened eligible participants were offered the opportunity to participate; informed consent 
was obtained from the interested participants. Initially, participants were approached for 
recruitment at their new patient chemotherapy planning visit. To bolster recruitment, the study 
protocol was amended to change the timing of recruitment to the second FOLFOX or 
FOLFIRINOX infusion visit. 
Control and Intervention Condition 
Participants were randomly assigned to join the PA education control or eight-week MI-
Walk Intervention group. The PA education was delivered by the interventionist (first author) at 
the patients’ second FOLFOX/FOLFIRINOX infusion verbally and in written form based on the 
Physical Activity and the Cancer Patient pamphlet (American Cancer Society, 2014). 
Additionally, all participants received five-minute telephone follow-up calls to assess whether 
they were experiencing any adverse events. The follow-up phone calls for the control group 
participants occurred at the one-, two-, four-, and six-week timepoints. 
The MI-Walk Intervention. The MI-Walk Intervention was an eight-week home-based 
aerobic walking program that supplemented the PA education and follow-up phone calls. The 
goal by the eight-week time point was for participants to reach or exceed the national aerobic PA 
guidelines: 150 minutes of moderate- to vigorous-intensity PA (MVPA) per week (American 





2018). The weekly walking dosages were tailored based on the participants’ baseline PA levels 
and preferences; the dosages ranged from 10 to 60 minutes, three to five days per week, at 
moderate intensity (a Borg rating of perceived exertion between 12 and 14).   
In addition to PA education, participants assigned to the walking intervention received 
the following: 
1. At orientation: semi-scripted motivational enhancement therapy (MET), supplemental 
cancer treatment and exercise education, and a tailored progressive walking plan, Fitbit 
Charge 2 device and app, exercise diary, and patient testimony about staying physically 
active during FOLFOX/FOLFIRINOX treatment.   
2. At two and four weeks: an MET session by phone or in-person, progress summary, and 
an updated walking plan, SMART goals, and if-then statements. 
3. Ongoing support through a private email group, weekly emailed scripted motivational 
messages and invitations to group walking events, and encouragement to engage in peer 
accountability phone calls. The walking sessions only occurred if participants expressed 
availability and interest by email.  
The MET sessions included semi-scripted motivational interviewing and collaborative 
goal setting and planning. Motivational interviewing is a “collaborative conversation style for 
strengthening a person’s own motivation and commitment to change” (Miller & Rollnick, 2013, 
p. 12). Motivational enhancement therapy is the combination of motivational interviewing with 
other self-efficacy-enhancing feedback techniques (e.g., progress summaries). Worksheets were 
provided to help the patients write specific measurable action-oriented realistic and time-bound 





barriers. The “if-then implementation intention” statement method was used to encourage 
participants to identify their major exercise barrier(s) and create a plan to address it/them. For 
example, if a participant’s major barrier was forgetting to walk, their intention statement could 
be “if it is six PM on Saturday, then I will walk for 10 minutes.”  
Measurement 
The participants completed the study surveys on a tablet at baseline and eight weeks. The 
baseline assessments coincided with the intervention orientation, which occurred during the 
participants’ second FOLFOX/FOLFIRINOX treatment. The eight-week assessments occurred 
eight weeks after baseline, often at the sixth FOLFOX/FOLFIRINOX  treatment. All study visits 
coincided with regularly scheduled clinic visits whenever possible. Adverse events were assessed 
via telephone at the one-, two-, four-, and six-week time points. 
Enrollment and attrition. The participants who were eligible for, enrolled in, and 
withdrew/were removed from the study were counted. Data were collected regarding the reasons 
for patient attrition. 
Adapted Acceptability E-Scale. After completing the intervention, participants rated the 
acceptability of the MI-Walk Intervention using the Adapted Acceptability E-Scale survey. This 
survey was derived from the original Acceptability E-Scale developed by Berry and colleagues 
(Mullen, Berry, & Zierler, 2004). Participants rated the MI-Walk Intervention based on 
individual domains of acceptability: satisfactoriness, difficulty, enjoyableness, helpfulness in 
managing OIPN symptoms, and acceptability of the time requirement of the intervention; and 
degree of clarity of the written intervention materials. Another survey question assessed 
participants’ perceived likelihood that they would “continue the walking program (walking for 





survey measured the helpfulness of each intervention component. The scale for each item ranged 
from one (e.g., very unacceptable/unhelpful) to five (very acceptable/helpful), and the 14-item 
survey score ranged from 14 to 70. Prior literature has suggested 80% of the highest possible 
score is sufficient to categorize the intervention as acceptable; thus, a score of at least 59 overall 
(4 for individual items) will be used to indicate that the intervention may be acceptable (Tariman, 
Berry, Halpenny, Wolpin, & Schepp, 2011). The original survey—which measured acceptability 
of a computerized QOL and symptom-assessment system—demonstrated strong internal 
consistency reliability (Cronbach’s α = 0.91) in cancer populations (Mullen et al., 2004).   
Intervention uptake. Uptake—also termed treatment receipt—is the degree of participant 
comprehension of, engagement in, and adherence to utilizing the provided skills and components 
of the intervention (Gearing et al., 2011). Uptake was examined based on participants’ use of the 
exercise diaries and Fitbits. Additionally, the number of weekly walking sessions held, 
participant attendance, and duration of each group walking session was recorded. Throughout the 
study, the interventionist continuously observed and collected qualitative data about the 
participants’ peer interactions, and acceptability and uptake of the intervention. 
Exercise interest and confidence. Although interest is not considered a construct of 
acceptability, the results are reported together, because the same timing and format of 
measurement were used to assess exercise interest and confidence. During each MET session, 
the interventionist used scripted standard motivational interviewing questions to ask participants 
to rate on a 0 to 10 scale their 1) interest and 2) confidence in increasing their amount of aerobic 
exercise over the next eight weeks. 
Adverse events. Intervention-related adverse events were assessed by the interventionist 





provided with the principle investigator’s contact information and encouraged to report their 
concerns anytime.  
Physical activity. The Fitbit Charge 2 was used to measure MVPA and total PA over the 
eight weeks of the MI-Walk Intervention. No baseline Fitbit data was collected, because the 
Fitbit was primarily intended as an intervention component and was provided when a participant 
initiated the MI-Walk Intervention. The cut-off for classifying minutes of MVPA was activity 
performed at or above 3 metabolic equivalent of tasks (METS) for at least 10 continuous minutes 
(American Cancer Society, 2014; Fitbit, 2019; U.S. Department of Health and Human Services, 
2018). The Fitbit also recorded the number of steps per day. Finally, total PA was estimated 
based on the sum of “lightly active” (~1.1 to 2.9 METS), “fairly active” (3 to 5.9 METS), and 
“very active” (greater than 6 METS) minutes per day (Fitbit, 2019; U.S. Department of Health 
and Human Services, 2018). 
Studies suggest convergent validity between research-grade activity monitor- and Fitbit 
Charge 2-measured minutes of MVPA (r = .658; ICC = .69) (Brewer, Swanson, & Ortiz, 2017; 
O’Driscoll et al., 2018; Reddy et al., 2018; Straiton et al., 2018; Tedesco et al., 2019) and step 
counts (r = .84-.86; ICC = .89-.95) in older adults in free-living conditions (Farina & Lowry, 
2017; Reid et al., 2017; Straiton et al., 2018). No studies of Fitbit test-retest reliability have been 
found (Evenson, Goto, & Furberg, 2015).  
Secondary self-report PA measures. Self-reported PA was evaluated in both the 
intervention and control groups, using the PA Vital Sign (VS) tool (Greenwood, Joy, & Stanford, 
2010) and Physical Activity Survey for the Elderly (PASE) (Washburn, McAuley, Katula, 





administered at baseline and eight weeks. Additionally, the PAVS was administered to the 
intervention group at two- and four-weeks. 
The PAVS tool—a two-question interview—was used to collect participant self-reported 
average weekly minutes of MVPA (Greenwood et al., 2010). The two interview questions were 
“How many days during the past week have you performed PA where your heart beats faster and 
your breathing is harder than normal for 30 minutes or more? How many days in a typical week 
do you perform activity such as this?” (Greenwood et al., 2010). The PAVS has demonstrated 
convergent validity, based on its ability to predict body mass index (BMI) (b = .91; p < .001) 
(Greenwood et al., 2010) and comorbidity (p < .05) (Ball, Joy, Gren, Cunningham, & Shaw, 
2016) and association with research-grade accelerometers (r = .52) (Ball et al., 2015) and PA 
surveys with strong validity (r = .71) (Ball, Joy, Gren, & Shaw, 2016; Golightly et al., 2017; 
Wald & Garber, 2018).  
The 28-item PASE survey was used to measure self-reported total PA levels (Washburn 
et al., 1999, 1993). Six four-point Likert scale items measured the frequency (0, never; 3, often) 
and usual session duration (0, less than 1 hour; 3, more than 4 hours) of time spent leisure 
activities. Six items measured engagement (1, yes; 0, no) in household activities; and one 
question quantified the time spent on occupational activities. A single weighted PA score (range 
= 0-793 [Washburn et al., 1999, p. 2]) was calculated based on the PASE scoring instructions. 
The PASE has demonstrated test-retest reliability (ICC = 0.67-0.9) (Dinger, Oman, Taylor, 
Vesely, & Able, 2004; Forsen et al., 2010; Washburn et al., 1993) and validity per its 
associations with performance status (r = .36-.59), objectively-measured (r = .4) and self-
reported physical function (r = .57) (Granger, Parry, & Denehy, 2015), and objectively-measured 





2014). The PASE has also demonstrated responsiveness to decreasing PA levels during lung 
cancer treatment (ES = .23-.24; p ≤ .023) (Granger et al., 2015). 
Participant characteristics. Clinical characteristics (e.g., cancer type, stage, and 
treatment, and analgesic drug use) were abstracted from the electronic medical record. 
Participants completed a battery of electronic surveys: a demographic survey of age, race, 
gender, and marital and employment status at baseline, and surveys of chemotherapy-induced 
neuropathy and QOL at baseline and eight weeks. The European Organisation for the Research 
and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-Chemotherapy-
Induced Peripheral Neuropathy 20-item supplement (CIPN20) (Postma et al., 2005) and Core 30-
item (C30) surveys (Aaronson et al., 1993) were used to evaluate the degree of cancer treatment-
related symptoms and QOL/function on a 0 (“not at all”) to 100 (“very much”) scale. Higher 
symptom item/subscale scores represented worse severity; higher QOL subscale scores equated 
to better QOL/function. A symptom score ≥ 25 (“a little”) indicated mild presence of a symptom. 
Only the symptoms that were at least mild in severity at eight weeks (based on the scoring 
criteria) or that significantly worsened from baseline to eight weeks were evaluated in relation to 
MVPA and acceptability. The EORTC surveys have been used in numerous studies among 
multiple cancer populations globally and have demonstrated strong reliability and validity 
(Aaronson et al., 1993; Alberti et al., 2014; Cavaletti et al., 2013; Knoerl et al., 2017; Lavoie 
Smith et al., 2013; Li, Lin, Qiu, Gao, & Xu, 2014; Nicklasson & Bergman, 2007; Niezgoda & 







Statistical analyses were performed using STATA version 15.0 statistical software 
(StataCorp, 2017). Given the exploratory nature of this pilot feasibility study, only 95% CIs and 
effect sizes are presented in this paper. An |r| ≥ .50 indicated a strong correlation and an |r| ≥ .30 
indicated moderate correlation, based on established conservative criteria (Cohen, 1988) and 
recent findings that demonstrated |r| = .20-.40 is a medium effect size in research on patient 
attitudes (Bosco, Aguinis, Singh, Field, & Pierce, 2015). Cohen’s criteria were also used to 
interpret the results of ANOVA (η2 of .14 was considered a medium to large effect size) (Cohen, 
1988). The magnitude of significance of the t-tests and linear and logistic regression models 
were evaluated based on differences in means (∆ ), b coefficients (𝑋∆), and odds ratios (OR); 
and the 95% confidence intervals (CIs).  
Descriptive statistics— n (%) and means with standard deviations (𝑋±SD)—were used to 
quantify study enrollment, attrition, participant characteristics, PA levels, intervention 
acceptability and fidelity, and exercise-related adverse events. The enrollment rate was 
calculated as the number of participants who enrolled in the study over the total number of 
contacted screened participants who had demonstrated preliminary eligibility via the medical 
record. The attrition rate was expressed as the percent of intervention group participants who did 
not complete the eight-week assessments out of the number of eligible participants randomized 
to the intervention. Logistic regression to obtain ORs and independent t-tests to identify inter-
group ∆ s were used to compare the characteristics of patients who enrolled versus declined 
participation and completed versus withdrew from the study. Additionally, Fisher’s exact tests 
were used to analyze inter-group differences for categorical variables if the sample size was too 





cancer treatment-related symptoms that significantly changed from baseline to eight weeks. The 
most severe symptoms at eight weeks and those that changed significantly over time were 
selected for evaluation in relation to acceptability of the intervention and Fitbit-measured weekly 
minutes of MVPA.  
Two-sided independent t-tests, Analysis of Variance (ANOVA), linear regression, and 
bivariate Pearson correlations were used to assess the relationships between the various 
participant characteristics and intervention acceptability and average MVPA weekly minutes. 
Line graphs were used to vizualize the patterns of Fitbit-measured minutes of MVPA and 
step counts over time. Independent t-tests, ANOVA with Tukey’s honestly significant difference 
test, and Bonferroni-corrected Pearson bivariate correlations were used to explore the 
relationships between the participant characteristics and (a) Fitbit-measured MVPA averaged 
over the eight weeks among the intervention participants, and (b) self-reported MVPA and PA 
levels in the control group at eight weeks. 
Results 
Figure IV.1 is a flowchart of study screening and recruitment and the flow of participants 
through the study. Sixty individuals enrolled; 30 participants received PA education alone (the 
control) and 29 participants received the MI-Walk Intervention.  
Enrollment 
The overall enrollment rate was 62%, out of the 97 screened and eligible patients for the 
study. Due to low (38%) enrollment rate in the first three months of the study when patients were 
screened at a new patient visit, a protocol amendment was made to screen patients at the second 
FOLFOX/FOLFIRINOX infusion instead. A key additional component of the amendment was 





who already met the ACSM PA guidelines. After protocol amendment, the enrollment rate was 
68%.  
Sample characteristics. Table IV.2 presents the differences in participant characteristics 
by enrollment. All but four participants resided in urban areas or clusters within the Bay, 
University, and Metro regions of Michigan. Most participants were male (60%), white (92%), 
married (78%), and full-time employed (32%) or retired (28%). The patients who enrolled—
mean age 57.93 (SD = 10.67) years—had stage II-IV mostly colon and/or rectal (65%) or 
pancreatic cancers (32%). Participants had a range of zero (n = 27) to three (n = 1) 
comorbidities: mostly hypertension alone (n = 10).  
Only the participants who enrolled completed the baseline surveys. Based on the surveys, the 
participants reported high physical (𝑋 = 91.00; SD = 14.25) and emotional function scores (𝑋 = 
85.69; SD = 12.09) at baseline. The worst baseline cancer treatment symptom was fatigue (𝑋 = 
27.59; SD = 18.47), followed by appetite loss (𝑋 = 23.89; SD = 26.10) and insomnia (𝑋 = 23.89; 
SD = 22.21). The baseline self-reported PA scores averaged 112.45 (SD = 91.79, range = 10-






Recruitment Flowchart B 
 
Citation: Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, et al. CONSORT 2010 
statement: extension to randomised pilot and feasibility trials. BMJ. 2016;355. 
Abbreviations. PN, peripheral neuropathy (self-reported). 
Assessed for eligibility (n = 129) 
Site 1 (n = 85); Site 2 (n = 44) 
Excluded  (n = 69) 
   Ineligible/PN (n = 32) 
   Declined to participate (n = 37) 
Assessed for objective (n = 25) 
 
Discontinued intervention 
 Medical complications (n = 1) 
 Overwhelmed (n = 1) 
 Lost to follow-up/changed hospitals (n = 1) 
 
Ineligible (n = 1) 
Allocated to intervention (n = 30) 
 Received allocated intervention (n = 29) 
 Did not receive allocated intervention  
 Excessive time requirement (n = 1) 
Discontinued control condition 
 Medical complications (n = 2) 
 
Ineligible (n = 1) 
Allocated to control condition (n = 30) 
 Received allocated condition (n = 30) 




Randomized (n = 60) 
Enrollment 
Screened prior to eligibility 
assessment (n = 1,343) 
Site 1 (n = 642); Site 2 (n = 701) 
Excluded  (n = 1,214) 






Characteristics associated with enrollment. Enrolled individuals reported significantly 
fewer comorbidities than patients who declined participation (95% CI -0.67, -0.01). As depicted 
in Table IV.2, no other differences were found between the individuals who enrolled and those 
who declined participation in the study.  
 
Table IV.2 
Characteristics of Patients by Enrollment 
Characteristic Declined 
n = 32 
Enrolled 
n = 60 
OR [       95% CI      ] 
 
 n (%)    
Male Gender 16 (50) 36 (60) 1.5 0.63 3.56 
Race 
   White 
   Black 
   Asian 



























   Colon 
   Rectal/Colorectal 
   Pancreatic 
   Other GI 
































   II 
   III 
   IV 






























𝑋 -𝑋  
 
[       95% CI      ] 
Age (years) 57.06 (15.35) 57.93 (10.67) 0.87 -4.56 6.30 
BMI (kg/m2) 25.82 (5.24) 25.78 (4.19) -0.05 -2.04 1.95 
Number of comorbidities 1.12 (0.48) 0.78 (0.88) -0.34* -0.67 -0.01 
Abbreviations. BMI, body mass index; CI, confidence interval; GI, gastrointestinal; OR, odds ratio; SD, standard deviation. 
*, medium to large effect 
 
Attrition 
Figure IV.1 includes participant attrition rates and reasons as described below. The 





MI-Walk Intervention group from here on (n = 30), one participant withdrew prior to initiating 
the MI-Walk Intervention due to perceived excessive time requirement of the intervention. After 
intervention initiation, one participant was removed from the study due to ineligibility (ECOG 
functional status = 2 prior to enrollment) and was not included in the attrition count. Three 
participants discontinued the intervention due to severe chemotherapy treatment side effects (n = 
1), feeling overwhelmed with external life circumstances (n = 1), and changing hospitals (n = 1).  
Characteristics associated with attrition. Table IV.3 presents the differences in baseline 
characteristics between the MI-Walk Intervention participants who withdrew from (n = 4) and 
completed the study (n = 25). The participants who completed the study were younger than those 
who withdrew from the study (𝑋 -𝑋  = -11.26; 95% CI -23.67, 1.15). Further, participants whose 
oxaliplatin was already dose reduced by the second chemotherapy dose had a 24 times higher 
odds of withdrawing from the study than those who received the planned chemotherapy dose at 
cycle two (95% CI 1.46, 394.88). The oxaliplatin doses had been reduced due to provider 
discretion. Levels of MVPA/PA and neither exercise interest nor confidence were no different 
based on attrition. 
Eight-week clinical characteristics. Based on the participants who completed the study, 
the worst symptoms at eight weeks were fatigue (𝑋 = 37.78; SD = 23.57) and appetite loss (𝑋 = 
34.67; SD = 36.62). Significant increases over the eight weeks were found in fatigue (𝑋∆= 13.78; 
95% CI 6.26, 21.30), sensory OIPN (𝑋∆= 5.04; 95% CI 1.54, 8.54), and motor OIPN (𝑋∆= 5.43; 
95% CI 1.89, 8.96). Participants had received 373.22 (SD = 55.79) mg/m2 of oxaliplatin by eight 
weeks. In addition to general demographics and oxaliplatin dose, the eight-week severities of 
these symptoms were explored in relation to intervention attrition, acceptability, and Fitbit-






Baseline Characteristics of the MI-Walk Intervention Participants by Attrition 
Characteristic 
Withdrew 
    n = 4 
Completed 
n = 25 
 n (%) 
Cancer Type 
   Colon 
   Rectal/Colorectal 





3 (75)  
 
10 (40) 
 9 (36) 
 6 (24)  
Cancer Stage 
   II 
   III 







 5 (20) 
 7 (28) 
12 (48) 
Marital Status 
   Married 
   Separated/Divorced 
   Widowed 









 2 (8) 
0 
 1 (4) 
Employment Status 
   Employed 








Highest Education Degree 
   ≤ High school degree 
   Some college 







 4 (16) 
 9 (36) 
12 (48) 
Smoking History 
   Never smoked 
   Former smoker 









 2 (8) 
Gender 
   Male 







 5 (20) 
ECOG  
   0 







 7 (28) 
Oxaliplatin dose 
   Given as planned 






 1 (4) 
   
 𝑿 (SD) 
Age (years) 66.50 (4.51) 55.24 (11.81) 
BMI (kg/m2) 23.03 (3.07) 25.32 (3.78) 
Number of comorbidities   0.75 (0.96)  0.52 (0.65) 
Number of analgesics/neuroprotectants   0.75 (0.96)  0.60 (0.76) 
Note. Test of statistical significance comparing groups not conducted due to inadequate and uneven sample size. 






Acceptability of the MI-Walk Intervention 
Figure IV.2 is a 100% stacked bar chart that depicts the domains of acceptability and the 
n (%) of participants that rated the acceptability of each domain a “1” (e.g., very unacceptable), 
“2,” “3,” “4,” or “5” (e.g., very acceptable). The overall acceptability score was 47.91 (SD = 
11.45) on a scale from 14 to 70. Most (80%) of the participants said they were satisfied with the 
intervention and/or would likely continue the intervention (i.e., “walking for exercise and using 
the materials and techniques given to [them] during the program”).  
 
Figure IV.2  
Acceptability of the MI-Walk Intervention 
 
Abbreviation. OIPN, oxaliplatin-induced peripheral neuropathy 
















































Helpfulness and uptake of the intervention components. Figure IV.3 is a 100% stacked 
bar chart of the n (%) of participants that gave each rating between one (e.g., very unhelpful) and 
five (e.g., very helpful) for each MI-Walk Intervention component. Participants rated the Fitbit 
(𝑋 = 3.67; SD = 1.43) and MET sessions (𝑋 = 3.44; SD = 1.36) as most helpful. However, five 
participants were non-compliant with wearing the Fitbit (i.e., they forgot or refused to wear the 
Fitbit for more than two of the eight intervention weeks). The MET sessions (𝑋 duration = 40.88; 
SD = 18.05 minutes) were well-attended (98% completed) among the participants who 
completed the study;); the ratings of the PA education given at orientation was neutral (𝑋 = 2.96; 
SD = 1.14). Allowing for three attempts to reach each patient, 86% of the follow-up telephone 
assessments were completed. Anecdotally, many patients expressed a preference for 
communicating by text or email instead of by telephone call. 
The participants were neutral regarding the helpfulness of the exercise diaries and 
worksheets (𝑋 = 3.08; SDs = 1.29 and 1.35). Fourteen (48%) of the intervention participants 
returned and were mostly compliant in completing the exercise diaries. Nine participants elected 
to keep their diary after turning in the required carbon copies of the pages they completed. 
Regarding the worksheets, most participants filled-out the SMART goals worksheet; however, 
no patients consistently utilized the if-then implementation (addressing exercise barriers) 
worksheet per interventionist observation. On the SMART goals worksheet, many participants 
also added strength training and/or step count-directed PA goals.  
Finally, most (64%-73%) participants rated the email and walking groups as unhelpful. One 
participant had a Facebook account and joined the intervention Facebook group before it was 
terminated and replaced by an email group. No continuous conversations occurred through the 





Five mall walking sessions (50 minutes – 1.5 hours in duration) occurred with one participant 
each between July 9, 2018 and June 17, 2019: one participant attended two late Saturday walking 
sessions and another participant attended three late Sunday morning walking sessions. No 
participants shared their phone number with a peer to engage in accountability phone calls.  
Figure IV.3 
Helpfulness of the MI-Walk Intervention Components 
 
Abbreviation. MET, motivational enhancement therapy. 
 
Exercise interest, confidence, and adverse outcomes. At baseline, the participants 
reported moderate interest in increasing (𝑋 = 6.38; SD = 3.14; range = 0-10) and moderate 
confidence in their ability to increase their amount of aerobic exercise over the next eight weeks 
(𝑋 = 7.88; SD = 2.03; range = 3-10). Many patients explained that they were giving a low score 
for their interest in increasing their aerobic exercise, because they preferred to focus on strength 
training to preserve muscle mass instead and/or just maintain their current level of PA, which 

















































low prioritization of/interest in trying to meet their PA goals, due to difficulty eating. Interest and 
confidence levels were unchanged at eight weeks. No study-related adverse events occurred. 
Associations between acceptability and participant characteristics. Table IV.4 illustrates 
data regarding the acceptability of the intervention by MI-Walk Intervention participant 
characteristic. Part-time or un-employed participants rated the intervention higher in 
acceptability compared to participants who were retired (𝑋∆ = 21.75; 95% CI 2.97, 40.53). 
Further part-time or un-employed participants were the only group of individuals that rated the 
acceptability of the intervention above the 80% acceptability threshold. Retired individuals were 
the only group to rate the MET sessions as unhelpful (see Table IV.5; 𝑋 = 2.50; SD = 1.52). 
Having a bachelor’s degree or above predicted higher overall acceptability scores (𝑋∆ = 13.92; 
95% CI = 0.25, 27.59). Additionally, baseline oxaliplatin dose was negatively correlated with 
acceptability (r = -.41) but eight-week oxaliplatin dose was positively correlated with ratings of 







Relationships between Intervention Acceptability Scores and Participant Characteristics  
Characteristic n Acceptability 
  𝑿 (SD)a   η2 [95% CI]b 
Employment Status 
   Full-time employed 
   Part time-/un-employed 
   Retired 














    .34 [ . , .52]** 
Cancer Type 
   Colon 
   Rectal/Colorectal 






  50.00 (12.46) 
  46.00 (10.15) 
  57.33 (12.48) 
.13 [ . , .35] 
    
Highest Education Degree 
   ≤ High school degree 
   Some college 








  49.22 (14.49) 
54.42 (9.76) 
  .17 [ . , .39]* 
Smoking History 
   Never smoked 
   Former smoker 






  52.25 (10.73) 
  50.00 (13.96) 
40.50 (3.54) 
.07 [ . , .26] 
    
         r   [95% CI]c 
BMI (kg/m2) 22      -.37 [-.69, .06]* 
Oxaliplatin dose (mg/m2) 
   Baseline 





    -.41 [-.71, .01]* 
     .36 [-.07, .68]* 
Fitbit – weeks 1 to 4 
   MVPA (min/week) 





    .01 [-.40, .42] 
    -.31 [-.64, .13]* 
Baseline PA    
   PAVS (min/week) 21       .33 [-.12, .67]* 
   Subjective PA (PASE) 19       .40 [-.07, .72]* 
Eight Weeks    
   Sensory OIPN 23       .34 [-.10, .66]* 
   Motor OIPN 23       .34 [-.09, .67]* 
Abbreviations. BMI, body mass index; CI, confidence interval; MVPA, moderate to vigorous physical activity; OIPN, 
oxaliplatin-induced peripheral neuropathy; PA, physical activity; PASE, physical activity survey for the elderly; PAVS, physical 
activity vital sign; SD, standard deviation. 
aMean (SD) of the acceptability scores within each characterized patient group. 
bMain effect of the characteristic (e.g., employment status) on acceptability scores. 
cCorrelation with eight-week overall acceptability scores. 
*, medium effect size (r ≥ .3; η2 ≥ .14) 
**, large effect size (r ≥ .5)  
 
 
Table IV.5 explores the relationships between the participant characteristics and 
helpfulness ratings of the Fitbit and MET (the intervention components with the highest uptake 





was BMI (r = -.50), which was also moderately associated with overall intervention acceptability 
(r = -.37). In contrast, helpfulness of the MET sessions, along with overall acceptability of the 
intervention, were associated with higher eight-week sensory (r = .34-.54) and motor OIPN 
severity (r = .34 -.37).  
Regarding PA, Fitbit-measured PA over the first four weeks was negatively correlated 
with the overall acceptability (r = -.31) and Fitbit helpfulness scores (r = -.30); however, baseline 
self-reported MVPA and PA were positively correlated with overall acceptability (r = .33 to .40). 
Age, marital and ECOG status, gender, cancer stage, and exercise interest and confidence were 
not associated with acceptability and helpfulness scores. Fatigue, appetite loss, QOL, and 
physical function at eight weeks were also not associated with acceptability and helpfulness; 
however, further exploratory analyses showed that increase in physical function was positively 






Table IV.5  
Helpfulness of the Fitbit and MET Sessions by MI-Walk Intervention Participant Characteristics  
Characteristic n Helpfulness 
  Fitbit  MET 
  𝑿 (SD)a     η2 [95% CI]  𝑿 (SD)a η2 [95% CI] 
Employment Status 
   Full-time employed 
   Not full-time employed 
   Retired 
















 .23 [ . , .42]* 
 
Cancer Type 
   Colon 
   Rectal/Colorectal 













 .20 [ . , .42]* 
       
Highest Education Degree 
          ≤ High school degree 
           Some college 













.07 [ . , .27] 
       
Smoking History 
   Never smoked 
   Former smoker 















 .17 [ . , .39]* 
       
         r  [95% CI]c        r  [95% CI]c 
BMI (kg/m2) 25    -.50 [-.75, -.13]**   -.07 [.45, .34] 
Baseline oxaliplatin dose (mg/m2) 25    -.29 [-.62, .13]      -.35 [-.65, .06]* 
Fitbit – weeks 1 to 4 
   MVPA (min/week) 





  -.29 [-.63, .15] 
  -.30 [-.65, .15]* 
   
 -.16 [-.54, .27] 
 -.19 [-.56, .26] 
Eight weeks       
   Sensory OIPN 25     .18 [-.24, .54]         .54 [.19, .77]** 
   Motor OIPN 25     .23 [-.19, .58]        .37 [-.04, .66]* 
Abbreviations. BMI, body mass index; CI, confidence interval; MET, motivational enhancement therapy; MVPA, moderate to 
vigorous physical activity; OIPN, oxaliplatin-induced peripheral neuropathy; PA, physical activity; QOL, quality of life; SD, 
standard deviation. 
aMean (SD) of the helpfulness scores within each characterized patient group. 
bMain effect of the characteristic (e.g., employment status) on helpfulness scores. 
cCorrelation with eight-week helpfulness scores 
*, medium effect size (r ≥ .3; η2 ≥ .14) 









Physical Activity Trends 
Figure IV.4 plots the Fitbit-recorded and self-reported minutes of MVPA exhibited by 
participants over the eight weeks. Per the Fitbit (N = 25), the participants averaged 236.58 (SD = 
197.60; range = 0-716.88) minutes of MVPA per week over the eight weeks: 205.91 (SD = 
167.10) minutes per week over the first four and 273.80 (SD = 252.34) minutes per week over 
the last four weeks. Per self-report, the participants averaged 238.27 (SD = 525.61; range = 0-
2,880). 
Figure IV.4 
Mean minutes of MVPA during the MI-Walk Intervention based on the Fitbit and self-report 
 






Figure IV.5 provides the Fitbit-recorded steps per day over the eight weeks. The 
participants (n = 25) averaged 5,918.82 (SD = 2,911.11) steps and 180.77 (SD = 65.54) minutes 
of total PA per day over the eight weeks: 7,922.91 (SD = 3,030.59) steps and 224.69 (SD = 
72.14) minutes of total PA per day over the last four weeks of the intervention.  
Figure IV.5  
Fitbit-measured steps per day of the MI-Walk Intervention participants 
 
Associations between MVPA and participant characteristics. Tables IV.6 and IV.7 
describe the eight-week mean Fitbit-measured MVPA relationships with the participant 
demographics and correlations with other clinical characteristics. Males exhibited higher Fitbit-
recorded minutes of MVPA per week than females (𝑋∆= 207.1; 95% CI 33.16, 381.03); however, 
80% of the intervention group were males. Participants who were full-time employed engaged in 































4.47, 525.18). Fatigue at eight weeks was strongly associated with lower levels of Fitbit-recorded 
MVPA (r = -.62). As depicted in Table IV.6, several other clinical factors demonstrated small to 
moderate correlations with Fitbit-measured MVPA, such as baseline self-reported PA (r = .34), 
and eight-week confidence in the ability to increase one’s amount of aerobic exercise (r = .34).  
Table IV.6 
Differences in Fitbit-Measured MVPA by Baseline Participant Characteristics among MI-Walk 
Intervention Participants (N = 25) 
Characteristic n MVPA (min/week)a 
  𝑿 (SD) Inter-group 𝑿𝟏-𝑿𝟐 [95% CI]  
Gender 
   Male 






  79.18 (70.82) 
207.1 [33.16, 381.03]** 
 
ECOG  
   0 








141.95 [-43.75, 327.65]* 
 
Marital status 
   Married 








160.55 [-56.46, 377.56]* 
   η2 [95% CI] 
Highest Education Degree 
   ≤ High school degree 
   Some college 









.01 [ . , .11] 
 
Smoking History 
   Never smoked 
   Former smoker 










.18 [ . , .40]* 
 
Cancer Stage 
   II 
   III 










.03 [ . , .18] 
 
Employment Status 
   Full-time employed 
   Part time-/un-employed 
   Retired 








 97.79 (45.26) 
253.10 (291.79) 
 90.43 (111.24) 
 
    .35 [ . , .53]** 
 
Cancer Type 
   Colon 
   Rectal/Colorectal 










.09 [ . , .29] 
Abbreviations. CI, confidence interval; ECOG, Eastern Cooperative Oncology Group functional status; MVPA, moderate-
vigorous physical activity; SD, standard deviation. 
aFitbit-measured minutes of MVPA per week. 
*, medium effect size (e.g., η2 ≥ .14) 





Anecdotally, some participants verbally reported that the cold weather (especially with 
the OIPN cold sensitivity) and cancer treatment side effects (especially fatigue) during the first 
three to six days were the main barriers to exercise.  
 
Table IV.7  
Exploration of MI-Walk Intervention Participant Characteristic Associations with Fitbit-
Measured MVPA 
Characteristic   Association with MVPAa 
 n 𝑿 (SD)b   r [   95% CI  ] 
Baseline      
   Age (years) 25 55.8 (12.27)  .01 -.39 .40 
   BMI (kg/m2) 25 25.33 (3.83)   .30* -.11 .62 
   Self-reported PA 
      PASE 
















   Exercise interest 23 6.39 (3.27)  .15 -.28 .53 
   Exercise confidence 23 7.91 (2.02)  .27 -.16 .61 
Eight Weeks      
   Oxaliplatin dose 23 379.63 (56.39)  .05 -.37 .46 
   Sensory OIPN 23 11.11 (8.65) -.28 -.62 .15 
   Motor OIPN 23 8.10 (8.35)  -.32* -.65 .11 
   Fatigue 23 36.71 (21.30)    -.62** -.82 -.28 
   Mood 23 84.67 (18.89)  .31 -.12 .64 
   Exercise interest 22 6.55 (3.32) -.02 -.43 .41 
   Exercise confidence 22 6.36 (2.72)    .34* -.10 .67 
Abbreviations. BMI, body mass index; CI, confidence interval; MVPA, moderate to vigorous physical activity; OIPN, 
oxaliplatin-induced peripheral neuropathy; PA, physical activity; PASE, physical activity survey for the elderly; PAVS, physical 
activity vital sign; SD, standard deviation. 
a Fitbit minutes of MVPA per week averaged over eight weeks. 
bMean (SD) of the presented characteristic. 
*Indicates a moderate correlation (r ≥ .3) 
**Indicates a strong correlation (r ≥ .5) 
 
 
Associations between MVPA and acceptability. Table IV.8 shows the correlations 
between MVPA level and acceptability scores. Participants’ satisfaction with the intervention 
were strongly correlated with Fitbit-measured MVPA (r = .55). Understandability of the written 
intervention materials (r = .49) and likelihood of continuing to use the techniques and materials 
provided during the intervention (r = .35), were moderately correlated with MVPA. Greater 
perceived helpfulness of the group walking sessions and Fitbit were moderately correlated with 





Table IV.8  
Correlations between Acceptability Scores and Fitbit-Measured MVPA 
Acceptability   Association with MVPAa 
 n r [       95% CI       ] 
Overall acceptability 23 .04 -.38 .45 
Easiness 23 -.22 -.58 .22 
Understandability 23 .49* .10 .75 
Enjoyableness 23 .03 -.39 .44 
Helpfulness in managing PN 23 -.11 -.50 .31 
Time requirement acceptability 23 .18 -.25 .55 
Satisfaction 23 .55** .19 .79 
Likelihood of continuing 23 .35* -.08 .67 
Helpfulness     
   MET sessions 23 -.11 -.50 .32 
   Group walking sessions 20 -.32* -.67 .14 
   Fitbit 22 -.32* -.65 .12 
   Email group 20 -.03 -.47 .42 
   PA educational pamphlet 22 -.06 -.47 .37 
   Exercise diary 22 .11 -.33 .51 
   Worksheets 23 .07 -.35 .47 
Abbreviations. CI, confidence interval; MET, motivational enhancement therapy; MVPA, moderate to vigorous physical activity; 
PA, physical activity; PN, peripheral neuropathy. 
aFitbit minutes of MVPA per week averaged over eight weeks. 
*Indicates a moderate correlation (r ≥ .3) 
**Indicates a strong correlation (r ≥ .5) 
 
Discussion 
Over 60% of patients screened at their second FOLFOX/FOLFIRINOX treatment 
enrolled in the trial and 83% of participants completed the MI-Walk Intervention. Most 
participants who enrolled in and completed the study were young (upper 50s), white, married, 
and with few comorbidities and high self-reported baseline PA levels. The overall acceptability 
of the intervention was low to moderate. Although participants reported high satisfaction with 
and likelihood of continuing the intervention, the mean helpfulness ratings of the intervention 
components were all below four out of five (80% the maximum score). The Fitbit and MET 
sessions were the sole intervention components that were rated “helpful” by most participants. 





minutes MVPA per week over the eight weeks); however, participants’ MVPA varied from zero 
to 716.88 minutes per week.  
The enrollment and attrition rates were in line with prior studies of home-based aerobic 
exercise interventions among patients receiving chemotherapy treatment. Prior similar studies 
have had an average enrollment rate of 53.16% (range = 33%-76.3%) out of the 233 (range = 
48-728) mean patients approached for the studies; prior attrition rates ranged from 7% to 26% 
(Courneya et al., 2013; Courneya, McKenzie, et al., 2014; Dhawan, Andrews, Kumar, Wadhwa, 
& Shukla, 2019; Kleckner et al., 2018; McCrary et al., 2019; Mizrahi et al., 2015; Streckmann et 
al., 2014; Vollmers et al., 2018). After changing the timing of recruitment—recruiting patients 
during their second FOLFOX/FOLFIRINOX infusion instead of at their new patient 
(chemotherapy-planning) visit—the study’s enrollment and completion rates exceeded those 
observed in prior trials. When approached during their new patient visit (prior to finalizing the 
chemotherapy treatment plan), most patients were overwhelmed and declined or asked to be 
approached at a later visit. Additionally, improved enrollment rates were observed after 
removing the eligibility criteria that had been excluding participants who were already meeting 
the national PA guidelines of 150 minutes per week of MVPA.  
The participants who enrolled reported fewer comorbidities than those who declined. 
Health complications and comorobidities are a common barrier and/or patient-reported reason 
for deferring participation in an exercise clinical trial (Backman et al., 2014; Speed-Andrews et 
al., 2012). 
The participants who completed the study were younger and had received higher doses 
(the planned dose) of oxaliplatin at the second cycle than participants who withdrew. In this 





discretion.” Clinically, the decision to reduce the oxaliplatin dose early in treatment is often 
based on the patient’s age and baseline functional status. Exploratory analysis of the current data 
showed that patients whose baseline oxaliplatin dose had been reduced were significantly older 
than patients who received the standard 85 mg/m2 dose (p < .01). A prior home-based aerobic 
exercise study has also shown a tendency for higher study completion rates among younger 
participants (Kleckner et al., 2018). Older age and age-related comorbidities have also been 
linked with lower engagement in MVPA (Speed-Andrews et al., 2012; van Putten et al., 2016). 
Acceptability of the intervention and participants’ baseline interest in increasing and 
confidence in their ability to increase their amount of aerobic exercise was wide-ranging and 
overall moderate. However, the overall acceptability ratings did not meet the arbitrary cut-off 
(80% of the maximum score) suggested in the literature to be considered acceptable (Tariman et 
al., 2011). The current study found that uptake and acceptance of the peer support components of 
the intervention (i.e., walking and email groups) were low. Although social support from a 
partner and family member is an empirical facilitator of exercise (Horne & Tierney, 2012; 
Mikkelsen et al., 2019; van Putten et al., 2016), prior evidence suggests that cancer survivors 
may prefer to receive exercise/lifestyle interventions individually during cancer treatment 
(Arthur et al., 2016). 
Multiple demographic and clinical factors were associated with higher intervention 
acceptability, including lower BMI and higher education level and eight-week OIPN severity and 
oxaliplatin dose received. Several prior studies have suggested obesity may influence one’s 
preferences in exercise type (Courneya, Segal, et al., 2014), and enjoyment of and purpose for 
exercising (Leone & Ward, 2013). Higher education level could be associated with a more 





treatment. Prior studies have also shown links between higher education level and increased 
autonomously performed PA (Speed-Andrews et al., 2012).  Most literature to date has focused 
on the (inverse) relationship between cancer treatment-related symptoms and adherence/MVPA 
levels but have not evaluated their relationship with intervention acceptability (Speed-Andrews 
et al., 2012). Part-time or un-employment (versus being retired) was also associated with higher 
acceptability ratings as well as MVPA and will be discussed further below. 
Although acceptability scores were low to moderate, MVPA levels were exceptionally 
high over the eight weeks (mean of 236.58 minutes of MVPA per week). Prior studies reported 
that participants could adhere to 117 to 209 mean minutes of MVPA per week (Courneya et al., 
2003; Djuric et al., 2011; Griffith et al., 2009; Mock et al., 2005; Shang, Wenzel, Krumm, 
Griffith, & Stewart, 2012). Both Fitbit-measured MVPA and self-reported PA levels were wide-
ranging. For example, the participants averaged zero to 716.88 weekly minutes of MVPA per the 
Fitbit and zero to 2,880 weekly minutes of MVPA per self-report. On average, participants were 
already compliant with the PA guidelines at baseline and still exhibited increases in weekly 
minutes of MVPA during the study.  
Fatigue exhibited the strongest associations with lower Fitbit-recorded minutes of MVPA 
but was not associated with intervention acceptability. Evidence suggests that fatigue is the most 
common and distressing cancer treatment-related symptom and is associated with sedentary 
behavior (Chou et al., 2017; Fernandez et al., 2015; Henriksson, Arving, Johansson, Igelstrom, & 
Nordin, 2016; Kamath, 2012; Kang et al., 2014; Mikkelsen et al., 2019).   
Male gender and full-time employment (versus on disability or leave of absence) were 





a prior population-based study of correlates with PA behavior in colorectal cancer survivors 
(Backman et al., 2014; Courneya et al., 2003; Djuric et al., 2011; Dodd et al., 2010; Speed-
Andrews et al., 2012; Swenson et al., 2010; Trost, Owen, Bauman, Sallis, & Brown, 2002; Yang 
et al., 2011). However, 80% of the intervention participants were male. Employment was a key 
factor associated with both acceptability ratings and MVPA levels. Although full-time employed 
and retired participants rated the helpfulness of the intervention the lowest, they exhibited the 
highest MVPA levels. Exploratory post-hoc analysis also showed that full-time employed and 
retired individuals exhibited the highest Fitbit-measured levels of MVPA during the first four 
weeks of the intervention (𝑋 = 258.29-260.48, SD = 127.26-256.23). Fitbit-measured PA during 
the first four weeks of the intervention and MVPA over the eight weeks were also negatively 
correlated with the acceptability scores. These results may indicate that the intervention was less 
helpful to patients who were already physically active at baseline. Prior studies also suggest that 
history of PA is among the greatest predictors of future PA (Backman et al., 2014; Courneya et 
al., 2003; Djuric et al., 2011; Dodd et al., 2010; Swenson et al., 2010; Yang et al., 2011).  
Other miscellaneous findings highlight the discrepancies and lack of clarity regarding the 
definition of and relationships among acceptability, interest, confidence, and objective and self-
reported PA. In contrast to the above findings, self-reported baseline PA was consistently 
positively correlated with the acceptability scores; and strong correlations were observed 
between satisfaction with the intervention and minutes of objective MVPA. Anecdotally, 
participants often explained that their ratings of interest in increasing and confidence in their 
ability to increase their amount of aerobic exercise were tied to their current MVPA levels. The 
participants who self-reported weekly MVPA that exceeded the national guidelines at baseline 





explained that they rated their interest low, because they prioritized strength training over aerobic 
exercise due to their experience of appetite loss and concerns for losing weight and muscle mass. 
These findings hint at a stronger feedback association with baseline PA and eight-week mean 
MVPA minutes predicting intervention acceptability among GI cancer survivors receiving 
FOLFOX/FOLFIRINOX.  
Limitations 
The results of this study may only be applicable to younger, white, baseline physically 
active, and relatively financially stable GI cancer survivors with few to no comorbidities, and 
patients with strong, exercise- and health-promoting family social support. No data were 
collected on participants’ specific home neighborhood conditions and walkability.  
The absolute MVPA levels observed in this study may be questionable due to prior 
studies that have suggested a tendency for Fitbits to overestimate energy expenditure and time 
spent in MVPA (Bai, Hibbing, Mantis, & Welk, 2018; Brooke et al., 2017; Feehan et al., 2018; 
Nazari, MacDermid, Sinden, Richardson, & Tang, 2019; Tedesco et al., 2019; Thomson et al., 
2019). Further, self-report bias likely influenced the measurements of total PA level, measured 
by the PASE. Self-reported minutes of MVPA (PAVS) may not have demonstrated increases 
over time correspondently with the Fitbit, because their self-report may have been inflated at 
baseline and were influenced by participation in the intervention (i.e., access to viewing their 
Fitbit stats).  
Further, the reliability of the PAVS and measures of exercise importance and confidence 
among patients receiving neurotoxic chemotherapy may be decreased due to the variability in 
cancer treatment side effects and fatigue levels between each treatment. Participants frequently 





accordance to the prior week; however, the participants’ PA the prior week differed grossly from 
the week before and fluctuated overall throughout treatment. Participants had difficulty 
responding about their interest and confidence without considering other factors, such as their 
current adequate MVPA levels (i.e., the participant just wanted to maintain their current level of 
exercise). For some participants, other cancer treatment-related concerns took precedence over 
increasing their aerobic PA (e.g., obtaining adequate nutritional intake and strength training to 
maintain muscle mass). 
Finally, the interventionist (first author) was trained but amateur in providing 
motivational interviewing. Thus, a more impartial and skilled motivational interviewer may have 
improved the acceptability of the intervention. Future studies may be needed to evaluate the level 
of motivational interviewing and oncology clinical competency required to maximize the 
efficacy of interventions similar to the MI-Walk Intervention in the future. 
Conclusions 
This dual-site pilot randomized controlled trial showed safety and potential feasibility of 
an eight-week MET- and home-based aerobic walking intervention among adults with stage II-
IV GI cancer who are receiving FOLFOX or FOLFIRINOX treatment. However, significant 
changes would be required to tailor the intervention based on key participant characteristics (e.g., 
age, employment status, and baseline PA levels) to improve the acceptability of the intervention.  
With strategic timing of recruitment (ideally once participants have already experienced 
their first chemotherapy treatment), an eight-week home-based aerobic walking intervention 
study is feasible among adult GI cancer survivors during the first half of FOLFOX or 
FOLFIRINOX treatment. On average, patients receiving FOLFOX or FOLFIRINOX 





of MVPA per week. However, the levels of MVPA and acceptability may vary considerably 
based on various patient and clinical characteristics. Altogether, less comorbidity, younger age, 
and participants already engaging in high levels of MVPA may be most likely to succeed in a 
home-based aerobic walking intervention but may not need nor perceive a multi-component 
intervention to be helpful. Simplifying and tailoring the intervention may help to conserve 
resources and amplify the benefits for participants.  
Future directions. Future studies are needed to identify the components of an aerobic 
exercise intervention that is most helpful for older adults, especially females, with functionally 
impairing disabilities, and higher levels of fatigue. Additionally, studies are needed to evaluate 
the intervention components that may be most helpful and satisfactory to individuals who are 
retired, overweight, and/or have varying levels of formal education and other physical barriers to 
exercise (e.g., fatigue, dyspnea from a history of smoking). Finally, exploratory studies are 
needed to evaluate the mediating factors between participant characteristics, such as employment 
status, and perceived helpfulness of various home-based aerobic walking intervention 
components. These studies may help to develop algorithms for tailoring future exercise 
interventions for GI cancer survivors who are receiving FOLFOX or FOLFIRINOX.  
Finally, investigation of the concepts of and best ways to measure acceptability and 
participant interest and confidence in aerobic exercise is also warranted among 
FOLFOX/FOLFIRINOX-receiving patients. The clarity will help to build theory and 
understanding of the relationships among acceptability, interest, confidence, and ultimately, 
aerobic exercise adherence. 
Practice implications. Eventually, the goal is to identify easily implementable, widely 





FOLFOX or FOLFIRINOX treatment. The current and prior studies have shown that home-
based aerobic exercise is safe and can lead to significant increases in aerobic exercise among 
chemotherapy-receiving cancer survivors. Specific components of the MI-Walk Intervention—
the Fitbits and MET—were helpful and should be studied to identify the types of participants 
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This dissertation presented the premises for and results of a dual-site pilot randomized 
controlled trial of an eight-week home-based aerobic walking intervention—the MI-Walk 
Intervention—to reduce oxaliplatin-induced peripheral neuropathy (OIPN). The sample was 
composed of gastrointestinal (GI) cancer survivors who had just begun FOLFOX or 
FOLFIRINOX (oxaliplatin-based chemotherapy) treatment. The control condition was physical 
activity education alone. The objectives of the study were exploratory: intended to observe trends 
in the effects of the MI-Walk Intervention on OIPN and quality of life (QOL). Additionally, 
exploratory analyses were conducted to observe patterns among participant characteristics and 
indicators of study feasibility (e.g., intervention acceptability and adherence).  
Efficacy Study Results 
The Chapter III provides the results of the first two study aims: to explore the effects of 
the MI-Walk Intervention, on 1) OIPN severity and 2) QOL at eight weeks, compared to physical 
activity (PA) education alone in oxaliplatin-receiving GI cancer survivors. The hypothesis was 
that the MI-Walk Intervention would lead to significantly reduced sensory OIPN severity at eight 
weeks in the intervention participants than patients who received PA education alone. 
The study revealed that the MI-Walk Intervention was no more or less effective than PA 
education alone at reducing sensory and motor OIPN and bolstering QOL. However, 





(MVPA), mood, and female gender may be associated with more severe eight-week sensory 
OIPN severity and worse QOL. Ultimately, the increase in PA in the control group per self-report 
was suspected to confound the results. Although the intervention group participants exhibited 
increases in Fitbit-measured minutes of MVPA, the PA education alone group also self-reported 
significant increases in PA. Insufficient data was collected from the research-grade activity 
monitors (ActiGraph GT9X Link) at the eight-week time point often due to lost ActiGraphs 
during walks, insufficient wear time, device errors, and participants refusing to wear the 
ActiGraph when they were engaging in less PA than usual. The lack of objective PA 
measurement limited the study findings, because the confounding effects of total PA could not be 
controlled for in the analysis of the outcomes nor compared between groups. Altogether, the 
results of the study emphasized the importance of evaluating the feasibility of the MI-Walk 
Intervention and best modes of PA measurement among GI cancer survivors receiving FOLFOX 
or FOLFIRINOX treatment. 
Feasibility Study Results 
The Chapter IV presented the results of the third study aim: to describe the rates of and 
explore the relationships between patient characteristics and 1) enrollment in and attrition from 
the study, 2) acceptability of the MI-Walk Intervention, and 3) intervention adherence. Chapter 
IV also further describes participants overall PA levels. 
The 60% enrollment and 14% intervention attrition rates were excellent compared to the 
average 50% enrollment (Courneya et al., 2013, 2014; Dhawan, Andrews, Kumar, Wadhwa, & 
Shukla, 2019; Kleckner et al., 2018; McCrary et al., 2019; Mizrahi et al., 2015; Streckmann et 
al., 2014; Vollmers et al., 2018) and 1%-30% attrition rates reported in the literature (Courneya et 





younger age and receiving the planned oxaliplatin dose by the second FOLFOX/FOLFIRNOX 
treatment was associated with intervention completion.  
The acceptability of some components of the multifaceted intervention were low, 
primarily attributed to the poor uptake of and perceived unhelpfulness of the walking and email 
groups. However, participants reported satisfaction with and likelihood of continuing the 
intervention. The Fitbit and motivational enhancement therapy (MET) sessions were the most 
helpful. Several demographic and clinical characteristics, consistent with the literature (e.g., part-
time or un-employment and lower body mass index) (Courneya et al., 2014; Leone & Ward, 
2013; Speed-Andrews et al., 2012), were associated with higher intervention acceptability 
ratings. 
Fitbit-measured minutes of MVPA and self-reported PA levels were exceptionally high 
but variable. The participants in the current study averaged 236.58 (SD = 197.60) minutes of 
MVPA per week. Fitbit-measured MVPA increased over the eight weeks despite the participants’ 
high baseline MVPA levels per self-report and Fitbit measurement during the first four weeks of 
the intervention. Fatigue, female gender, and employment status of “on disability/leave of 
absence” were associated with lower adherence. In general, higher Fitbit-measured PA levels 
were associated with a lower perceived helpfulness of most of the intervention components; 
however, higher satisfaction with the intervention was associated with higher MVPA levels. 
Participants anecdotally had difficulty responding to the confidence rulers asking their interest in 
increasing and confidence in their ability to increase their amount of aerobic exercise; neither 





Gaps and Limitations 
No treatments have been found that prevent or cure OIPN (Hershman et al., 2014; 
Majithia et al., 2016). A primary contributing factor toward the lack of progress in developing 
treatments may be due to the current lack of understanding about the pathophysiologic 
mechanisms of OIPN. This study was developed, based on the understanding that oxaliplatin 
accumulates around the collections of peripheral nerve cell bodies (i.e., the dorsal root ganglia) 
and induces oxidative stress and nerve cell death. Thus, the MI-Walk Intervention was designed 
with a focus on aerobic walking to promote blood circulation and the sweeping of oxaliplatin 
away from the dorsal root ganglia to reduce OIPN.  
Based on the integrative review conducted in Chapter II, three studies have demonstrated 
potentially clinically significant benefits of light to moderate-intensity aerobic exercise in 
reducing OIPN and other types of chemotherapy-induced peripheral neuropathy among patients 
receiving neurotoxic chemotherapy (Henke et al., 2014; Kleckner et al., 2018; Zimmer et al., 
2018). However, the prior studies all had a moderate to high risk of bias, mainly due to lack of 
strong OIPN measurement, control for OIPN-influencing (i.e., confounding) factors, and 
intervention design. Further, no studies have focused on testing home-based aerobic exercise to 
reduce OIPN among individuals actively receiving oxaliplatin treatment.  
Due to the unclear and/or lack of efficacy of the MI-Walk Intervention in increasing 
MVPA, the current study could not adequately evaluate the effects of home-based aerobic 
walking on sensory OIPN severity compared to PA education alone. The primary study limitation 
was insufficient assay sensitivity. Specifically, increases in self-reported PA from baseline to 
eight weeks were observed among the control but not intervention group participants. Reliable 





the effects of the intervention on OIPN and QOL. Finally, timing of outcome measurement may 
have been premature in the study. Sensory and motor OIPN severity was still mild in severity at 
the eight-week time point (coinciding with the sixth infusion). 
The current study highlighted several gaps in the knowledge regarding the feasibility of 
home-based aerobic exercise among FOLFOX/FOLFIRINOX-receiving GI cancer survivors. 
First, no studies have specifically evaluated the helpfulness of individual aerobic exercise 
intervention components for GI cancer survivors who are receiving FOLFOX/FOLFIRINOX and 
generally show the lowest rates of adherence (e.g., females or people who are on disability or 
leave of absence). Additionally, there remains a lack of clarity regarding the definitions of and 
relationships among acceptability, adherence and interest and confidence. Only one recent 
review has attempted to empirically define acceptability and factors associated with acceptability 
(Sekhon, Cartwright, & Francis, 2017).  
Future Directions 
Given the study results and the current state of the science, future studies are still needed 
to evaluate the (a) effects of home-based aerobic exercise on OIPN and (b) most helpful 
components of a home-based aerobic exercise intervention among GI cancer survivors who are 
receiving FOLFOX or FOLFIRINOX. The current data can be used to evaluate trends in results 
from the intervention group participants and further explore the associations between Fitbit-
measured minutes of MVPA and tingling in the fingers and hands (the most severe acute OIPN 
symptom), as well as other sensory and motor OIPN symptoms. Additionally, future exploratory 
studies could evaluate other factors (e.g., mood) that may be associated with aerobic exercise 
adherence, self-reported PA levels, and OIPN outcomes. Finally, the current study data may be 





minutes of MVPA and QOL outcomes. This data may be used to direct future prospective trials 
of aerobic exercise for OIPN. 
Future prospective trials of aerobic exercise for OIPN among FOLFOX/FOLFIRINOX-
receiving GI cancer survivors should focus on improving assay sensitivity by using a strong 
measurement approach; delaying the outcome measurement time point (e.g., at the eighth 
infusion or later) to maximize the ability to detect clinically significant differences; focusing on 
the most bothersome symptom at the given outcome time point (e.g., tingling in the fingers and 
hands if evaluating acute OIPN); and ensuring the control condition receives no PA education or 
intervention. A strong measurement approach may include using both clinical assessment of pre-
clinical OIPN signs (especially important for preventative trials) and repeated measurements of 
self-reported OIPN at each timepoint. 
Further investigation is also needed of 1) OIPN mechanisms and 2) potential biological 
mediators (e.g., vascular function) of the effects of aerobic exercise on OIPN. A better 
understanding of the mechanisms of OIPN will allow for stronger future studies that evaluate 
whether and how aerobic exercise can biologically combat OIPN. If home-based aerobic walking 
demonstrates potential efficacy and biological mechanisms involved in reducing OIPN, future 
studies will be needed to identify optimal exercise prescriptions and behavioral interventions to 
promote adherence.  
Feasibility studies are needed to help identify the most helpful components of an aerobic 
exercise intervention for individuals with GI cancer who are receiving FOLFOX/FOLFIRINOX. 
The participants in the current study showed a preference toward engaging in independent 
exercise or exercise with their own family member. Studies are needed to evaluate the types of 





weight) who benefit most from a group versus individual home-based intervention. Further 
research is also needed to evaluate technological supports that may be used to assist participants, 
given that most patients in the current study found the Fitbit tool to be helpful. Additionally, 
research is needed to identify the types of participants that would benefit from motivational 
interviewing/MET; as well as the training requirements of the therapist and motivational 
interviewing dosage required for efficacy.  
Evaluation of adherence and control for PA as a confounding factor in future studies will 
depend on the successful acquisition of PA data from FOLFOX or FOLFIRINOX-receiving 
cancer survivors. Yet, obtaining good data can be challenging. Participants exhibited fluctuating 
PA levels between oxaliplatin infusions due to the chemotherapy side effects. Thus, the optimal 
timing (in relation to chemotherapy) and duration of PA measurement must be studied. New 
activity count cut-offs to quantify PA time and identify valid wear time may need to be 
established that are specific to individuals receiving neurotoxic chemotherapy every other week. 
Thus, future studies are needed to evaluate the validity and reliability of ActiGraph data and 
other PA trackers among oxaliplatin-receiving survivors, based on the timing of ActiGraph 
measurement (the week before and/or after oxaliplatin treatment), required hours per day and 
days per week of wear, and location of wear (wrist versus hip). Defining ActiGraph validity 
based on the number of week and weekend days of measurement required may be inappropriate 
for oxaliplatin-receiving survivors. The variation in treatment side effects between the first and 
second weeks after oxaliplatin infusion may be a larger influencer of PA levels in this population. 
The number of days required for valid ActiGraph measurement may best be defined in relation to 
the oxaliplatin infusion (e.g., at least one day of measurement within days one to four, one day 





Implications for Practice 
Patients with GI cancer who are receiving FOLFOX or FOLFIRINOX are at a high risk 
of developing OIPN. Transient acute OIPN often causes discomfort and difficulty with daily 
tasks such as grabbing a cold item out of the refrigerator or typing on a laptop. Acute OIPN may 
also evolve into long-lasting sensory and motor deficits that interfere with QOL and increase 
patients’ risks for adverse outcomes, including falls and social isolation and depression. Due to 
the lack of proven interventions to prevent or cure OIPN, patient education should be a priority 
to maintain safety and optimize patient outcomes.  
Although the efficacy of aerobic walking to reduce OIPN is unknown, the general health 
benefits and safety of home-based aerobic exercise is well established for GI cancer survivors 
with no other contraindicators to PA. Further, this study demonstrated that GI cancer survivors 
are capable of surpassing the national physical activity recommendations of participating in at 
least 150 minutes of MVPA per week during FOLFOX/FOLFIRINOX treatment; however, the 
levels of MVPA may be wide-ranging. Some participants with the lowest levels of MVPA may 
benefit from MET. Participants in the current study found that the time requirement of MET was 
highly acceptable, potentially because the MET sessions were delivered while the participants 
were receiving their several hour-long oxaliplatin infusion. Thus, employing a therapist to visit 
the most-in-need patients during their infusions may be an excellent way to promote home-based 
aerobic exercise and other healthy behaviors. 
Various patient and clinical characteristics may influence a patients’ receptiveness to and 
acceptability of an exercise intervention. Thus, clinicians should tailor the exercise intervention 
to the participant to optimize aerobic exercise adherence and optimize physical and mental health 





without motivational interviewing may be most beneficial and feasible. Ultimately, further 
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